<SEC-DOCUMENT>0001047469-17-007756.txt : 20171220
<SEC-HEADER>0001047469-17-007756.hdr.sgml : 20171220
<ACCEPTANCE-DATETIME>20171219204727
ACCESSION NUMBER:		0001047469-17-007756
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20171220
DATE AS OF CHANGE:		20171219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MADRIGAL PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001157601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-206135
		FILM NUMBER:		171265554

	BUSINESS ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		404-380-9263

	MAIL ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20010815
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2234106z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P style="font-family:arial;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333-206135  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> PROSPECTUS SUPPLEMENT<BR>  </B></FONT><FONT SIZE=2>(To Prospectus dated October&nbsp;16, 2015) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>1,506,025 Shares </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g467069.jpg" ALT="LOGO" WIDTH="337" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>Common Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are selling 1,506,025 shares of our common stock in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock trades on The Nasdaq Global Market under the trading symbol "MDGL". On December&nbsp;18, 2017, the last reported sale price of our common stock on The
Nasdaq Global Market was $84.04 per share. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described under the heading "Risk Factors" beginning on
page&nbsp;S-8 of this prospectus supplement before buying shares of our common stock.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="87pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Per Share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Total<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$83.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$125,000,075</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$4.98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$7,500,005(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$78.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$117,500,071</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>We
have agreed to reimburse the underwriters for certain expenses in connection with the offering and have paid certain other amounts to one of the underwriters. See
"Underwriting."  </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to reimburse the underwriters for certain expenses in connection with this offering. See "Underwriting". </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have the option to purchase up to 225,904 additional shares of our common stock at the public offering price, less the underwriting discounts and commissions payable by
us, within 30&nbsp;days from the date of this prospectus supplement. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are offering the common stock as set forth under "Underwriting". The underwriters expect to deliver the shares against payment therefor in New York, New York on or
about December&nbsp;21, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="200pt" style="font-family:arial;"></TD>
<TD WIDTH="5%" style="font-family:arial;"></TD>
<TD WIDTH="161pt" style="font-family:arial;"></TD>
<TD WIDTH="5%" style="font-family:arial;"></TD>
<TD WIDTH="167pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><FONT SIZE=3><B>Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=3><B>Evercore ISI</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="114pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="161pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="167pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3><B>JMP Securities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3><B>Roth Capital Partners</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=3><B>H.C. Wainwright&nbsp;&amp;&nbsp;Co.</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The date of this prospectus supplement is December&nbsp;18, 2017 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=185828,FOLIO='blank',FILE='DISK128:[17ZDN1.17ZDN42401]BC42401A.;36',USER='HYUNG',CD='19-DEC-2017;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG42401A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> TABLE OF CONTENTS  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG42401_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Page<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#bi42401_about_this_prospectus_supplement"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#bi42401_about_this_prospectus_supplement"><FONT SIZE=2>S-1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#ca42401_prospectus_supplement_summary"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#ca42401_prospectus_supplement_summary"><FONT SIZE=2>S-3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42401_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42401_risk_factors"><FONT SIZE=2>S-8</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42401_business"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BUSINESS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42401_business"><FONT SIZE=2>S-36</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A1"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A1"><FONT SIZE=2>S-58</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A2"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A2"><FONT SIZE=2>S-59</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A3"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A3"><FONT SIZE=2>S-60</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A4"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRICE RANGE OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A4"><FONT SIZE=2>S-61</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A5"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIVIDEND POLICY</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A5"><FONT SIZE=2>S-61</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A6"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A6"><FONT SIZE=2>S-62</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A7"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITING</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A7"><FONT SIZE=2>S-66</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A8"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A8"><FONT SIZE=2>S-71</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A9"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A9"><FONT SIZE=2>S-71</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A10"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A10"><FONT SIZE=2>S-71</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A11"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#A11"><FONT SIZE=2>S-72</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>

<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PROSPECTUS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG42401_TOC2"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Page<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_about_this_prospectus"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_prospectus_summary"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_prospectus_summary"><FONT SIZE=2>2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_risk_factors"><FONT SIZE=2>3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_ratio_of_earnings_to_fixed_charges"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIO OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_special_note_regarding_forward-looking_statements"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_use_of_proceeds"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_use_of_proceeds"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_plan_of_distribution"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#da42403_plan_of_distribution"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_common_stock"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_common_stock"><FONT SIZE=2>7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_preferred_stock"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_preferred_stock"><FONT SIZE=2>7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_debt_securities"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_debt_securities"><FONT SIZE=2>9</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_warrants"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dc42403_description_of_warrants"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de42403_description_of_rights"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF RIGHTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de42403_description_of_rights"><FONT SIZE=2>16</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de42403_description_of_purchase_contracts"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PURCHASE CONTRACTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de42403_description_of_purchase_contracts"><FONT SIZE=2>17</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de42403_description_of_units"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#de42403_description_of_units"><FONT SIZE=2>18</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de42403_certain_provisions_of_delaware__cer03850"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN PROVISIONS OF DELAWARE LAW AND OF THE COMPANY'S CERTIFICATE OF INCORPORATION AND
BY-LAWS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de42403_certain_provisions_of_delaware__cer03850"><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_legal_matters"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_legal_matters"><FONT SIZE=2>21</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_experts"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_experts"><FONT SIZE=2>21</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_where_you_can_find_more_information"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_where_you_can_find_more_information"><FONT SIZE=2>22</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_incorporation_of_documents_by_reference"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg42403_incorporation_of_documents_by_reference"><FONT SIZE=2>22</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1001370,FOLIO='blank',FILE='DISK128:[17ZDN1.17ZDN42401]BG42401A.;8',USER='CHE106812',CD='16-DEC-2017;19:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_bi42401_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bi42401_about_this_prospectus_supplement"> </A>
<A NAME="toc_bi42401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document is part of a registration statement that was filed with the Securities and Exchange Commission, or the SEC, using a "shelf"
registration process and consists of two parts. The first part is the prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this
offering. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more general information. In general, when we refer only to the prospectus,
we are referring to both parts of this document combined. Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by
reference herein and therein, as well as the additional information described under the heading "Where You Can Find More Information." These documents contain information you should carefully consider
when deciding whether to invest in our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent there is a conflict between the information contained in this
prospectus supplement and the accompanying prospectus, you should rely on information contained in this prospectus supplement, provided that if any statement in, or incorporated by reference into, one
of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. Any
statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information contained in this prospectus supplement, the accompanying prospectus, any document incorporated by reference herein or therein, or any free
writing prospectuses we may provide to you in connection with this offering. Neither we nor any of the sales agents has authorized anyone to provide you with any different information. We take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus supplement, the
accompanying prospectus, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of
operations and prospects may have changed since that date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the shares of common stock
to which it relates, nor do this prospectus supplement and the accompanying prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person
to whom it is unlawful to make such offer or solicitation in such jurisdiction. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, information contained in or incorporated by reference into this prospectus concerning our industry and the markets in which we operate, including market
opportunity, market position and competitive landscape, is based on information from our management's estimates, as well as from industry publications, surveys and studies conducted by third parties.
Management estimates are derived from publicly available information, our knowledge of our industry, and assumptions based on such information and knowledge, which we believe to be reasonable. In
addition, while we believe that information contained in the industry publications, surveys and studies has been obtained from reliable sources, the accuracy and completeness of such information is
not guaranteed, and we have not independently verified any of the data contained in these third-party sources. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompanying prospectus, and any documents incorporated by reference herein or therein, include statements that are based on various assumptions and
estimates that are subject to numerous known and unknown risks and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=528706,FOLIO='S-1',FILE='DISK128:[17ZDN1.17ZDN42401]BI42401A.;4',USER='CHE108065',CD='16-DEC-2017;19:39' -->
<A NAME="page_bi42401_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>uncertainties.
Some of these risks and uncertainties are described under the heading "Risk Factors" beginning on page&nbsp;S-8 of this prospectus supplement and in the section titled "Risk Factors"
in our most recent Annual Report on Form&nbsp;10-K, and our Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2017, which are incorporated by reference into the
prospectus. These and other important factors could cause our future results to be materially different from the results expected as a result of, or implied by, these assumptions and estimates. You
should read the information contained in this prospectus supplement and the accompanying prospectus, and the documents incorporated by reference herein and therein, completely and with the
understanding that future results may be materially different and worse from what we expect. See the information included under the heading "Special Note Regarding Forward-Looking Statements." </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made
solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a
representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated or the context otherwise requires, the terms "Company," "Madrigal Pharmaceuticals," "we," "us" and "our" refer to Madrigal Pharmaceuticals,&nbsp;Inc., a
Delaware corporation, and its predecessors and consolidated subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=20505,FOLIO='S-2',FILE='DISK128:[17ZDN1.17ZDN42401]BI42401A.;4',USER='CHE108065',CD='16-DEC-2017;19:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca42401_1_3"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca42401_prospectus_supplement_summary"> </A>
<A NAME="toc_ca42401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights information contained elsewhere in this prospectus supplement and the accompanying prospectus
and in the documents we incorporate by reference. This summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should read this
entire prospectus supplement and the accompanying prospectus carefully, including the "Risk factors" section contained in this prospectus supplement and our consolidated financial statements and the
related notes and the other documents incorporated by reference herein.</I></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the
treatment of cardiovascular, metabolic and liver diseases. Our lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor-&szlig;, or
THR-&szlig;, agonist that can potentially be used to treat a number of disease states with high unmet medical need. THR-&szlig; is known to regulate cholesterol and triglyceride
metabolism, which we believe suggests potential therapeutic benefits for patients suffering from hypercholesterolemia, genetic dyslipidemias and diseases resulting from accumulation of fat in liver
tissue, such as non-alcoholic steatohepatitis, or NASH. Based on scientific publications in human and animal studies, we believe that human NASH livers have a deficiency in THR-&szlig; activity
that leads to features of NASH including fatty liver, inflammation and fibrosis, and that treatment with MGL-3196 may potentially replace this hormone deficiency and be an effective NASH treatment. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 is a first-in-class, highly selective, liver-directed THR-&szlig; agonist. We are developing MGL-3196 for NASH and we have initiated a Phase&nbsp;2
clinical trial in this indication. We are also developing MGL-3196 for dyslipidemia, particularly genetic dyslipidemias such as familial hypercholesterolemia, or FH, including both homozygous and
heterozygous forms of the disease. We have initiated a Phase&nbsp;2 clinical trial in heterozygous FH, or HeFH, patients and we are planning to conduct a proof-of-concept clinical trial in
homozygous FH, or HoFH, patients. MGL-3196 is a once-daily oral pill that has been studied in four completed Phase&nbsp;1 trials in a total of 129 subjects. MGL-3196 appeared to be safe and
well-tolerated in these trials, which included a single ascending dose trial, a multiple ascending dose trial, and two drug interaction trials with statins. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the multiple ascending dose Phase&nbsp;1 clinical trial in healthy volunteers with mildly elevated low-density lipoprotein cholesterol, or LDL-C, the administration of MGL-3196 in
once daily doses of
up to 200 mg per day for 14&nbsp;days demonstrated statistically significant reductions of LDL-C, apolipoprotein B, or apoB, and non-high density lipoprotein cholesterol, or non-HDL-C, of up to 30%,
and a reduction of triglycerides, or TG, of up to 60%. Increased levels of LDL-C, commonly known as "bad cholesterol", apoB and non-HDL-C are each strongly associated with increased risk of heart
disease. The lipid parameter reductions observed with MGL-3196 treatment occurred rapidly in the trial, becoming apparent within the first few days of dosing. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=89123,FOLIO='S-3',FILE='DISK128:[17ZDN1.17ZDN42401]CA42401A.;11',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_ca42401_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following chart summarizes the status of our product candidate development programs for MGL-3196 and MGL-3745, a preclinical compound which has similar thyroid receptor selectivity
to MGL-3196 and is thus a potential backup compound for MGL-3196: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g819290.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="291">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Developments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recently announced top-line results from our Phase&nbsp;2 clinical trial in NASH. In this trial, MGL-3196 demonstrated statistically
significant results for the primary endpoint, the percent change in hepatic fat versus placebo as measured by MRI-PDFF, a non-invasive imaging test, at 12&nbsp;weeks. Recent published data have
shown a high correlation of the reduction of liver fat of 30% or more as measured by MRI-PDFF to improvement in NASH on liver biopsy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statistically
significant reductions in alanine aminotransferase, or ALT, and aspartate aminotransferase, or AST, were observed in MGL-3196 treated patients; greater reductions in ALT
and AST, statistically significant relative to placebo, were observed in the pre-specified group with relatively higher MGL-3196 drug levels. In drug-treated relative to placebo patients,
statistically significant improvements were also seen in multiple secondary endpoints considered to be potentially clinically relevant in patients with NASH including LDL-C, triglycerides,
apolipoprotein B (ApoB), and Lp(a). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGL-3196
has been well-tolerated with mostly mild adverse events, or AEs, and a few moderate AEs, the numbers of which are balanced between placebo and drug-treatment groups. There are
no adverse effects of MGL-3196 on safety laboratory or vital sign parameters. There have been three serious adverse effects in the study, all considered unrelated to MGL-3196. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
on-going clinical trial remains blinded. Safety, efficacy of NASH resolution by biopsy, and repeat MRI-PDFF will be assessed at 36&nbsp;weeks. Multiple inflammatory and fibrosis
serum biomarkers at 12 and 36&nbsp;weeks are being and will be assessed, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leading biopharmaceutical company developing and commercializing innovative liver-directed, &szlig;-selective
thyroid hormone receptor agonists for the treatment of cardio- </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=583301,FOLIO='S-4',FILE='DISK128:[17ZDN1.17ZDN42401]CA42401A.;11',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_ca42401_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>metabolic
and liver disease, fibrosis and inflammation. A key element is building a multi-therapy NASH focused company. To achieve our goal, we plan to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Complete clinical development and seek regulatory approval of MGL-3196 in
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have reported data for the primary endpoint from our Phase&nbsp;2 study in NASH in December 2017. NASH is a disease driven by the
growing epidemic of obesity, with a significant unmet need for approved therapies that are effective and well tolerated. We believe MGL-3196 is an excellent candidate for the chronic treatment of NASH
due to its safety profile and first-in-class dual mechanism of action targeting fibrosis-generating cells.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Establish commercial capabilities to market MGL-3196 as a leading treatment for
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;If approved, we may choose either to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize MGL-3196, or to collaborate with one or more third parties to accomplish these tasks. Patients with NASH are primarily managed by a concentrated group of liver
specialists in the United States and Europe. We believe this will enable us to launch MGL-3196 in NASH in a cost-effective, targeted manner.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Grow our pipeline through additional indications for MGL-3196 including orphan
indications.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe that MGL-3196 has the potential to be an effective treatment for other disease indications that are rare diseases or may
be designated rare diseases, including HoFH and severe HeFH, and we plan to pursue orphan drug designation where possible. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market Opportunity in NASH  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASH is a serious inflammatory form of nonalcoholic fatty liver disease, or NAFLD. NAFLD has become the most common liver disease in the United
States and other developed countries and is characterized by an accumulation of fat in the liver with no other apparent causes. The rising worldwide prevalence of obesity-related disorders has
contributed to a rapid increase in the global prevalence of NASH and NAFLD. In the United States, NAFLD is estimated to affect approximately 27% to 34% of the population, or an estimated
86&nbsp;million to 108&nbsp;million people, and approximately 10% to 20% of those will progress from NAFLD to NASH. Current estimates place NASH prevalence at approximately 9&nbsp;million to
15&nbsp;million people in the United States, or 3% to 5% of the population, with similar prevalence in Europe and Asia. The
prevalence of NASH is also increasing in developing regions due to the adoption of a more sedentary lifestyle and a diet consisting of processed foods with high fat and fructose content. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Centers for Disease Control and Prevention projects the prevalence of obesity to increase from 34% of the United States population to 42% of the United States population by 2030.
Driven by this epidemic of obesity, NASH is projected to become the leading cause of liver transplants by 2020. Given the extremely limited availability of organ donors and high transplant costs, NASH
patients who require transplantation will place a significant economic burden on the healthcare system. As such, there is a significant unmet medical need for well-tolerated oral treatments for NASH.
Because there are currently no therapeutic products approved for the treatment of NASH, the market size is difficult to estimate. However, based on our analysis of multiple market assessments, we
estimate that the addressable NASH population is several million patients worldwide, and that NASH could become a multi-billion dollar market able to support multiple approved drug products. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in Delaware in September 2011. On July&nbsp;22, 2016, Synta Pharmaceuticals Corp., or Synta, completed its business
combination with Madrigal </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=904410,FOLIO='S-5',FILE='DISK128:[17ZDN1.17ZDN42401]CA42401A.;11',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_ca42401_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>Pharmaceuticals,&nbsp;Inc.,
a privately-held Delaware corporation, or Private Madrigal, in accordance with the terms of an Agreement and Plan of Merger and Reorganization, dated as of
April&nbsp;13, 2016, whereby a wholly-owned subsidiary of Synta merged with and into Private Madrigal, or the Merger, with Private Madrigal surviving the Merger as a wholly-owned subsidiary of
Synta. Following the Merger, Synta changed its name to "Madrigal Pharmaceuticals,&nbsp;Inc.", and our business became the business conducted by Private Madrigal prior to the Merger. In addition, the
Merger provided us with $42.6&nbsp;million in cash, cash equivalents and marketable securities. Our principal executive offices are located at 200 Barr Harbor Drive, Suite&nbsp;400, West
Conshohocken, PA 19428. Our telephone number is (484)&nbsp;380-9263. Our Internet website address is www.madrigalpharma.com. The contents
of our website are not incorporated into, and do not form&nbsp;a part of, this prospectus or the registration statement of which it forms&nbsp;a part. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=171713,FOLIO='S-6',FILE='DISK128:[17ZDN1.17ZDN42401]CA42401A.;11',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc42401_1_7"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cc42401_the_offering"> </A>
<A NAME="toc_cc42401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary contains basic information about our common stock and the offering and is not intended to be
complete. It does not contain all of the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled "Description of Capital
Stock."</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Issuer</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Madrigal Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Common stock offered by us</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1,506,025&nbsp;shares. We have also granted the underwriters a 30-day option to purchase up to 225,904&nbsp;additional
shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Common stock to be outstanding after this offering</B></FONT><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>14,001,730 shares (or 14,227,634 shares if the underwriters exercise their option to purchase additional shares in
full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Use of Proceeds</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that the net proceeds from this offering will be approximately $117.5&nbsp;million based on the sale of
1,506,025 shares of our common stock offered hereby (or approximately $135.1&nbsp;million if the underwriters exercise their option to purchase 225,904 additional shares in full), at the public offering price of $83.00 per share, after deducting
estimated underwriting discounts and commissions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We intend to use the net proceeds from this offering, if any, for general corporate purposes, including, without limitation,
research and development expenditures, clinical trial expenditures, manufacture and supply of drug substance and drug products, acquisitions of new technologies, capital expenditures and working capital. See "Use of Proceeds" beginning on
page&nbsp;S-59 of this prospectus.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Nasdaq Global Market Symbol</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MDGL</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Risk Factors</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:11pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Your investment in our common stock involves substantial risks. You should read carefully the "Risk Factors" included and
incorporated by reference in this prospectus, including the risk factors incorporated by reference from our filings with the SEC.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
common stock outstanding after the offering is based on approximately 12,495,705 shares of our common stock outstanding as of September&nbsp;30,
2017 and excludes the following:</FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,969,797 shares of common stock issuable upon conversion of our Series&nbsp;A Convertible Preferred
Stock outstanding as of September&nbsp;30, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">991,711 shares of our common stock issuable upon the exercise of options outstanding as of
September&nbsp;30, 2017, having a weighted average exercise price of $11.96 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">an aggregate of 1,443,561 shares of our common stock reserved for future issuance as of
September&nbsp;30, 2017 under our 2015 Stock Plan. </FONT></DD></DL>
</DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise noted, we have presented the information in this prospectus supplement assuming no exercise by the underwriters of the option to purchase up to 225,904 additional
shares of our common stock in this offering. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=586738,FOLIO='S-7',FILE='DISK128:[17ZDN1.17ZDN42401]CC42401A.;15',USER='HYUNG',CD='19-DEC-2017;16:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da42401_1_8"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da42401_risk_factors"> </A>
<A NAME="toc_da42401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Before making an investment decision, you should carefully consider the risks described below and discussed in the
section titled "Risk Factors" in our most recent Annual Report on Form&nbsp;10-K, as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms&nbsp;10-K,
10-Q and 8-K and in other documents incorporated by reference in this prospectus. We expect to update these Risk Factors from time to time in the periodic and current reports that we file with the SEC
after the date of this prospectus. These updated Risk Factors will be incorporated by reference in this prospectus.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our common stock
could decline due to any of these risks, and you may lose all or part of your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and
uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition results of operations and
prospects. Certain statements below are forward-looking statements. See the information included under the heading "Special Note Regarding Forward-Looking Statements."</I></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Business  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have limited operating history, we have incurred significant operating losses since inception and we
expect to incur significant operating losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future as we
continue our clinical trial and development programs for MGL-3196 and other future product candidates. As of September&nbsp;30, 2017, we had an accumulated deficit of $98.0&nbsp;million. Losses
have principally resulted from costs incurred in our preclinical and clinical trials, research and development programs and from our general and administrative expenses. As of September&nbsp;30,
2017, we had cash, cash equivalents and marketable securities of $62.1&nbsp;million. In the future, we intend to continue to conduct research and development, clinical testing, regulatory compliance
and, if MGL-3196 or other future product candidates are approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring
further significant losses for the foreseeable future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently generate no revenue from product sales, and we may never be able to commercialize MGL-3196 or other future product candidates. We do not currently have the required
approvals to market MGL-3196 or any other future product candidates, and we may never receive them. We may not be profitable even if we or any of our future development partners succeed in
commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the
extent of any future losses or when we will become profitable, if at all. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business depends on the success of MGL-3196, which is still in clinical development and has not completed
a pivotal trial. If we are unable to obtain regulatory approval for and successfully commercialize MGL-3196, or we experience significant delays in doing so, our business will be materially harmed.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, the sole focus of our product development has been MGL-3196, a liver-directed selective thyroid hormone receptor beta agonist for
potential use in non-alcoholic steatohepatitis, or NASH, and FH. Successful continued development and ultimate regulatory approval of MGL-3196 for NASH or genetic dyslipidemias, such as FH, is
critical to the future success of our business. We have invested, and will continue to invest, a significant portion of our time and financial resources in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=379393,FOLIO='S-8',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>the
clinical development of MGL-3196. We will need to raise sufficient funds to successfully complete our clinical development program for MGL-3196 in NASH and FH. The future regulatory and commercial
success of MGL-3196 is subject to a number of risks, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not have sufficient financial and other resources to complete the necessary clinical trials for MGL-3196, including but not limited to
our currently ongoing Phase&nbsp;2 clinical trials and, later, registrational clinical trials to obtain drug approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the mechanism of action of MGL-3196 is complex and we do not know the degree to which it will translate into a therapeutic benefit, if any, in
NASH, FH or any other indication, and we do not know the degree to which the complex mechanism of action may contribute to long term safety issues or adverse events, if any, when MGL-3196 is taken for
prolonged periods such as in the treatment of NASH, FH or any other indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not be able to obtain adequate evidence from clinical trials of efficacy and safety for MGL-3196 in NASH, FH or any other indication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we do not know the degree to which MGL-3196 will be accepted as a therapy by physicians, patients and payors, even if approved; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in our clinical programs for MGL-3196, we may experience variability in patients, adjustments to clinical trial procedures and the need for
additional clinical trial sites, which could delay our clinical trial progress; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign
regulatory bodies for marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> patients in our clinical trials may die or suffer other adverse effects for reasons that may or may not be related to MGL-3196, which could
delay or prevent further clinical development; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the standards implemented by clinical or regulatory agencies may change at any time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we cannot be certain what efficacy endpoints FDA or foreign clinical or regulatory agencies may require in a Phase&nbsp;3 trial of NASH or FH
or for approval of our product candidates; we also cannot be certain if we will be able to gain accelerated approval of any of our product candidates based on surrogate endpoints; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or foreign clinical or regulatory agencies will likely require efficacy endpoints for Phase&nbsp;3 clinical trials for the treatment
of NASH or FH that differ from the endpoints of our current trials and the results of our Phase&nbsp;3 trials may not be as favorable as the results we have observed to date in our current trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if we obtain accelerated approval of a product candidate based on a surrogate endpoint, we will likely be required to conduct a post-approval
clinical outcomes trial to confirm the clinical benefit of the product candidate and if the post-approval trial is not successful we may not be able to continue marketing the product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if approved for NASH, MGL-3196 will likely compete with the off-label use of currently marketed products and other therapies in development
that may reach approval for NASH prior to MGL-3196; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if approved for FH, MGL-3196 will likely compete with currently approved and marketed products and other therapies in development that may
reach approval for FH prior to MGL-3196; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not be able to obtain, maintain or enforce our patents and other intellectual property rights. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=97147,FOLIO='S-9',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the large number of drugs in development in the pharmaceutical industry, only a small percentage results in the submission of a new drug application, or NDA, to the FDA and even
fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market MGL-3196, any such approval may be subject to limitations on the indicated uses or patient
populations for which we may market the products. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we may be unable to successfully
develop or commercialize MGL-3196. If we or any of our future development partners
are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize MGL-3196, we may not be able to generate sufficient revenue to continue our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical trials are very expensive, time-consuming and difficult to design and implement and involve
uncertain outcomes. Furthermore, the results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials,
including MGL-3196, may not have favorable results in later clinical trials or receive regulatory approval.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drug development has inherent risk. We will be required to demonstrate through adequate and well-controlled clinical trials that our product
candidates are safe and effective, with a favorable benefit-risk profile, for use in our target indications before we can seek regulatory approvals for its commercial sale. Clinical studies are
expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. Delay or failure can occur at any stage of development, including after commencement of
any of our clinical trials. In addition, success in early clinical trials does not mean that later clinical trials will be successful, because later-stage clinical trials may be conducted in broader
patient populations and involve different study designs. For instance, our Phase&nbsp;1 results and our Phase&nbsp;2 primary endpoint results in NASH may not be predictive of any future
Phase&nbsp;2 results or of results in any Phase&nbsp;3 trial in NASH. Furthermore, our future trials will need to demonstrate sufficient safety and efficacy in larger patient populations for
approval by regulatory authorities. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results, and we cannot be
certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their
product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. In addition, only a small percentage of
drugs under development result in the submission of an NDA to the FDA and even fewer are approved for commercialization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that any of our ongoing or future clinical trials will be successful, and any safety concerns observed in any one of our clinical trials in our targeted indications
could limit the prospects for regulatory approval of our product candidates in those and other indications. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because MGL-3196 has not yet received regulatory approval for any indication, it is difficult to predict the
time and cost of development and our ability to successfully complete clinical development and obtain the necessary regulatory approvals for commercialization.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGL-3196 has not yet received regulatory approval for the treatment of NASH, FH or any other indication, and unexpected problems may arise that
could cause us to delay, suspend or terminate our development efforts in any or all indications. Further, MGL-3196 has not
yet demonstrated efficacy in patients with NASH or FH, and the long-term safety consequences of a liver-directed thyroid hormone receptor beta agonist are not known. Regulatory approval of new product
candidates such as MGL-3196 can be more expensive and take longer than approval for candidates for the treatment of more well-understood diseases with previously approved products. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=553979,FOLIO='S-10',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If clinical trials or regulatory approval processes for our product candidates are prolonged, delayed or
suspended, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product
sales.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We cannot predict whether we will encounter problems with any of our completed, ongoing or planned clinical trials that will cause us or any
regulatory authority to delay, suspend, or terminate those clinical trials or delay the analysis of data derived from them. A number of events, including any of the following, could delay or impede
completely the completion of our ongoing and planned clinical trials and negatively affect our ability to obtain regulatory approval for, and to market and sell, a particular product
candidate:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conditions imposed on us by the FDA or other regulatory authorities regarding the scope or design of our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> insufficient supply of our product candidates or other materials necessary to conduct and complete our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> slow enrollment and retention rate of subjects in our clinical trials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> serious and unexpected drug-related side effects related to the product candidate being tested. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercialization
of our product candidates may be delayed by the imposition of additional conditions on our clinical trials by the FDA or any other applicable foreign regulatory
authority or the requirement of additional supportive studies by the FDA or such foreign regulatory authority. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not know whether our clinical trials will begin as planned, will need to be restructured, will enroll an adequate number of patients on time, or will be completed on schedule, if
at all. Delays in the initiation, enrollment or completion of our clinical trials will result in increased development costs for our product candidates, and our financial resources may be insufficient
to fund any incremental costs. In addition, if our clinical trials are delayed, our competitors may be able to bring products to market before we do and the commercial viability of our product
candidates could be limited. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we inadvertently fail to comply with foreign regulatory requirements governing human clinical trials and
marketing approval for drugs, we could be prevented from selling our drug candidates in foreign markets, which may adversely affect our operating results and financial condition.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement for marketing our drug candidates
outside the United States vary greatly from country to country and may require additional testing. We expect that our future clinical development of our drug candidates will involve a number of
clinical trials in foreign jurisdictions, particularly in Europe. We have no experience in obtaining foreign regulatory approvals. The time required to obtain approvals outside the United States may
differ from that required to obtain FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not guarantee approval by regulatory authorities
in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Failure to comply with these regulatory
requirements or obtain required approvals could impair our ability to develop foreign markets for our drug candidates and may have a material adverse effect on our results of operations and financial
condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=460780,FOLIO='S-11',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We depend on enrollment of patients in our clinical trials for our product candidates. If we encounter
difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. We may not be able
to initiate, continue, or complete clinical trials required by the FDA or foreign regulatory agencies for MGL-3196 if we are unable to locate and enroll a sufficient number of eligible patients to
participate in these clinical trials. Patient enrollment, a significant factor in the timing to conduct and complete clinical trials, is affected by many factors, including the size and nature of the
patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, and clinicians' and patients'
perceptions as to the potential advantages and disadvantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the
indications we are investigating. For instance, we are aware that other companies conducting clinical trials in NASH patients have had delays in recruiting patients for their trials. In the proposed
clinical trials, patient willingness to undergo a liver biopsy in our NASH trials, and identification of patients willing to participate in our FH trials due to the rarity of the disease, are also
risk factors. Potential patients for MGL-3196 may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our studies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA typically requires sponsors of lipid-lowering product candidates to conduct drug-drug interaction studies with statins because statins may have increased safety risks when
administered together with other drug therapies that affect their pharmacokinetic profile. We have completed two clinical drug interaction studies of MGL-3196 and statins in 129 subjects, which showed
MGL-3196 to have a favorable safety profile and to be well-tolerated. We have completed enrollment of a Phase&nbsp;2 clinical study in NASH including patients taking low dose statins. We have also
completed enrollment of a Phase&nbsp;2 clinical study in HeFH including patients taking high dose statins. In general, drug interactions between MGL-3196 and statins and any other drug that might
result in adverse events could delay development in later clinical trials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will be required to identify and enroll a sufficient number of patients for each of our ongoing and planned clinical trials of MGL-3196 for NASH and FH indications, respectively. We
also may encounter difficulties in identifying and enrolling NASH patients and FH patients with a stage of disease appropriate for our ongoing or future clinical trials. We may not be able to initiate
or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other foreign regulatory agencies. In
addition, the process of finding and diagnosing patients may prove costly. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or
may require us to abandon one or more clinical trials. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any product candidate in our current or future clinical trials may cause unacceptable adverse events or side
effects or have other properties that may delay or prevent its regulatory approval or commercialization or limit its commercial potential.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unacceptable adverse events or undesirable side effects caused by any of our product candidates in current or future clinical trials could
cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted
indications and markets. This in turn could prevent us from completing development of or commercializing the affected product candidate and generating revenue from its sale. If any of our product
candidates cause unacceptable adverse events in clinical trials, we may not be able to obtain regulatory approval or commercialize such product candidate. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=14,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=305914,FOLIO='S-12',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Occurrence
of serious treatment-related side effects could impede subject recruitment and clinical trial enrollment or the ability of enrolled patients to complete the trial, require us
to halt the clinical trial, and prevent receipt of regulatory approval from the FDA. They could also adversely affect physician or patient acceptance of our product candidates or result in potential
product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates will remain subject to ongoing regulatory review even if they receive marketing
approval, and if we fail to comply with continuing regulations, we could lose these approvals and the sale of any approved commercial products could be suspended.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we receive regulatory approval to market a particular product candidate, the manufacturing, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion, sampling, and record keeping related to the product will remain subject to extensive regulatory requirements. These requirements include submissions
of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP, regulations and GCPs, for any clinical trials that we conduct post-approval, all of
which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to
limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including
Phase&nbsp;4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA
may also require a REMS Program as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to
ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail to comply with the regulatory requirements of the FDA and other applicable domestic and foreign regulatory authorities, or previously unknown problems with any approved
product, manufacturer, or manufacturing process are discovered, we could be subject to administrative or judicially imposed sanctions, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions on the products, manufacturers, or manufacturing processes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> warning letters or untitled letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> civil or criminal penalties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injunctions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product seizures or detentions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pressure to initiate voluntary product recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspension or withdrawal of regulatory approvals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal to approve pending applications for marketing approval of new products or supplements to approved applications. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of these events occurs, our ability to sell such products may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could
adversely affect our business, financial condition and results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=15,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=198206,FOLIO='S-13',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_14"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We operate in a highly competitive and rapidly changing industry, and our product candidates may become
obsolete.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are engaged in a rapidly evolving field. Competition from other pharmaceutical companies, biotechnology companies and research and academic
institutions is intense and likely to increase. Many of those companies and institutions have substantially greater financial, technical and human resources than us. Those companies and institutions
also have substantially greater experience in developing products, conducting clinical trials, obtaining regulatory approval and in manufacturing and marketing pharmaceutical products. Our competitors
may succeed in obtaining regulatory approval for their products more rapidly than we do. Competitors have developed or are in the process of developing technologies that are, or in the future may be,
the basis for competitive products. Some of these competitive products may have an entirely different approach or means of accomplishing the desired therapeutic effect than products being developed by
us. Our competitors may succeed in developing products that are more effective and/or cost competitive than those we are developing, or that would render our product candidates less competitive or
even obsolete. In addition, one or more of our competitors
may achieve product commercialization or patent protection earlier than us, which could materially adversely affect our business. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or other applicable regulatory authorities approve generic products that compete with any of our
or any of our partners' product candidates, the sales of our product candidates would be adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an NDA or marketing authorization application outside the United States is approved, the product covered thereby becomes a "listed drug"
that can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application in the United States. Agency regulations and other applicable regulations and
policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an abbreviated new drug application or other application for generic
substitutes in the United States and in nearly every pharmaceutical market around the world. These manufacturers might only be required to conduct a relatively inexpensive study to show that their
product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use, or labeling, as our product and that the generic product is bioequivalent to our
product, meaning it is absorbed in the body at the same rate and to the same extent as our product. These generic equivalents, which must meet the same quality standards as branded pharmaceuticals,
would be significantly less costly than our product to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the
introduction of a generic competitor, a significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our
product or any of our partners' future products, if any, would materially adversely affect our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on
the investments we have made and expect to make in our or any of our partners' product candidates, including MGL-3196. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition
that our or any of our partners' products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash
flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If physicians and patients do not accept our future products or if the market for indications for which any
product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if any of our product candidates obtain regulatory approval, they may not gain market acceptance among physicians, patients, and
third-party payers. Efforts to educate the medical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=16,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=19030,FOLIO='S-14',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<A NAME="page_da42401_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>community
and third-party payers on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates do not achieve an adequate
level of acceptance, we may not generate significant product revenue or any profits from operations. Physicians may decide not to recommend its treatments for a variety of reasons
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> timing of market introduction of competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> demonstration of clinical safety and efficacy compared to other products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cost-effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> limited or no coverage by third-party payers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> convenience and ease of administration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> prevalence and severity of adverse side effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions in the label of the drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other potential advantages of alternative treatment methods; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> ineffective marketing and distribution support of its products. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates are approved, but fail to achieve market acceptance or such market is smaller than anticipated, we may not be able to generate significant revenue and
our business would suffer. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As we evolve from a company that is primarily involved in clinical development to a company that is also
involved in commercialization, we may encounter difficulties in expanding our operations successfully.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As we advance our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, and marketing
and sales capabilities and may need to further contract with third parties to provide these capabilities. As our operations expand, we likely will need to manage additional relationships with such
third parties, as well as additional collaborators, distributors, marketers and suppliers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintaining
third party relationships for these purposes will impose significant added responsibilities on members of our management and other personnel. We must be able to effectively
manage our development efforts; recruit and train sales and marketing personnel, effectively manage our participation in the clinical trials in which our product candidates are involved and improve
our managerial, development, operational and finance systems, all of which may impose a strain on our administrative and operational infrastructure. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we enter into arrangements with third parties to perform sales, marketing or distribution services, any product revenues that we receive, or the profitability of these product
revenues to us, are likely
to be lower than if we were to market and sell any products that we develop without the involvement of these third parties. In addition, we may not be successful in entering into arrangements with
third parties to sell and market our products or in doing so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the
necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third
parties, we will not be successful in commercializing our products. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=17,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=395882,FOLIO='S-15',FILE='DISK128:[17ZDN1.17ZDN42401]DA42401A.;9',USER='CHE108065',CD='16-DEC-2017;19:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc42401_1_16"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The uncertainty associated with pharmaceutical reimbursement and related matters may adversely affect our
business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market acceptance and sales of any one or more of our product candidates will depend on reimbursement policies and may be affected by future
healthcare reform measures in the United&nbsp;States and in foreign jurisdictions. Government authorities and third-party payers, such as private health insurers and health maintenance
organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that reimbursement will be available for any of our product candidates. Also, we cannot be certain
that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, we may not be able to
successfully commercialize any product candidates that we develop. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and
pays
for pharmaceutical products. The legislation established Medicare Part&nbsp;D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for
limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. The
United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our
ability to sell our products profitably. Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has
been significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develops due to the trend toward managed
healthcare, the increasing influence of health maintenance organizations, and additional legislative proposals. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2010, the ACA became law in the United States. The goal of ACA is to reduce the cost of healthcare and substantially change the way healthcare is financed by both government
and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, the ACA may result in downward
pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receives regulatory approval. We also cannot
predict the impact of ACA on us as many of the ACA reforms require the promulgation of detailed regulations implementing the statutory provisions, which have not yet been fully implemented. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If any product liability lawsuits are successfully brought against us or any of our collaborative partners,
we may incur substantial liabilities and may be required to limit commercialization of our product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients and will face
an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our partners by participants
enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any
such claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> decreased demand for any of our future approved products; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=913553,FOLIO='S-16',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injury to our reputation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> termination of clinical trial sites or entire trial programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> significant litigation costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> substantial monetary awards to or costly settlements with patients or other claimants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product recalls or a change in the indications for which products may be used; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> diversion of management and scientific resources from our business operations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be
adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are
asserted to be, harmful to patients. Also, because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients' use or
misuse of our products or any similar products distributed by other companies could have a material adverse impact on our results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not currently hold product liability insurance coverage. Prior to commercialization of our product candidates, we will need to purchase insurance coverage. As a result, we may be
unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. These liabilities could prevent or
interfere with our product development and commercialization efforts. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance
coverage, could decrease our cash resources and adversely affect our business, financial condition and results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees, contractors, vendors and partners may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements and insider trading.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of fraud or other misconduct by our employees, contractors, vendors or partners. Misconduct by these parties could
include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial
information or data timely, completely or accurately, or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to
extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Third-party misconduct could also involve the improper use of information obtained
in the course of
clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and
deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us resulting from this misconduct and we are </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=71486,FOLIO='S-17',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_18"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We enter into various contracts in the normal course of our business in which we indemnify the other party to
the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other
agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from
claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our potential
sublicensees' exercise of rights under the agreement. With respect to our commercial agreements, we indemnify our vendors from any third-party product liability claims that could result from the
production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
our obligation under an indemnification provision exceed applicable insurance coverage or if we are denied insurance coverage, our business, financial condition and results of
operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the
applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to develop and commercialize other product candidates, we may be unable to grow our business.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although the development and commercialization of MGL-3196 is our primary focus, as part of our longer-term growth strategy, we plan to
evaluate the development and commercialization of other therapies related to thyroid hormone, orphan and other diseases. We will evaluate internal opportunities from our compound libraries, and also
may choose to in-license or acquire other product candidates as well as commercial products to treat patients suffering from thyroid hormone, orphan or other disorders with high unmet medical needs
and limited treatment options. These other product candidates may require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and
approval by the FDA and/or applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the
possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are
approved will be manufactured or produced economically, be successfully commercialized, be widely accepted in the marketplace, or be more effective than other commercially available alternatives. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our
ability to identify, develop and commercialize products will be impaired.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on principal members of our management team, including our Chief Executive Officer, Paul A. Friedman, M.D., and our
Chief Medical Officer, Rebecca Taub, M.D. These executives each have significant pharmaceutical industry experience. The loss of any member of our management team or scientific staff, including Drs.
Friedman and Taub, would impair our ability to identify, develop and market new products. Our management and other employees may </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=150876,FOLIO='S-18',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>voluntarily
terminate their employment with us at any time. The loss of the services of these or other key personnel, or the inability to attract and retain additional qualified personnel, could
result in delays to development or approval, loss of sales and diversion of management resources. In addition, we depend on our ability to attract and retain other highly skilled personnel.
Competition for qualified personnel is intense, and the process of hiring and integrating such qualified personnel is often lengthy. We may be unable to recruit such personnel on a timely basis, if at
all, which would negatively impact our development and commercialization programs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
we do not currently maintain "key person" life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not receive
adequate compensation for the loss of the services of these individuals. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have no marketing, sales or distribution infrastructure with respect to our product candidates.
If we are unable to develop our sales, marketing and distribution capabilities on our own or through collaborations with marketing partners, we will not be successful in commercializing our product
candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no marketing, sales or distribution capabilities and have limited sales or marketing experience within our organization. If
our product candidate, MGL-3196, is approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize
MGL-3196, or to outsource this function to a third party. Either of these options would be expensive and time-consuming. Some or all of these costs may be incurred in advance of any approval of
MGL-3196. In addition, we may not be able to hire a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure
or delay in the development of our internal sales, marketing and distribution capabilities would adversely affect the commercialization of MGL-3196 and other future product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to
augment our own sales force and distribution systems or as an alternative to our own sales force and distribution systems. To the extent that we enter into co-promotion or other licensing
arrangements, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these
third parties, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully
commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product
revenue will suffer and we may incur significant additional losses. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain FDA approval of MGL-3196 or any other future product candidate, we or our partners may
never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of
other countries regarding clinical trial design, safety and efficacy. Clinical trials conducted in one country may not
be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary
among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays,
difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to
country and could delay or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=598685,FOLIO='S-19',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>prevent
the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition,
our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We and our partners do not have any product
candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our partners fail
to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of
our products will be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation by extending
the term of patents covering each of our product candidates, our business may be materially harmed.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States
patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory
review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable
requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the
period during which we can enforce our patent rights for that product may not extend beyond the current patent expiration dates and our competitors may obtain approval to market competing products
sooner. As a result, our revenue could be potentially materially reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our
clinical and preclinical data and launch their product earlier than might otherwise be the case. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicable, and
even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our strategy includes filing for orphan drug designation where available for our product candidates. Under the Orphan Drug Act, the FDA may
grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States,
or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United
States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee
waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan
drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not obtained orphan designation for any product candidates to date, although we believe some of the potential indications of our product candidates could qualify for orphan drug </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=22,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=274540,FOLIO='S-20',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>designation
and the related benefits if approved for such indications and we may file for orphan drug designation with respect to such indications. Even if we obtain such designations, we may not be
the first to obtain regulatory approval of a product candidate for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive
marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for
designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the orphan-designated disease or condition. Further, even if
we obtain orphan drug designation exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may
receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is
approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer,
more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any
advantage in the regulatory review or approval process. In addition, while we may seek orphan drug designation for our product candidates, we may never receive such designations. Failure to obtain an
orphan drug designation for our product candidates may have a material adverse effect on our business, results of operations and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we or our partners market products in a manner that violates fraud and abuse and other healthcare laws, or
if we or our partners violate government price reporting laws, we or our partners may be subject to administrative civil and/or criminal penalties.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we do not currently have any products on the market, if we obtain FDA approval for our product candidates, and begin commercializing
those products in the United States, our operations may be directly, or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws
and regulations. These laws include, among others, the U.S. federal Anti-Kickback Statute and the U.S. federal civil and criminal false claims laws. At such time, if ever, as we or any of our partners
market any of our future approved products, it is possible that some of our business activities and/or our partners could be subject to challenge under one or more of these laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal
false claims, false statements and civil monetary penalties laws prohibit, among others, any person from knowingly presenting, or causing to be presented, a false claim for
payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program Anti-Kickback Statute prohibits, among other
things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any
healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common
activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to
scrutiny if they do not qualify for an exception or safe harbor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we and/or our partners may be subject to patient data privacy and security regulation, including the Health Insurance Portability and Accountability Act of 1996, as amended
by the Health Information Technology for Economic and Clinical Health Act, and their respective </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=23,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=740066,FOLIO='S-21',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>implementing
regulations, which impose specified requirements relating to the privacy, security and transmission of individually identifiable health information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most
states also have statutes or regulations similar to these federal laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. We
and/or our partners may be subject to administrative, civil and criminal sanctions for violations of any of these federal and state laws. Pharmaceutical and other healthcare companies have been
prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to
prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting
inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is
possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and
abuse or other healthcare laws and regulations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the third parties on which we rely for the conduct of our clinical trials and results do not perform our
clinical trial activities in accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for or commercialize our product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We use third-party service providers to conduct and/or oversee the clinical trials of our product candidates and expect to continue to do so
for the foreseeable future. We rely heavily on these parties for successful execution of our clinical trials. Nonetheless, we are responsible for confirming that each of our clinical trials is
conducted in accordance with FDA requirements and our general investigational plan and protocol. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA requires us and our third-party service providers to comply with regulations and standards, commonly referred to as good clinical practices, or GCP, for conducting, recording
and reporting the results of clinical trials to assure that data and reported results are credible and accurate, and that the trial participants are adequately protected. Our reliance on third parties
that we do not control does not relieve us of these responsibilities and requirements. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with
regulatory or GCP requirements or the respective trial plans and protocols. In addition, third parties
may not be able to repeat their past successes in clinical trials. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and
commercialization of our product candidates or result in enforcement action against us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our relationship with these third-party providers terminates, we may not be able to enter into arrangements with alternative providers or do so on commercially reasonable terms.
Switching or adding additional third-party providers involves substantial cost and requires management time and focus, and could delay development and commercialization of our product candidates.
Though we intend to carefully manage our relationships with our third-party providers, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or
challenges will not have a negative impact on our business and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have relied on, and expect to continue to rely on, third-party manufacturers to produce our product
candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we
lack the resources and the capabilities to do so. As a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=24,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=368043,FOLIO='S-22',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>result,
we currently rely, and expect to rely for the foreseeable future, on third-party manufacturers to supply our product candidates. Reliance on third-party manufacturers entail risks to which we
would not be subject if we manufactured our product candidates or products ourselves, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reliance on third-parties for manufacturing process development, regulatory compliance and quality assurance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> limitations on supply availability resulting from capacity and scheduling constraints of third-parties; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the possible breach of manufacturing agreements by third-parties because of factors beyond our control; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the possible termination or non-renewal of manufacturing agreements by third-parties, at a time that is costly or inconvenient to us. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our
ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers, we may not be able to enter into
agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign regulatory
authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding foreign regulators also inspect these facilities
to confirm compliance with current good manufacturing practices, or cGMPs. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment
delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, European Medicines
Agency, or EMA, and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products
following approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop our
product candidates and commercialize any products that receive regulatory approval on a timely basis. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We previously identified a material weakness in our internal control over financial reporting and may
identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or
cause us to fail to meet our reporting obligations or fail to prevent fraud; and in that case, our stockholders could lose confidence in our financial reporting, which would harm our business and
could negatively impact the price of our stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we fail to maintain an effective
system of internal controls, we may be unable to report our financial results accurately or prevent fraud; and in that case, our stockholders could lose confidence in our financial reporting, which
would harm our business and could negatively impact the price of our stock. On March&nbsp;31, 2017, we filed with the SEC an amendment to our Quarterly Report on Form&nbsp;10-Q for the quarter
ended September&nbsp;30, 2016 to correct certain errors therein. Management reported a material weakness in our system of internal control over financial reporting as of September&nbsp;30, 2016. A
material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=25,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=586036,FOLIO='S-23',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<A NAME="page_dc42401_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>misstatement
of our annual or interim financial statements will not be prevented or detected on a timely basis. We remediated this material weakness. We cannot assure you that the measures we have
taken to date will be sufficient to avoid future material weaknesses. Even when we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, because of its inherent limitations, internal control over financial reporting may not
prevent or detect fraud or misstatements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
reporting obligations as a public company will require significant managerial, operational and financial resources for the foreseeable future. If we fail to maintain the adequacy of
our internal control over financial reporting, we may not be able to produce reliable financial reports or help prevent fraud. Our failure to maintain effective internal control over financial
reporting could prevent us from filing our periodic reports on a timely basis which could result in the loss of investor confidence in the reliability of our financial statements, harm our business
and negatively impact the trading price of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Relating to Our Intellectual Property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our rights to develop and commercialize our product candidates are subject in part to the terms and
conditions of a license to MGL-3196 granted to us by Roche.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a research, development and commercialization agreement, or the Roche Agreement, with Hoffmann-La Roche Pharmaceutical Company
Limited, or Roche, on December&nbsp;18, 2008. Pursuant to the terms of the Roche Agreement, we assumed control of all development and commercialization of MGL-3196 and hold exclusive worldwide
rights for all potential indications. Under the license agreement, Roche exclusively licensed certain patent rights and know-how relating to MGL-3196 in exchange for consideration consisting of an
upfront payment, milestone payments tied to the achievement of product development and regulatory milestones, and royalty payments based on net sales of products containing MGL-3196 or another
licensed product, subject to certain reductions. We must use commercially reasonable efforts to conduct clinical and commercial development programs for products containing MGL-3196. If we determine
that it is not reasonable to continue clinical trials or other development of MGL-3196, we may elect to cease further development and Roche may terminate the license. If we determine not to pursue the
development or commercialization of MGL-3196 in certain jurisdictions, including the United States, Roche may terminate the license for such territories. The Roche Agreement will expire, unless
earlier terminated pursuant to other provisions of the agreement, on the last to occur of (i)&nbsp;the expiration of the last valid claim of a licensed patent covering the manufacture, use or sale
of products containing MGL-3196, or (ii)&nbsp;ten years after the first sale of a product containing MGL-3196. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Roche Agreement, Roche controls prosecution of the licensed patent rights, although we have a right to comment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have, nor have we had, any material disputes with Roche regarding the Roche Agreement. However, if there is any future dispute between us and Roche regarding the parties'
rights under the Roche Agreement, our ability to develop and commercialize MGL-3196, or any other product candidate covered by the Roche Agreement, may be materially harmed. Any uncured, material
breach under the Roche Agreement could result in our loss of exclusive rights to MGL-3196 and may lead to a complete termination of the Roche Agreement and force us to cease product development
efforts for MGL-3196. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=26,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=950669,FOLIO='S-24',FILE='DISK128:[17ZDN1.17ZDN42401]DC42401A.;9',USER='CHE109867',CD='16-DEC-2017;19:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de42401_1_25"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to comply with any of our obligations under agreements pursuant to which we license rights or
technology, which could result in the loss of rights or technology that are material to our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may enter into license agreements from time to time. Licensing of intellectual property is important to our business and involves complex
legal, business and scientific issues. Disputes may arise regarding intellectual property subject to a license agreement, including but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope of rights granted under the license agreement and other interpretation-related issues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the sublicensing of patent and other rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our licensors and
collaborators; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the priority of invention of patented technology. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our success depends on our ability to protect our intellectual property and our proprietary technologies.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends on our ability to protect our intellectual property and our proprietary technologies. Our commercial success depends in
part on our ability to obtain and
maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses, as well as our ability to operate without infringing upon the proprietary
rights of others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
can provide no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient
protection against competitors with similar technologies, nor can we provide any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued
patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our
proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly
protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations. Composition-of-matter patents on
the biological or chemical active pharmaceutical ingredients are generally considered to offer the strongest protection of intellectual property and provide the broadest scope of patent protection for
pharmaceutical products, as such patents provide protection without regard to any method of use or any method of manufacturing. While we have licensed rights to issued composition-of-matter patents in
the United States and other jurisdictions for MGL-3196, we cannot be certain that the claims in issued composition-of-matter patents will not be found invalid or unenforceable if challenged. We cannot
be certain that the claims in owned and licensed patent applications covering our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, and valid
by courts in the United States or by the patent offices and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=104347,FOLIO='S-25',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>courts
in foreign jurisdictions. Even if we owned and licensed patent applications covering our product candidates, the patents may not be enforced against competitors. For example, a formulation
patent will not be enforced against those making and marketing a product that has the same active pharmaceutical ingredient in a different formulation that is not claimed in the formulation patent.
Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. This type of patent may not be enforced against competitors making and
marketing a product that has the same active pharmaceutical ingredient but is used for a method not claimed in the patent. Moreover, even if competitors do not actively promote their product for our
targeted indications, physicians may prescribe these products "off-label." Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is
common and such infringement is difficult to prevent or prosecute. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
licensed composition-of-matter patent licensed from Roche for MGL-3196 is expected to expire in the United States in 2026. Our co-owned patents and pending patent applications that
cover our particular solid form, dosage, method of manufacturing, and uses of MGL-3196 to treat various indications are expected to expire in 2033. While patent term adjustments or patent term
extensions could result in later expiration dates for each of these patents, there can be no assurances that we will receive any patent adjustments or patent term extensions. The patent application
process and
patent maintenance and enforcement are subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our
product candidates by obtaining and defending patents. These risks and uncertainties include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
provisions during the patent process and after a patent has issued. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> patent applications may not result in any patents being issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive
advantage; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> us and our licensor(s) may not have been the first to make the inventions covered by pending patent applications or issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> us and our licensor(s) may not have been the first to file patent applications for our product candidates or the compositions developed, or for
their uses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may independently develop identical, similar or alternative products or compositions and uses thereof; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> us and our licensor(s)' disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may design around our owned and licensed patent claims to produce competitive products which fall outside of the scope of the patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may identify prior art or other bases which could invalidate our or licensor(s)' patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from
patent infringement claims for certain research and development activities, as well as in countries where us and our licensor(s) do </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=997328,FOLIO='S-26',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>not
have patent rights, and then use the information learned from such activities to develop competitive products for sale in major commercial markets; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> there may be significant pressure on the United States government and international governmental bodies to limit the scope of patent protection
both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing
foreign competitors a better opportunity to create, develop and market competing product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we rely on the protection of our trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets and unpatented know-how, including
entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that any
of these parties would not breach the agreements to disclose any proprietary information, including trade secrets, and we may not be able to obtain adequate remedies for such breaches. Further, third
parties may still obtain this information by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Moreover, third parties may come upon this or similar information lawfully and independently. We would have no
right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. Further, intellectual property rights have limitations and do not necessarily
address all potential threats to our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, our business may be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a
number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the
Leahy-Smith Act, the United States transitioned in March 2013 to a "first inventor to file" system in which the first inventor to file&nbsp;a patent application will be entitled to the patent. Third
parties are allowed to submit prior art before the issuance of a patent by the USPTO, and a patent may become subject to post-grant proceedings including opposition, derivation, reexamination, </FONT> <FONT SIZE=2><I>inter partes</I></FONT><FONT
SIZE=2> review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such
submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Claims by third parties that we infringe their proprietary rights may result in liability for damages or
prevent or delay our developmental and commercialization efforts.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S.
and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands
and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained
in secrecy until the application is published, we may be unaware of third party patents that may be infringed by commercialization of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=727442,FOLIO='S-27',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>MGL-3196
or our other product candidates. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents
that our product candidates may infringe. In addition, identification of third party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to
differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time
consuming and could likely:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> result in costly litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> divert the time and attention of our technical personnel and management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cause development delays; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> prevent us from commercializing MGL-3196 for NASH or FH or our other product candidates until the asserted patent expires or is held finally
invalid or not infringed in a court of law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require us to enter into royalty or licensing agreements. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
no third party has asserted a claim of patent infringement against us as of the filing date of this report, others may hold proprietary rights that could prevent MGL-3196 or
our other product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes
could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market MGL-3196 or our other product candidates. We cannot predict whether we would
prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could
redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary
licenses, could prevent us from developing and commercializing MGL-3196 or our other product candidates, which could harm our business, financial condition and operating results. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
we may be subject to a third party preissuance submission of prior art to the USPTO or in addition to interference proceedings, may become involved in opposition, derivation,
reexamination, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, post-grant review or other post-grant proceedings challenging our patent rights or the patent rights of others. An
adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and
compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or
strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future
product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could
be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we or any of our future development partners were to initiate legal proceedings against a third party to enforce a patent directed at one of
our product candidates, or one of our future product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=55527,FOLIO='S-28',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness,
non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information
from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the
patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interference
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or
patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our
business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful,
may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise
the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring
our product candidates to market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of
our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in obtaining or maintaining necessary rights to our product candidates through
acquisitions and in-licenses.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have rights to the intellectual property, through licenses from third parties and under patents that we own or co-own, to develop
our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or
use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We
may be unable to acquire or in-license any compositions, methods of use, processes, or other third party intellectual property rights from third parties that we identify as necessary for our product
candidates. The licensing and acquisition of third party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or
acquire third party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater
clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license
or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may collaborate with U.S. and foreign academic institutions and industry collaborators to accelerate our preclinical or clinical research. Typically, these institutions provide us
with an option </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=695863,FOLIO='S-29',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>to
negotiate a license to any of the institution's rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified
timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue
our program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon
development of that program and our business and financial condition could suffer. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a
competitor will discover them or that our trade secrets will be misappropriated or disclosed.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to research and develop and to manufacture our product candidates, we must, at times, share trade secrets with
them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar
agreements with our advisors, employees, third party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets
and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in
violation of these agreements. Any of these could impair our competitive position. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, these agreements typically restrict the ability of our advisors, employees, third party contractors and consultants to publish data potentially relating to our trade
secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future will usually expect to be granted
rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure
patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. In the
future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts
to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any
of our third party collaborators. A competitor's discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be
infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of
interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there
could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or
trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade
names, then we may not be able to compete effectively and our business may be adversely </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=32,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=84664,FOLIO='S-30',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>affected.
Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in
substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we have licensed from Roche issued composition-of-matter patents directed at MGL-3196 in the United States and other countries, filing,
prosecuting and defending patents on MGL-3196 in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States
can be less extensive than those in the United States. In addition, the laws of some foreign countries may not protect intellectual property rights to the same extent as federal and state laws in the
United States. Consequently, we may not be able to prevent third parties from practicing their inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products
and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with
MGL-3196, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and
our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Position and Need for Capital  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to obtain the capital necessary to fund our operations, we will be unable to successfully develop
and commercialize MGL-3196 and other future product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we believe that our existing cash and cash equivalents will be sufficient to fund our current operations through at least the next
12&nbsp;months, we will require substantial future working capital in order to complete the remaining clinical development for MGL-3196 and our other product candidates through potential regulatory
approval and through potential commercialization of these product candidates. In particular, in order to initiate our Phase&nbsp;3 clinical program for MGL-3196 in NASH, we will need to collaborate
with a strategic partner or raise significant financing. We expect our spending levels to increase in connection with our clinical trials of MGL-3196 as well as other corporate activities. The amount
and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the type, number, scope, progress, expansion costs, results of and timing of our ongoing or future clinical trials or the need for additional
clinical trials of MGL-3196 for NASH and FH or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=33,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=823077,FOLIO='S-31',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>any
of our other product candidates which we are pursuing or may choose to pursue in the future; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs and timing of obtaining regulatory approval for MGL-3196 for NASH and FH and any of our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs and timing of obtaining or maintaining manufacturing for MGL-3196 for NASH and FH and any of our other product candidates, including
commercial manufacturing if any product candidate is approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs and timing of establishing sales, marketing and reimbursement capabilities and enhanced internal controls over financial reporting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the terms and timing of establishing and maintaining collaborations, license agreements and other partnerships; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs associated with any new product candidates that we may develop, in-license or acquire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effect of competing technological and market developments; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the costs associated with operating as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and
commercialization of our product candidates. We expect that we will need to raise substantial additional funds in the future. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through future debt and
equity financings, as well as potential additional collaborations or strategic partnerships with other companies or through non-dilutive financings. Additional funding may not be available to us on
acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. In addition, the issuance of additional shares by us, or the
possibility of such issuance, may cause the market price of our shares to decline. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to obtain additional funding on a timely basis, we may be unable to complete ongoing and planned clinical trials for MGL-3196 for NASH and FH and any of our other
product candidates, and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise
that may require us to relinquish rights to our product candidates or otherwise agree to terms unfavorable to us. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce
future tax payments may be limited by provisions of the Internal Revenue Code.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net operating losses have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax
benefits. Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an "ownership change" (generally
defined as a greater than 50% change (by value) in its equity ownership over a three year period), the corporation's ability to use its pre-change net operating loss carryforwards and other pre-change
tax attributes to offset its post-change income may be limited. Similar rules may apply under state tax laws. We have not performed a detailed analysis to determine whether an ownership change under
Section&nbsp;382 of the Code, or similar state provisions, has previously occurred. As a result, if </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=34,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=562877,FOLIO='S-32',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_33"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>we
earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result
in increased future tax liability to us and may be substantial. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Relating to Ownership of Our Common Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock has been, and may continue to be, volatile.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, the market price of our common stock has fluctuated over a wide range, and it is likely that the price of our common stock will
continue to be volatile in the future. The market price of our common stock could be impacted due to a variety of factors, including, in addition to global and industry-wide
events:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the losses we may incur; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developments in patent or other proprietary rights owned or licensed by us, our collaborative partners or our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> public concern as to the safety and efficacy of products developed by us or others; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> litigation. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, due to one or more of the foregoing factors in one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors.
In that event, the market price of our common stock could materially decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A small number of our stockholders beneficially own a substantial amount of our common stock and have
substantial control over us; therefore, your ability to influence corporate matters may be limited.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain stockholders affiliated with our officers and directors collectively beneficially own or control approximately 51.1% of our outstanding
common stock as of September&nbsp;30, 2017 and acting together, may have the ability to affect matters submitted to our stockholders for approval. This concentration of ownership may have the effect
of delaying, deferring or preventing a strategic transaction, even if such a transaction would benefit other stockholders. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our
company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our charter and bylaws may delay or prevent a merger, acquisition or other change of control that stockholders may consider
favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions include a classified board of directors. In addition, we are governed by the
provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or
combining with us. Although we believe these provisions together provide for an opportunity to receive higher bids by
requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future sales and issuances of our common stock or rights to purchase common stock could result in additional
dilution of the percentage ownership of our stockholders and could cause our share price to fall.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise
additional capital by issuing equity securities, our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=35,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=771021,FOLIO='S-33',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stockholders
may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also
result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock in the public market could cause our stock price
to fall.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market by us, by our existing stockholders, or by our holders of
Series&nbsp;A Convertible Preferred Stock upon conversion or the perception that these sales might occur, could significantly reduce the market price of our common stock and impair our ability to
raise adequate capital through the sale of additional equity securities. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not anticipate paying cash dividends on our common stock, and accordingly, stockholders must rely on
stock appreciation for any return on their investment.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividend on our common stock and do not anticipate paying cash dividends on our common stock in the
future. As a result, the only return to stockholders will be appreciation in the price of our common stock, which may never occur. Investors seeking cash dividends should not invest in our common
stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Stockholders' Sales of Shares, Including Those Issued under the Securities Purchase
Agreement  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a significant number of shares of our common stock in the public markets or significant short sales
of our common stock, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;30, 2017, there were 1,969,797&nbsp;shares of Series&nbsp;A Convertible Preferred stock outstanding, all of which
are readily convertible into common stock at the option of the holders. In addition, there are an additional 991,711&nbsp;shares of our common stock issuable upon the exercise of outstanding stock
options. Sales of a substantial number of shares of our common stock or other equity-related securities in the public markets, could depress the market price of our common stock. If there are
significant sales or short sales of our stock, the price decline that could result from this activity may cause the share price to decline further, which, in turn, may cause long holders of the common
stock to sell their shares, thereby contributing to sales of common stock in the market. Such sales also may impair our ability to raise capital through the sale of additional shares in the future at
a time and price that our management deems acceptable, if at all. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to This Offering  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Investors in this offering will pay a much higher price than the book value of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you purchase common stock in this offering, you will incur an immediate and substantial dilution of $70.73 per share after giving effect to
the sale by us of 1,506,025 shares of our common stock offered in this offering at the public offering price of $83.00 per share, and after deducting underwriting discounts and commissions for shares
sold in the public offering. See "Dilution." To the extent outstanding options or warrants we have issued are ultimately exercised, you will incur additional dilution. Furthermore, if the underwriters
exercise their option to purchase additional shares, you will also incur additional dilution. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=36,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=312612,FOLIO='S-34',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<A NAME="page_de42401_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our management will have broad discretion over the use of the net proceeds from this offering; you may not
agree with how we use the proceeds and the proceeds may not be invested successfully.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management will have broad discretion as to the use of the net proceeds from this offering by us and could use them for purposes other than
those contemplated at the time of this offering. Accordingly, you may be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity,
as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any,
return for us. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of additional shares of our common stock, including by us or our directors, officers and significant
stockholders following expiration or early release of the 90&nbsp;day lock up, could cause the price of our common stock to decline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of substantial amounts of our common stock in the public market, or the availability of such shares for sale, by us or others, including
the issuance of common stock upon exercise of outstanding options or upon the conversion of our Series&nbsp;A Convertible Preferred Stock, could adversely affect the price of our common stock. Based
on the total number of outstanding shares of our common stock as of September&nbsp;30, 2017, upon completion of this offering, we will
have outstanding 14,001,730 shares of common stock (or 14,227,634 shares of common stock if the underwriters exercise their option to purchase additional shares in full). In connection with this
offering, we, our directors and officers and certain of our significant stockholders have entered into lock-up agreements with the underwriters under which we, our directors and officers and
significant stockholders have agreed, subject to specific exceptions described in the section titled "Underwriting", not to sell, directly or indirectly, any shares of common stock without the
permission of Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC for a period of 90&nbsp;days following the date of this prospectus. Upon expiration or earlier release of the lock-up, we, our directors or
officers or significant stockholders may sell shares into the market, which could adversely affect the market price of shares of our common stock. Sales of a substantial number of such shares upon
expiration of the lock-up agreements, the perception that such sales may occur, or early release of these agreements, could cause our market price to fall or make it more difficult for you to sell
your common stock at a time and price that you deem appropriate. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax reform may significantly affect our operations and stockholders.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Trump Administration and the U.S.&nbsp;Congress are close to passing substantial revisions to U.S. federal income tax law, and such
revisions could significantly impact our company and the tax treatment of our operating results. There is substantial uncertainty around the likelihood, timing and details of any such tax reform being
enacted, but any such reform, if enacted, could have a significant impact on our company and its stockholders. Potential investors should consult their tax advisors about such developments, and their
potential impact before investing in our securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=37,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=735210,FOLIO='S-35',FILE='DISK128:[17ZDN1.17ZDN42401]DE42401A.;9',USER='CHE109868',CD='18-DEC-2017;21:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg42401_1_36"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg42401_business"> </A>
<A NAME="toc_dg42401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the
treatment of cardiovascular, metabolic and liver diseases. Our lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor-&szlig;, or
THR-&szlig;, agonist that can potentially be used to treat a number of disease states with high unmet medical need. THR-&szlig; is known to regulate cholesterol and triglyceride
metabolism, which we believe suggests potential therapeutic benefits for patients suffering from hypercholesterolemia, genetic dyslipidemias and diseases resulting from accumulation of fat in liver
tissue, such as non-alcoholic steatohepatitis, or NASH. Based on scientific publications in human and animal studies, we believe that human NASH livers have a deficiency in THR-&szlig; activity
that leads to features of NASH including fatty liver, inflammation and fibrosis, and that treatment with MGL-3196 may potentially replace this hormone deficiency and be an effective NASH treatment. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 is a first-in-class, highly selective, liver-directed THR-&szlig; agonist. We are developing MGL-3196 for NASH and we have initiated a Phase&nbsp;2
clinical trial in this indication. We are also developing MGL-3196 for dyslipidemia, particularly genetic dyslipidemias such as familial hypercholesterolemia, or FH, including both homozygous and
heterozygous forms of the disease. We have initiated a Phase&nbsp;2 clinical trial in heterozygous FH, or HeFH, patients and we are planning to conduct a proof-of-concept clinical trial in
homozygous FH, or HoFH, patients. MGL-3196 is a once-daily oral pill that has been studied in four completed Phase&nbsp;1 trials in a total of 129 subjects. MGL-3196 appeared to be safe and
well-tolerated in these trials, which included a single ascending dose trial, a multiple ascending dose trial, and two drug interaction trials with statins. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the multiple ascending dose Phase&nbsp;1 clinical trial in healthy volunteers with mildly elevated low-density lipoprotein cholesterol, or LDL-C, the administration of MGL-3196 in
once daily doses of up to 200 mg per day for 14&nbsp;days demonstrated statistically significant reductions of LDL-C, apolipoprotein B, or apoB, and non-high density lipoprotein cholesterol, or
non-HDL-C, of up to 30%, and a reduction of triglycerides, or TG, of up to 60%. Increased levels of LDL-C, commonly known as "bad cholesterol", apoB and non-HDL-C are each strongly associated with
increased risk of heart disease. The lipid parameter reductions observed with MGL-3196 treatment occurred rapidly in the trial, becoming apparent within the first few days of dosing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=407073,FOLIO='S-36',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_dg42401_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following chart summarizes the status of our product candidate development programs for MGL-3196 and MGL-3745, a preclinical compound which has similar thyroid receptor selectivity
to MGL-3196 and is thus a potential backup compound for MGL-3196: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g343675.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="306">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Developments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recently announced top-line results from our Phase&nbsp;2 clinical trial in NASH. In this trial, MGL-3196 demonstrated statistically
significant results for the primary endpoint, the percent change in hepatic fat versus placebo as measured by MRI-PDFF, a non-invasive imaging test at 12&nbsp;weeks. Recent published data have shown
a high correlation of the reduction of liver fat of 30% or more as measured by MRI-PDFF to improvement in NASH on liver biopsy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statistically
significant reductions in alanine aminotransferase, or ALT, and aspartate aminotransferase, or AST, were observed in MGL-3196 treated patients; greater reductions in ALT
and AST, statistically significant relative to placebo, were observed in the pre-specified group with relatively higher MGL-3196 drug levels. In drug-treated relative to placebo patients,
statistically significant improvements were also seen in multiple secondary endpoints considered to be potentially clinically relevant in patients with NASH including LDL-C, triglycerides,
apolipoprotein B (ApoB), and Lp(a). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGL-3196
has been well-tolerated with mostly mild adverse events, or AEs, and a few moderate AEs, the numbers of which are balanced between placebo and drug-treatment groups. There are
no adverse effects of MGL-3196 on safety laboratory or vital sign parameters. There have been three serious adverse effects in the study, all considered unrelated to MGL-3196. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
on-going clinical trial remains blinded. Safety, efficacy of NASH resolution by biopsy, and repeat MRI-PDFF will be assessed at 36&nbsp;weeks. Multiple inflammatory and fibrosis
serum biomarkers at 12 and 36&nbsp;weeks are being and will be assessed, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lead Product Candidate&nbsp;&#151; MGL-3196  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Active thyroid hormone, known as T3, interacts with two nuclear receptors, THR-<FONT FACE="SYMBOL">a</FONT>, which is the
predominant receptor expressed in most human tissues, including heart and bone, and THR-<FONT FACE="SYMBOL">b</FONT>, which has more restricted tissue expression, and is the predominant
receptor responsible for metabolic actions in the liver, including both cholesterol- and TG-lowering. Selective activation of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=426924,FOLIO='S-37',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_dg42401_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
THR-&szlig; receptor in liver tissue is believed to favorably affect cholesterol and lipoprotein levels&nbsp;via multiple mechanisms, which may be complementary to those of other
lipid-lowering therapies such as statin drugs. We believe that these characteristics of THR-<FONT FACE="SYMBOL">b</FONT> activation by MGL-3196 will in turn lead to clinically meaningful
reductions in LDL-C, plasma and liver TGs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 is the first selective small molecule THR-<FONT FACE="SYMBOL">b</FONT> agonist compound. MGL-3196, along with other
THR-<FONT FACE="SYMBOL">b</FONT>-selective small molecules, such as MGL-3745, a potential backup compound to MGL-3196, was discovered at Hoffmann-La Roche, or Roche, in Nutley, New Jersey,
by utilizing a novel functional assay that, unlike a simple receptor binding assay, assessed the functional activity of compounds which interacted with thyroid hormone receptors. In a published study
by us and Roche in the Journal of Medicinal Chemistry using this functional assay, MGL-3196 was shown to be highly selective for the THR-&szlig; receptor, with almost no effect on
THR-<FONT FACE="SYMBOL">a</FONT>, unlike other compounds purported in published studies to be b-selective based on binding affinity, but which were shown to equally activate
THR-<FONT FACE="SYMBOL">a</FONT> and THR-<FONT FACE="SYMBOL">b</FONT> in the novel functional assay. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the &szlig;-selectivity and liver-targeting properties of MGL-3196 are critically important for MGL-3196's beneficial metabolic actions in the liver, and enable
avoidance of safety issues associated with THR-<FONT FACE="SYMBOL">a</FONT> activation by thyroid hormone and/or less selective THR agonists in tissues such as heart and bone. In a variety
of preclinical animal model studies, MGL-3196 showed enhanced safety relative to T3 or other thyroid agonists. In animal models, MGL-3196 demonstrated cholesterol lowering, liver triglyceride
lowering, and reduction of markers of NASH-related liver inflammation and fibrosis at drug levels similar to those that lowered LDL-C in human clinical trials, providing data to support the
advancement of MGL-3196 into NASH and FH clinical trials. In chronic animal toxicology studies in dogs and rats, no effects on bone or cartilage histology were seen at any MGL-3196 dose in either
species. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 may be the first product candidate in development for NASH or FH that selectively targets the THR-&szlig; pathway and has shown a lack of liver enzyme
elevations in Phase&nbsp;1 clinical studies as well as an absence of bone and cartilage histologic findings in chronic animal toxicology studies. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 Clinical and Non-Clinical Development Program  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have completed a series of Phase&nbsp;1 clinical studies, Phase&nbsp;2-enabling preclinical good laboratory practice, or GLP,
toxicology studies, and drug manufacturing studies to support further clinical development, including active pharmaceutical ingredient, or API, manufacturing and drug product development studies, drug
metabolism studies, acute, subchronic and chronic animal toxicology studies, and other safety pharmacology and toxicology studies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed Phase&nbsp;1 studies with MGL-3196 in a total of 129 subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of MGL-3196. Our
Phase&nbsp;1 studies included randomized, placebo-controlled, double-blind, single and 14-day multiple-dose escalation studies, as well as a drug-interaction study in healthy volunteers. In
Phase&nbsp;1 studies, MGL-3196 appeared safe and was well-tolerated at all doses tested. The results of these studies suggest that MGL-3196 has pharmacokinetic properties suitable for once-daily
oral dosing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the multiple ascending dose study, lipid parameters were assessed as initial markers of MGL-3196 pharmacodynamic activity (Atherosclerosis 230:373-380, 2013). As illustrated in the
figure below, daily doses of MGL-3196 ranging from 50 to 200 mg showed highly statistically significant reductions relative to placebo of up to 30% for LDL-C (range, p=.05-&#60;0.0001), 28%
for non-HDL-C (range, p =0.027-p&#60;0.0001) and 24% for apoB (range, p =0.008-0.0004), and statistical trends of up to 60% reduction in TG (range, p =0.13-0.016). The near maximal lipid
effects were observed at a MGL-3196 dose of 80 mg once-daily. MGL-3196 was well-tolerated at all doses, with no dose-related adverse events or liver enzyme, electrocardiography or vital-sign changes.
At the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=401770,FOLIO='S-38',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_dg42401_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>highest
dose of MGL-3196 (200 mg), there was a reversible reduction of 20% in the level of a precursor hormone to T3, free T4, which was significantly different from placebo (p &#60;
0.0001) that may be explained by increased liver metabolism of free T4. There was no change in thyrotropin, a pituitary hormone that regulates the level and production of thyroid hormone by the
thyroid gland or T3, or other evidence of central thyroid axis dysfunction at any dose of MGL-3196. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg42401_change_in_lipids_after_14_days"> </A>
<A NAME="toc_dg42401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Change in Lipids After 14 Days    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g72021.jpg" ALT="GRAPHIC" WIDTH="597" HEIGHT="310">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Change from Baseline (CFB) by mean % CFB calculated for each individual subject 24th&nbsp;after 14th&nbsp;dose; baseline value obtained just prior to first
dose; ApoB, apolipoprotein B; Chal, total cholesterol; LDL-C, LDL cholesterol directly measured; Non-HDL-C, non-HDL cholesterol; TG, triglycerides (median %CFB) </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we are encouraged by these results, they are based on a small number of patients in early-stage clinical trials and are not necessarily
predictive of results in later-stage clinical trials with larger and more diverse patient populations. In addition, the FDA typically requires sponsors of lipid-lowering product candidates to conduct
drug-drug interaction studies with statins because statins may have increased safety risks when administered together with other drug therapies that affect their pharmacokinetic profile. We have
completed two clinical drug interaction studies of MGL-3196 and three commonly used statins in 39 normal healthy volunteers, which showed MGL-3196 to have a favorable safety profile and to be
well-tolerated. We have initiated a Phase&nbsp;2 clinical study in NASH including patients taking low dose statins. We have also initiated a 12&nbsp;week Phase&nbsp;2 clinical study in HeFH
including patients taking high dose statins that is fully enrolled (116&nbsp;patients) and will be completed in early 2018. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
randomized, double-blind, placebo-controlled, multi-center NASH Phase&nbsp;2 study enrolled 125 patients 18&nbsp;years of age and older with liver biopsy-confirmed NASH and
included approximately 25 clinical sites in the United States. Patients were randomized to receive either placebo or MGL-3196 with twice as many patients receiving MGL-3196 as placebo. The starting
dose in MGL-3196-treated patients was 80 mg once a day. The study employed an adaptive dosing design whereby, in a
blinded fashion, the dose could be adjusted by small amounts (i.e.&nbsp;20 mg up or down) or remain at 80 mg in each MGL-3196-treated patient based on a pharmacokinetic analysis of drug level
performed in each patient at 2&nbsp;weeks. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary endpoint of the study is the reduction of liver fat at 12&nbsp;weeks compared with baseline (relative change), assessed by MRI-PDFF, with efficacy confirmed at the end of
the trial </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=41,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=665404,FOLIO='S-39',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_dg42401_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>(36&nbsp;weeks)
by repeat MRI-PDFF and conventional liver biopsy to examine histological evidence for the resolution of NASH. A total of 116 patients completed the 12&nbsp;week MRI-PDFF; the 9
discontinuations were balanced between placebo and drug treated; 2/9 discontinuations were AE-related. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
secondary endpoints include changes in clinically relevant biomarkers at 12 and 36&nbsp;weeks, improvement in fibrosis by at least one stage with no worsening of
steatohepatitis, and safety and tolerability. Results at 36-weeks are expected in the second quarter of 2018. In this trial, MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid
hormone receptor (THR) <FONT FACE="SYMBOL">b</FONT>&nbsp;-selective agonist, demonstrated statistically significant results for the primary endpoint, the percent change in hepatic fat
versus placebo as measured by MRI-PDFF, a non-invasive imaging test. Recent published data have shown a high correlation of the reduction of liver fat of 30% or more as measured by MRI-PDFF to
improvement in NASH on liver biopsy. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="88pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="110pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> ALL MGL-3196</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> HIGH MGL-3196**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> Placebo<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Numbers of patients</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Relative change in MRI-PDFF (% change from baseline, median) Significance relative to placebo</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#150;36.3%<BR>
p&#60;0.0001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#150;42.0%<BR>
p&#60;0.0001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#150;9.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Percentage of patients attaining <FONT FACE="SYMBOL">&#179;</FONT>30% liver fat reduction Significance relative to placebo</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>60.3%<BR>
p&#60;0.0001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75.0%<BR>
p&#60;0.0001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18.4<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%<BR></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">**</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Prespecified
group of patients (44/78) with relatively higher MGL-3196 drug levels </FONT></DD></DL>
 </DIV>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statistically
significant reductions in ALT and AST were observed in MGL-3196 treated patients; greater reductions in ALT and AST, statistically significant relative to placebo, were
observed in the prespecified group of 44/78 patients with relatively higher MGL-3196 drug levels. In drug-treated relative to placebo patients, statistically significant improvements were also seen in
multiple secondary endpoints considered to be potentially clinically relevant in patients with NASH including LDL-C, triglycerides, apolipoprotein B (ApoB), and Lp(a). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGL-3196
has been well-tolerated with mostly mild AEs, and a few moderate AEs, the numbers of which are balanced between placebo and drug-treatment groups. There are no adverse effects
of MGL-3196 on safety laboratory or vital sign parameters. There have been three serious adverse effects in the study, all considered unrelated to MGL-3196. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
on-going study remains blinded. Safety, efficacy of NASH resolution by biopsy, and repeat MRI-PDFF will be assessed at 36&nbsp;weeks. Multiple inflammatory and fibrosis serum
biomarkers at 12 and 36&nbsp;weeks are being and will be assessed. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leading biopharmaceutical company developing and commercializing innovative liver-directed, &szlig;-selective
thyroid hormone receptor agonists for the treatment of cardio-metabolic and liver disease, fibrosis and inflammation. A key element is building a multi-therapy NASH focused company. To achieve our
goal, we plan to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Complete clinical development and seek regulatory approval of MGL-3196 in
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have reported data for the primary endpoint from our Phase&nbsp;2 study in NASH in December 2017. NASH is a disease driven by the
growing epidemic of obesity, with a significant unmet need for approved therapies that are effective and well tolerated. We believe MGL-3196 is an </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=42,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=955756,FOLIO='S-40',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_dg42401_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>excellent
candidate for the chronic treatment of NASH due to its safety profile and first-in-class dual mechanism of action targeting fibrosis-generating cells.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Establish commercial capabilities to market MGL-3196 as a leading treatment for
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;If approved, we may choose either to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize MGL-3196, or to collaborate with one or more third parties to accomplish these tasks. Patients with NASH are primarily managed by a concentrated group of liver
specialists in the United States and Europe. We believe this will enable us to launch MGL-3196 in NASH in a cost-effective, targeted manner.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Grow our pipeline through additional indications for MGL-3196 including orphan
indications.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe that MGL-3196 has the potential to be an effective treatment for other disease indications that are rare diseases or may
be designated rare diseases, including HoFH and severe HeFH, and we plan to pursue orphan drug designation where possible. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Target Indications  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview and Market Opportunity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASH is a serious inflammatory form of nonalcoholic fatty liver disease, or NAFLD. NAFLD has become the most common liver disease in the United
States and other developed countries and is characterized by an accumulation of fat in the liver with no other apparent causes. The rising worldwide prevalence of obesity-related disorders has
contributed to a rapid increase in the global prevalence of NASH and NAFLD. In the United States, NAFLD is estimated to affect approximately 27% to 34% of the population, or an estimated
86&nbsp;million to 108&nbsp;million people, and approximately 10% to 20% of those will progress from NAFLD to NASH. Current estimates place NASH prevalence at approximately 9&nbsp;million to
15&nbsp;million people in the United States, or 3% to 5% of the population, with similar prevalence in Europe and Asia. The prevalence of NASH is also increasing in developing regions due to the
adoption of a more sedentary lifestyle and a diet consisting of processed foods with high fat and fructose content. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the accumulation of fat in the liver, NASH is characterized by inflammation and cellular damage with or without fibrosis, the first stage of liver scarring, which may
ultimately progress to cirrhosis. NASH is a severe condition that can lead to fibrosis and eventually progress to cirrhosis, portal hypertension, esophageal varices, ascites, liver cancer and liver
failure. NASH is strongly associated with cardiovascular disease, or CVD, and the most common cause of death in NASH patients is CVD. Progression to cirrhosis and other late-stage complications can
occur within 5 to 10&nbsp;years after an initial NASH diagnosis. NASH patients with type-2 diabetes have a heightened risk of NASH disease progression. Once the disease advances beyond NASH to such
life-threatening conditions as liver cancer and failure, then liver transplantation is the only treatment alternative. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Centers for Disease Control and Prevention projects the prevalence of obesity to increase from 34% of the United States population to 42% of the United States population by 2030.
Driven by this epidemic of obesity, NASH is projected to become the leading cause of liver transplants by 2020. Given the extremely limited availability of organ donors and high transplant costs, NASH
patients who require transplantation will place a significant economic burden on the healthcare system. As such, there is a significant unmet medical need for well-tolerated oral treatments for NASH.
Because there are currently no therapeutic products approved for the treatment of NASH, the market size is difficult to estimate. However, based on our analysis of multiple market </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=43,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=14942,FOLIO='S-41',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<A NAME="page_dg42401_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>assessments,
we estimate that the addressable NASH population is several million patients worldwide, and that NASH could become a multi-billion dollar market able to support multiple approved drug
products. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 in NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing MGL-3196 for NASH. Based on the scientific literature in human and animal studies, we believe that NASH livers in humans
frequently have a deficiency in THR-&szlig; activity that leads to features of NASH, including fatty liver, inflammation and fibrosis, and that treatment with MGL-3196 will replace this hormone
deficiency and be an effective NASH treatment. We believe that MGL-3196 is an excellent candidate for the chronic treatment of NASH because of its safety and tolerability profile observed to date in
healthy subjects, its effects in reducing cardiovascular risk factors such as LDL-C and TGs in early-stage clinical trials, and its multiple beneficial effects in animal models of NASH. CVD is the
most common cause of death in patients with NASH. We have completed multiple studies in animal models of metabolic diseases, dyslipidemia and NASH in which MGL-3196 demonstrated a statistically
significant reduction in liver TGs, insulin resistance, liver enzymes (which may be elevated in NASH), and markers of inflammation and fibrosis (Figures). The figures below show the beneficial effects
of MGL-3196 to reduce these parameters in NASH animal models. We believe that MGL-3196 will treat the underlying lipotoxicity that drives the inflammation and liver cell damage observed in NASH
patients, and after the underlying lipotoxicity is treated, NASH-related liver fibrosis will resolve as the liver regenerates. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196: Preclinical NASH Animal Model Study  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg42401_upper_panels__24d_study_in_17___upp04720"> </A>
<A NAME="toc_dg42401_3"> </A></FONT> <FONT SIZE=2><B>  Upper panels: 24d study in 17 wk old DIO mice (po, qd) on high fat diet (HFD) 13 wks;<BR>  lower panels: 24d study in 40 wk old DIO mice on HFD 35 wks    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g837899.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="361">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=44,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=267203,FOLIO='S-42',FILE='DISK128:[17ZDN1.17ZDN42401]DG42401A.;17',USER='CHE109867',CD='16-DEC-2017;19:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_di42401_1_43"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 Preclinical NASH Animal Model Gene Expression Study  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="di42401_25_week_study_in_dio,_lean_con__25_03625"> </A>
<A NAME="toc_di42401_1"> </A></FONT> <FONT SIZE=2><B>  25&nbsp;week study in DIO, lean control mice and HFD mice treated with 0.1 to 3 mg/kg<BR>  MGL-3196 or Rosiglitazone (3mg/kg)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g715173.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="376">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">"HFD", lane 1 means HFD gene expression normalized to mean Lean; Lanes (2-7) mean gene expression normalized to mean of DIO; "Rosi" (rosiglitazone, 3 mg/kg,
24&nbsp;weeks) TIMP1 tissue inhibitor metalloproteinase; CTGF connective tissue growth factor; SMA smooth muscle actin; SAA serum amyloid A; CRP C-reactive protein; Red, higher expression; blue
decreased expression </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 NASH Phase&nbsp;2 Clinical Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, we initiated a Phase&nbsp;2 proof of concept clinical trial in approximately 117 patients with liver biopsy documented NASH,
including those with type-2 diabetes, dyslipidemia and hypertension. In the study we have randomized NASH patients 2:1, MGL-3196 or placebo QD in a double-blind, placebo-controlled, study of
once-daily MGL-3196 versus placebo in patients with NASH, including those with type-2 diabetes. Patients are to continue treatment through 36&nbsp;weeks. The study is being conducted in the United
States. The primary endpoint is to evaluate the efficacy of MGL-3196 as measured by the reduction of liver fat at 12&nbsp;weeks, and the secondary endpoint will be to evaluate the efficacy of
MGL-3196 as measured by a reduction of NASH, which will be assessed by liver biopsy, at 36&nbsp;weeks. Other secondary and exploratory endpoints include safety and tolerability, and effects on serum
biomarkers at 12 and 36&nbsp;weeks, lipid parameters, and biomarker measures of insulin sensitivity. We reached our top-line analysis of the primary endpoint in December 2017 and we expect to reach
our top-line analysis of the secondary endpoint (NASH assessment on liver biopsy) by spring of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2013, the American Association for the Study of Liver Disease and the FDA conducted a joint workshop focused on trial designs and endpoints in drug and diagnostic
development for liver disease secondary to NAFLD, including NASH. In December 2014, the journal Hepatology accepted for publication a manuscript summarizing the workshop output, including potentially
acceptable surrogate endpoints for clinical studies supporting the approval of agents for NASH and liver fibrosis. We believe that our Phase&nbsp;2 NASH study design incorporates surrogate </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=45,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1004576,FOLIO='S-43',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>secondary
endpoints consistent with the current FDA requirements for demonstration of efficacy in registrational trials. Following completion of our Phase&nbsp;2 clinical trial of MGL-3196 in NASH
patients we intend to meet with FDA and other regulatory agencies to discuss a phase&nbsp;3 clinical plan for MGL-3196 in NASH. We cannot be certain what efficacy endpoints and other elements FDA or
other regulatory agencies would require for approval of MGL-3196 in NASH. However, currently there are ongoing phase&nbsp;3 clinical trials of compounds to treat NASH by other companies in which it
is contemplated that accelerated approval of the compounds under FDA subpart&nbsp;H, which provides for accelerated approval of certain new drug products that have been studied for their safety and
effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments, would be based on the surrogate endpoint of
histological evidence of NASH resolution without the worsening of fibrosis. It is expected that these trials would continue after approval to confirm the long term clinical benefit of NASH resolution
based on a reduction in patients progressing to cirrhosis and other liver related events. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Familial Hypercholesterolemia  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview and Market Opportunity  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FH is a genetic disorder characterized by aggressive and early onset CVD. In people with FH, genetic mutations make the liver incapable of
metabolizing or removing excess LDL-C, causing very high LDL-C levels in the blood. There are two forms of FH: HoFH, a less common condition where mutation is inherited from both parents, and HeFH, a
more common condition where mutation is inherited from just one parent. The vast majority of the cholesterol circulating in a person's body is produced by the liver. Cholesterol is a necessary
component in the structure and function of human cells. Individuals with FH are unable to recycle this natural supply of cholesterol that their bodies are constantly producing. Therefore, the
cholesterol levels of an individual with FH are exceedingly high. Over time, the elevated blood cholesterol can lead to blockages in the arteries of the heart and/or brain. The longer a person
experiences high LDL-C, the more likely he or she will be to experience a cardiovascular event (</FONT><FONT SIZE=2><I>i.e.</I></FONT><FONT SIZE=2>, heart attack or stroke). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HoFH
has an estimated worldwide prevalence of 1 in 160,000 to 1 in 1,000,000 and is a life-threatening condition characterized by markedly elevated levels of LDL-C. This is
predominantly due to inactivating mutations in the LDL receptor, with onset of atherosclerotic CVD in childhood to early adulthood. HeFH, more common than HoFH, has an estimated worldwide prevalence
of 1 in 200 to 1 in 500 and is characterized by early onset CVD in middle age, typically caused by an inactivating mutation in one of the two LDL receptor genes. While HeFH patients have a range of
disease severity, we believe approximately 10% of the HeFH population can be characterized as having severe FH, with higher baseline LDL-C levels (&gt;309 mg/dL; 8 mmol/L) than those of a majority of the
HeFH population. Despite multiple therapeutics currently available for the treatment of HoFH, including statins, ezetimibe, and newer agents such as lomitapide, mipomersen, and anti-PCSK9 antibodies,
we believe that the treatment target goal to reduce LDL-C to recommended levels is rarely achieved. In HeFH, with the recent addition of anti-PCSK9 antibodies to the treatment regimen, we believe that
LDL-C target treatment goals (&#60;100 mg/dL; &#60; 70 mg/dL in patients with CVD or diabetes) may be achieved in &gt; 50% of the patients; however, many HeFH patients, particularly
those with severe FH or who cannot tolerate treatment with high-dose statins, are not at goal and are in need of additional lipid-lowering therapies beyond current therapeutic approaches. In addition,
elevation of lipoprotein(a), or Lp(a), a severely atherogenic lipoprotein particle, which is frequently elevated in FH patients, is not effectively lowered by current therapeutic approaches. In 2014,
an estimated $16.6&nbsp;billion was spent on drug therapy in the United States, five major European Union markets, and Japan to treat dyslipidemias, according to Datamonitor. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=46,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=166749,FOLIO='S-44',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 in FH  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing MGL-3196 for FH and potentially other genetic dyslipidemias. We believe that experimental results from various sources,
including Madrigal, academic groups and other pharmaceutical companies, support targeting the THR-&szlig; pathway as a potential novel approach to lipid-lowering in FH. We believe that MGL-3196
has a unique and complementary lipid-lowering profile that will bring an added benefit to the standard of care treatment of FH patients, particularly those with severe HeFH (~10% of FH patients with
high baseline LDL-C, typically &gt;309 mg/dL) and those with HoFH who do not achieve LDL-C target levels with current therapies. Specifically, in preclinical animal studies MGL-3196 lowered LDL-C in a
variety of species as a monotherapy and also when dosed in combination with statins. MGL-3196 also showed the potential to lower Lp(a), a severely atherogenic particle that is frequently elevated in
patients with FH. A previous THR agonist, eprotirome, demonstrated clinical proof of concept for the THR target in Phase&nbsp;2 and Phase&nbsp;3 FH clinical trials by significantly lowering LDL-C
and Lp(a) in patients with HeFH who were on standard treatments such as statins and ezetimibe. The development of eprotirome ceased during the Phase&nbsp;3 FH trial due to liver toxicity observed in
the trial as well as eprotirome-induced cartilage damage seen in chronic toxicology studies in dogs.
Because of its high level of THR-&szlig; selectivity, its liver-targeting properties, and its absence of findings in chronic animal toxicology studies, we believe that MGL-3196 will avoid the
toxicity issues of previous THR agonist compounds and may be a beneficial treatment for FH patients. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 FH Phase&nbsp;2 Clinical Plan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2017, we initiated a Phase&nbsp;2 clinical trial of MGL-3196 for the treatment of HeFH. In the study we have randomized HeFH
patients 2:1, MGL-3196 or placebo QD in double-blind, placebo-controlled fashion. Patients are to continue treatment through 12&nbsp;weeks. The study is being conducted in Europe. In this
12&nbsp;week clinical trial, the primary endpoint is to evaluate the efficacy of MGL-3196 as measured by the percent reduction in LDL-C as compared with placebo. Secondary endpoints include safety
and tolerability, and evaluate the efficacy of MGL-3196 to reduce a variety of lipid parameters, including non-HDL-C, apoB, TGs, Lp(a), apoA/B, and lipoprotein particles. Based on efficacy and safety
data obtained from this HeFH study, we plan to conduct a proof of concept open-label Phase&nbsp;2 study of 6-8 patients with HoFH at sites in the United States and Europe. We expect that top-line
results of the HeFH clinical trial will be available in early 2018. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Collaborations  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VIA Pharmaceuticals,&nbsp;Inc., or VIA, entered into a research, development and commercialization agreement, or the Roche Agreement, with
Hoffmann-La Roche Pharmaceutical Company Limited, or Roche, on December&nbsp;18, 2008. We subsequently assumed all of VIA's rights in, to and under, and all of VIA's obligations under, the Roche
Agreement pursuant to an asset purchase agreement dated September&nbsp;14, 2011. Pursuant to the terms of the Roche Agreement, we, as successor-in-interest to VIA, assumed control of all development
and commercialization of MGL-3196 and will hold exclusive worldwide rights for all potential indications. Under the license agreement, Roche exclusively licensed certain patent rights and know-how
relating to MGL-3196 in exchange for consideration consisting of an upfront payment, milestone payments, the remainder of which total $10&nbsp;million and are tied to future commencement of
Phase&nbsp;3 clinical trials and regulatory approval in the United States and Europe of MGL-3196 or any derivative product, and single-digit royalty payments based on net sales of MGL-3196 and any
derivative products, subject to certain reductions. In 2011, we commenced Phase&nbsp;1 clinical trials and subsequently paid Roche a related milestone payment. In October 2016, we commenced a
Phase&nbsp;2 study in NASH and subsequently paid Roche a related milestone payment. Except as described above, we have not </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=47,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=72879,FOLIO='S-45',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_46"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>achieved
any additional product development or regulatory milestones under the Roche Agreement and have generated no net sales of products developed from MGL-3196. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Roche Agreement, we must use commercially reasonable efforts to conduct clinical and commercial development programs for products containing MGL-3196. If we determine
that it is not reasonable to continue clinical trials or other development of MGL-3196, we may elect to cease further development and Roche may terminate the license. If we determine not to pursue the
development or commercialization of MGL-3196 in certain jurisdictions, including the United States, Roche may terminate the license for such territories. The Roche Agreement will expire, unless
earlier terminated pursuant to other provisions of the agreement, on the last to occur of (i)&nbsp;the expiration of the last valid claim of a licensed patent covering the manufacture, use or sale
of products containing MGL-3196, or (ii)&nbsp;ten years after the first sale of a product containing MGL-3196. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development and commercialization of new drugs is highly competitive. We will face competition with respect to all product candidates we
may develop or commercialize in the future from pharmaceutical and biotechnology companies worldwide. The key factors affecting the success of any approved product will be its efficacy, safety
profile, drug interactions, method of administration, pricing, reimbursement and level of promotional activity relative to those of competing drugs. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
potential competitors may have substantially greater financial, technical, and personnel resources than us. In addition, many of these competitors have significantly greater
commercial infrastructures. Our ability to compete successfully will depend largely on our ability to leverage our collective experience in drug discovery, development and commercialization
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> discover and develop medicines that are differentiated from other products in the market, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain patent and/or proprietary protection for our products and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain required regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain a commercial partner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> commercialize our drugs, if approved; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> attract and retain high-quality research, development and commercial personnel. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are currently no therapeutic products approved for the treatment of NASH. There are several commercially available products that are currently used off-label for NASH, such as
vitamin&nbsp;E, an antioxidant, insulin sensitizers, such as pioglitazone, anti-hyperlipidemic agents, such as gemfibrozil, pentoxifylline, ursodiol and others. In addition, there are numerous drugs
in development for the treatment of NASH. We are aware of several companies that have product candidates in clinical development for the treatment of NASH, including Intercept
Pharmaceuticals,&nbsp;Inc., Gilead Sciences,&nbsp;Inc., Galectin Therapeutics,&nbsp;Inc., Allergan&nbsp;plc / Tobira Pharmaceuticals,&nbsp;Inc., Galmed Medical Research&nbsp;Ltd., Genfit
Corp., Novartis AG, Novo Nordisk A/S, Takeda, Immuron&nbsp;Ltd., Shire&nbsp;plc, Boehringer Ingelheim&nbsp;GmbH, and Conatus Pharmaceuticals&nbsp;Inc., and there are other companies with
candidates in earlier stages of development. Given MGL-3196's actions on the underlying biological pathways across the spectrum of early to late stages of NASH, its CV beneficial effects, and its
complementary mechanism to other therapies, we believe that MGL-3196 has the potential to be used alone or in combination with some of these potential NASH products. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=48,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=608421,FOLIO='S-46',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are several marketed products, both generic and proprietary, available for the treatment of HoFH and HeFH. We believe that MGL-3196 has the potential to be used in combination
with several of these products. Available marketed products include: various statins, Merck's ezetimibe, Aegerion's lomitapide, Ionis' mipomersen, Amgen's evolocumab and Sanofi/Regeneron's alirocumab.
In addition, there are multiple drugs in development for the treatment of FH, including Gemphire's gemcabene, Merck's anacetrapib, Esperion's ETC-1002, and drugs at an earlier stage of development.
Given MGL-3196's pleoitropic lipid-lowering actions, its complementary mechanism to statins and other lipid-lowering drugs, and its potential for lowering Lp(a), we believe that MGL-3196 has the
potential to be used in combination with the standard of care to treat patients with HoFH and HeFH. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sales and Marketing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we are focused on discovery and development of our product candidates, we currently have no sales, marketing or distribution
capabilities in order to commercialize any approved product candidates. If our product candidates are approved, we intend either to establish a sales and marketing organization with technical
expertise and supporting distribution capabilities to commercialize our products, or to outsource this function to a third party. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to rely, on
third-party contract manufacturers, or CMOs, for the manufacture of any product candidates that we may develop for larger-scale preclinical and clinical testing, as well as for commercial quantities
of any drug candidates that are approved. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses primarily consist of costs associated with our research activities, including the preclinical and clinical
development of our product candidates. Our research and development expenses were $15.9&nbsp;million for the year ended December&nbsp;31, 2016 compared to $2.4&nbsp;million for the same period
in 2015. The large increase in research and
development expenses was primarily due to the advancement of clinical programs to Phase&nbsp;2 studies, further API manufacturing studies and the continuation of preclinical studies. We expect
research and development expenses to increase over time as we advance our clinical and preclinical development programs for MGL-3196. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will be able to protect our technology and products from unauthorized use by third parties only to the extent we are covered by valid and
enforceable patents or such knowledge is effectively maintained as trade secrets. Patents and other proprietary rights are thus an essential element of our business. We also rely on trade secrets,
know-how, continuing technological innovation and licensing opportunities to develop and maintain our competitive position. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our current and future product candidates, technology and know-how, to
operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights. We seek to protect our proprietary position by, among other methods,
filing United States and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
own, co-own or have exclusive rights to three United States and 69 foreign issued patents and allowed patent applications, and two United States and 25 foreign pending patent
applications, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=49,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=693196,FOLIO='S-47',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>relating
to composition-of-matter of MGL-3196, including certain dosage forms, and its use in the treatment of key disease indications. Our current patent portfolio covers the United States and
certain other jurisdictions worldwide. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issued
United States patents directed to MGL-3196, including certain dosage forms, have statutory expiration dates between 2026 and 2033, excluding any patent term extensions that might
be available following the grant of marketing authorizations. Issued patents outside of the United States directed to MGL-3196, including certain dosage forms, have statutory expiration dates between
2026 and 2033. We have pending patent applications for MGL-3196 that, if issued, would be
expected to expire in the United States and in countries outside of the United States between 2026 and 2033, excluding any patent term adjustment that might be available following the grant of the
patent and any patent term extensions that might be available following the grant of marketing authorizations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, pursuant to the Roche Agreement, Roche granted us an exclusive license to certain patents and know-how relating to MGL-3196, including many of the patents and patent
applications referred to above. The Roche Agreement imposes various diligence, milestone payment, royalty payment, insurance, indemnification, and other obligations on us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
trademarks are protected under the common law and/or by registration in the United States and other countries. We seek to protect our proprietary processes, in part, by
confidentiality agreements and invention assignment agreements with our personnel, including consultants and commercial partners. These agreements are designed to protect our proprietary information. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of MGL-3196's target disease indications are rare diseases or may be designated rare diseases, including HoFH and severe HeFH, and we plan
to pursue orphan drug designation where possible. If granted, each such designation might provide for regulatory exclusivity for seven years in the United States and ten years in the European Union
from the date of product approval for individual indications. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation and Product Approval  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import
of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process before it may be legally marketed in the United States, and must
be approved by foreign regulatory authorities via various procedures before it can be marketed in the applicable country. The animal and other non-clinical data and the results of human clinical
trials performed under an Investigational New Drug application, or IND, and under similar foreign applications will become part of the NDA. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Drug Development Process  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and
financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=50,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=30169,FOLIO='S-48',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>approval
process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other things, the FDA's refusal to approve pending
applications, withdrawal of an approval, a clinical hold, warning letters and other types of enforcement-related letters, requesting product recalls, product seizures, changes to the conditions
surrounding marketing approval such as labeling changes or changes to a Risk Evaluation and Mitigations Strategies, or REMS, program, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, debarment, restitution, disgorgement of profits, or civil or criminal investigations and penalties. Any agency or judicial enforcement action
could have a material adverse effect on us. The process required by the FDA before a drug or biologic may be marketed in the United States generally involves the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies according to GLP or other applicable regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of an IND, which must become effective before human clinical trials may begin; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCP, to establish the safety and
efficacy of the proposed drug for its intended use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of an NDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> completion of registration batches and validation of the manufacturing process to show ability to consistently produce quality batches of
product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance
with current Good Manufacturing Practice, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA review and approval of the NDA. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity
and formulation, as well as animal studies, to assess the safety and quality of the product. Animal studies must be performed in compliance with FDA's GLP regulations and the U.S. Department of
Agriculture's Animal Welfare Act. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. The
sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective
30&nbsp;days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold or a partial clinical hold. In such a case, the IND sponsor and the
FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during studies due to safety concerns or
non-compliance, or other reasons. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with good clinical practice regulations. They must be conducted under
protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted
to the FDA as part of the IND, and progress reports detailing the results of the clinical trials must be submitted at least annually. In addition, timely safety reports must be submitted to the FDA
and the investigators for serious and unexpected adverse events or animal test results that suggest a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=51,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=187815,FOLIO='S-49',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>significant
risk to human subjects. An institutional review board, or IRB, at each institution participating in the clinical trial must review and approve each protocol before a clinical trial
commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the
study until completed and otherwise comply with IRB regulations. Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the U.S. Data from a
foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with GCP and the FDA is able to validate the data. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Phase&nbsp;1:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The product candidate is initially introduced into healthy
human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer,
especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target diseases. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Phase&nbsp;2:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;This phase involves studies in a limited patient population
to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Phase&nbsp;3:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;This phase involved trials undertaken to further evaluate
dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the
product candidate and provide, if appropriate, an adequate basis for product approval and product labeling. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an
unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's
requirements or if the drug has been associated with unexpected serious harm to patients. Phase&nbsp;1, Phase&nbsp;2, and Phase&nbsp;3 testing may not be completed successfully within any
specified period, if at all. Further, success in either preclinical studies or early-stage clinical trials does not assure success in later-stage clinical trials. Sponsors of all controlled clinical
trials, except for Phase&nbsp;1 trials, are required to submit certain clinical trial information for inclusion in the public clinical trial registry and results data bank maintained by the National
Institutes of Health, which are publicly available at http://clinicaltrials.gov. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of
Phase&nbsp;2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to
date, for the FDA to provide advice, and for the sponsor and FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase&nbsp;2 meeting to discuss their
Phase&nbsp;2 clinical results and present their plans for the pivotal Phase&nbsp;3 clinical trial that they believe will support approval of the new drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of
the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=52,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=426655,FOLIO='S-50',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<A NAME="page_di42401_1_51"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>methods
for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Review and Approval Processes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of
an NDA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA conducts a preliminary review of all NDAs submitted to ensure that
they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept a NDA for filing. In this event, the NDA must be
resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an
in-depth substantive review. The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The approval process is lengthy and often difficult, and the FDA may refuse to
approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information are submitted, the FDA may
ultimately decide that the NDA does not satisfy the regulatory criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we
interpret the same data. The FDA may issue a complete response letter, which generally outlines the deficiencies in the submission and may require additional clinical or other data or impose other
conditions that must be met in order to secure final approval of the NDA, or an approval letter following satisfactory completion of all aspects of the review process. The FDA reviews an NDA to
determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product's identity, strength,
quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. In addition, the FDA often will conduct a bioresearch monitoring
inspection of the clinical trial sites involved in conducting pivotal studies to ensure data integrity and compliance with applicable GCP requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NDAs
receive either standard or priority review. A drug representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. Priority
review for an NDA for a new molecular entity will be six months from the date that the NDA is filed. The FDA has ten months in which to complete its initial review of a standard new molecular entity
NDA. The FDA does not always meet its goal dates and in certain circumstances the goal date may be extended. In addition, products studied for their safety and effectiveness in treating serious or
life-threatening illnesses and which provide meaningful therapeutic benefit over existing treatments, may receive accelerated approval. In that situation, the product may be approved on the basis of
adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on the basis of an effect
on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of
approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Priority review and accelerated approval do
not change the standards for approval, but may expedite the approval process. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=53,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=854123,FOLIO='S-51',FILE='DISK128:[17ZDN1.17ZDN42401]DI42401A.;13',USER='CHE108067',CD='17-DEC-2017;17:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dk42401_1_52"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a product receives regulatory approval, the approval may be significantly limited to specific diseases, dosages or patient populations, or the indications for
use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase&nbsp;4 testing which involves clinical trials
designed to further assess a drug's safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been
commercialized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted in 2012, made permanent the Pediatric Research Equity Act, or PREA, which requires a sponsor to
conduct pediatric studies for most drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and
supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the product for the
claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may
request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for
approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. After
April 2013, the FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric
formulation. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Term Restoration and Marketing Exclusivity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of FDA approval of our product candidates, some of our United States patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent
restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining
term of a patent beyond a total of 14&nbsp;years from the product's approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the
submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the period is reduced by any time during which the applicant failed to
exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent and within 60&nbsp;days
of approval. The United States Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity is another type of marketing exclusivity available in the United States. The FDASIA made permanent the Best Pharmaceuticals for Children Act, or BPCA, which
provides for an additional six months of marketing exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA, or a Written Request. If the Written
Request does not include studies in neonates, the FDA is required to include its rationale for not requesting those studies. The FDA may request studies on approved or unapproved indications in
separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described studies. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biological product intended to treat a rare disease or
condition, which is generally a disease or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=733562,FOLIO='S-52',FILE='DISK128:[17ZDN1.17ZDN42401]DK42401A.;6',USER='CHE106812',CD='16-DEC-2017;19:45' -->
<A NAME="page_dk42401_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>condition
that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of
developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be
requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug
designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives the first FDA
approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same
drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, also could block the approval of one of our product candidates for seven years if
a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is determined to be contained within the competitor's product for the same indication or disease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA also administers a clinical research grants program, whereby researchers may compete for funding to conduct clinical trials to support the approval of drugs, biologics, medical
devices, and medical foods for rare diseases and conditions. A product does not have to be designated as an orphan drug to be eligible for the grant program. An application for an orphan grant should
propose one discrete clinical study to facilitate FDA approval of the product for a rare disease or condition. The study may address an unapproved new product or an unapproved new use for a product
already on the market. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fast Track Designation and Accelerated Approval  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or
life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for such a disease or condition. Under the fast track
program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for
the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60&nbsp;days of receipt of the sponsor's request. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the fast track program, the FDA may designate a drug for fast-track status if it is intended to treat a serious or life-threatening illness and nonclinical or clinical data
demonstrate the potential to address an unmet medical need. Similarly, the agency may designate a drug for accelerated
approval if it treats a serious condition and generally provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to
predict clinical benefit, or on a clinical endpoint that can be measured earlier than IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the
severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels,
functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing
compliance requirements, including the completion of Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies,
or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under
accelerated regulations are subject to prior review by the FDA. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=634770,FOLIO='S-53',FILE='DISK128:[17ZDN1.17ZDN42401]DK42401A.;6',USER='CHE106812',CD='16-DEC-2017;19:45' -->
<A NAME="page_dk42401_1_54"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
FDASIA, Congress encouraged the FDA to utilize innovative and flexible approaches to the assessment of products under accelerated approval. The law required the FDA to issue related
draft guidance within a year after the law's enactment and also promulgate confirming regulatory changes. In May 2014, the FDA published a Guidance for Industry entitled, "Expedited Programs for
Serious Conditions-Drugs and Biologics" which provides guidance on FDA programs that are intended to facilitate and expedite development and review of new drugs as well as threshold criteria generally
applicable to concluding that a drug is a candidate for these expedited development and review programs. In addition to the Fast Track, accelerated approval and priority review programs discussed
above, the FDA also provided guidance on a new program for Breakthrough Therapy designation. A request for Breakthrough Therapy designation should be submitted concurrently with, or as an amendment to
an IND. The FDA has already granted this designation to over 30 new drugs and has approved several. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an approval is granted, products are subject to continuing regulation by the FDA. The FDA may withdraw the approval if, among other
things, compliance with regulatory standards is not maintained or if safety or efficacy problems occur after the product reaches the market. Later discovery of previously unknown problems with a
product may result in restrictions on the product or even complete withdrawal of the product from the market. If new safety issues are
identified following approval, the FDA may require the NDA sponsor to take certain measures, such as revising the approved labeling to reflect the new safety information, conducting post-market
studies or clinical trials to assess the new safety information, and/or implementing or changing a REMS Program to mitigate newly-identified risks. After approval, some types of changes to the
approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved
in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the
FDA and certain state agencies for compliance with cGMP and other laws and regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial
quantities of our product candidates. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our contract manufacturers that may disrupt
production or distribution, or require substantial resources to correct. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping
requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain
electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information
on products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing
of products regulated by the FDA. In addition to new legislation, FDA regulations and guidance are often revised or interpreted by the agency in ways that may significantly affect our business and our
products. It is impossible to predict whether further legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=823650,FOLIO='S-54',FILE='DISK128:[17ZDN1.17ZDN42401]DK42401A.;6',USER='CHE106812',CD='16-DEC-2017;19:45' -->
<A NAME="page_dk42401_1_55"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and
commercial sales and distribution of its products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable
regulatory authorities of foreign countries or economic areas, such as the 28-member European Union, before we may commence clinical trials or market products in those countries or areas. The approval
process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that
required for FDA approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure,
which is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of AIDS, cancer,
neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing
application is submitted to the EMA where it will be evaluated by the Committee for Medicinal Products for Human Use and a favorable opinion typically results in the grant by the European Commission
of a single marketing authorization that is valid for all European Union member states within 67&nbsp;days of receipt of the opinion. The initial marketing authorization is valid for five years, but
once renewed is usually valid for an unlimited period. The decentralized procedure provides for approval by one or more "concerned" member states based on an assessment of an application performed by
one member state, known as the "reference" member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member
state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120&nbsp;days after receipt of a valid application. Within
90&nbsp;days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials. If a member state
does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
conducting clinical trials in the EU, we must adhere to the provisions of the EU Clinical Trials Directive and the laws and regulations of the EU Member States implementing them.
These provisions require, among other things, that the prior authorization of an Ethics Committee and the submission and approval of a clinical trial authorization application be obtained in each
Member State before commencing a clinical trial in that Member State. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
in the United States, it may be possible in foreign countries to obtain a period of market and/or data exclusivity that would have the effect of postponing the entry into the
marketplace of a competitor's generic product. For example, in the EU, if any of our products receive marketing approval in the European Economic Area, or EEA which is comprised of the 28 member
states of the EU plus Norway, Iceland and Liechtenstein, we expect that we will benefit from eight years of data exclusivity and an additional two years of marketing exclusivity. An additional
one-year extension of marketing exclusivity is possible if during the data exclusivity period we obtain an authorization for one or more new therapeutic indications that is deemed to bring a
significant clinical benefit compared to existing therapies. The data exclusivity period begins on the date of the product's first marketing authorization in the EU and prevents biosimilars from
relying on the holder of the marketing authorization for the reference biological medicine's pharmacological, toxicological and clinical data for a period of eight years. After eight years, a
biosimilar product application may be submitted and the sponsoring companies may rely on the marketing authorization holder's data. However, a biosimilar medicine cannot launch until 2&nbsp;years
later (or a total of ten years after the first </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=947554,FOLIO='S-55',FILE='DISK128:[17ZDN1.17ZDN42401]DK42401A.;6',USER='CHE106812',CD='16-DEC-2017;19:45' -->
<A NAME="page_dk42401_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>marketing
authorization in the EU of the innovator product), or 3&nbsp;years later (or a total of eleven years after the first marketing authorization in the EU of the innovator product) if the
marketing authorization holder obtains marketing authorization for a new indication with significant clinical benefit within the eight year data exclusivity period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
in the United States, a sponsor may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for marketing
authorization is made. Orphan drugs in Europe enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that
its product is safer, more effective or otherwise clinically superior to the orphan-designated product. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reimbursement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant uncertainty exists regarding the coverage and reimbursement status of products approved by the FDA and other government
authorities. In the United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in significant part on the availability and adequacy of coverage
and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining
whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage
to specific products on an approved list which might not include all of the FDA-approved products for a particular indication. Moreover, a payor's decision to provide coverage for a product does not
imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on
our investment in product development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-party
payors are increasingly challenging the prices charged for, examining the medical necessity of, and assessing the cost-effectiveness of medical products and services, in
addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order
to demonstrate the medical necessity and cost-effectiveness of any products, in addition to the costs required to obtain regulatory approvals. Our drug candidates may not be considered medically
necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit
under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
U.S. government and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including
price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Affordability Reconciliation Act, or collectively, ACA, contains provisions that may reduce the profitability of drug products, including, for example,
increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and
annual fees based on pharmaceutical companies' share of sales to federal health care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions
with existing controls and measures, could limit payments for pharmaceuticals. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and
reimbursement. In addition, an increasing emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=726312,FOLIO='S-56',FILE='DISK128:[17ZDN1.17ZDN42401]DK42401A.;6',USER='CHE106812',CD='16-DEC-2017;19:45' -->
<A NAME="page_dk42401_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>pricing.
Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from
country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or
indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for
pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the
United States and generally tend to be significantly lower. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;12, 2017, we had eight full-time employees, including four engaged in research, development, and regulatory activities,
and four in executive, general and administrative functions, and multiple part-time consultants. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=362541,FOLIO='S-57',FILE='DISK128:[17ZDN1.17ZDN42401]DK42401A.;6',USER='CHE106812',CD='16-DEC-2017;19:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dm42401_1_58"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A1"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, any accompanying prospectus supplement, and the documents we incorporate by reference in this prospectus and any accompanying
prospectus supplement contain forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. These forward-looking
statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are
forward-looking statements. We have attempted to identify forward-looking statements by using words such as "may," "believe," "will," "could," "project," "anticipate," "expect," "estimate," "should,"
"continue," "potential," "plan," "forecasts," "goal," "seek," "intend," other forms of these words or similar words or expressions or the negative thereof. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
particular, this prospectus supplement, and the documents we incorporate by reference in this prospectus supplement, contain forward-looking statements relating to, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Anticipated or estimated future results, including the risks and uncertainties associated with our future operating performance and financial
position; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Market demand for and acceptance of our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Research, development and commercialization of new products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Risks associated with meeting the objectives of clinical studies, including, but not limited to, delays or failures in enrollment, and the
occurrence of adverse safety events; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Risks related to our ability to accomplish our business development objectives and realize the anticipated benefit of any such transactions;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Assumptions underlying any of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have based our forward-looking statements on our expectations and projections about trends affecting our business and industry and other future events. Although we do not make
forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties
that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking
statement. Some of the risks and uncertainties that may cause actual results to differ from those expressed or implied in the forward-looking statements are described in the section entitled "Risk
Factors" in this prospectus supplement, as well as in our other filings with the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently
unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=176467,FOLIO='S-58',FILE='DISK128:[17ZDN1.17ZDN42401]DM42401A.;9',USER='CHE109570',CD='18-DEC-2017;21:19' -->
<A NAME="page_dm42401_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A2"></A>USE OF PROCEEDS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The net proceeds from the sale of shares of common stock that we are selling in this offering will be approximately $117.5&nbsp;million based
on the sale of 1,506,025 shares of our common stock offered hereby, or approximately $135.1&nbsp;million if the underwriters exercise in full their option to purchase up to 225,904 additional shares
of common stock, at the public offering price of $83.00 per share, after deducting estimated underwriting discounts and commissions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to use the net proceeds from this offering, if any, for general corporate purposes, including, without limitation, research and development expenditures, clinical trial
expenditures, manufacture and supply of drug substance and drug products, acquisitions of new technologies, capital expenditures and working capital. We may temporarily invest the net proceeds in
short-term, interest-bearing instruments or other investment-grade securities. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will
retain broad discretion over the allocation of net proceeds. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=61,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=584945,FOLIO='S-59',FILE='DISK128:[17ZDN1.17ZDN42401]DM42401A.;9',USER='CHE109570',CD='18-DEC-2017;21:19' -->
<A NAME="page_dm42401_1_60"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A3"></A>DILUTION  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you purchase our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering
price per share and the net tangible book value per share of our common stock after this offering. We calculate net tangible book value per share by subtracting our total liabilities from our total
tangible assets and dividing the difference by the number of outstanding shares of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
net tangible book value at September&nbsp;30, 2017 was approximately $54.3&nbsp;million, or $4.35 per share, based on 12,495,705 shares of our common stock then outstanding.
Historical net tangible book value per share is equal to our total tangible assets, less total liabilities, divided by the number of outstanding shares of our common stock. Dilution in net tangible
book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock
immediately after this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
giving effect to the sale by us of 1,506,025 shares of common stock in this offering at the public offering price of $83.00 per share, less the underwriting discounts and
commissions, our pro forma net tangible book value at September&nbsp;30, 2017 would have been approximately $171.8&nbsp;million, or approximately $12.27 per share. This represents an immediate
increase in net tangible book value of $7.92 per share to existing stockholders and an immediate dilution of $70.73 per share to investors in this offering. The following table illustrates this per
share dilution: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>83.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value per share as of September&nbsp;30, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.35</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to new investors purchasing shares in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.92</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12.27 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>70.73 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above discussion and table are based on approximately 12,495,705 shares of our common stock outstanding as of September&nbsp;30, 2017 and excludes the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 1,969,797 shares of common stock issuable upon conversion of our Series&nbsp;A Convertible Preferred Stock outstanding as of
September&nbsp;30, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 991,711 shares of our common stock issuable upon the exercise of options outstanding as of September&nbsp;30, 2017, having a weighted average
exercise price of $11.96 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an aggregate of 1,443,561 shares of our common stock reserved for future issuance as of September&nbsp;30, 2017 under our 2015 Stock Plan. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the amounts in the table above assume no exercise by the underwriters of their option to purchase additional shares of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=62,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=890750,FOLIO='S-60',FILE='DISK128:[17ZDN1.17ZDN42401]DM42401A.;9',USER='CHE109570',CD='18-DEC-2017;21:19' -->
<A NAME="page_dm42401_1_61"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A4"></A>PRICE RANGE OF COMMON STOCK  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on The Nasdaq Global Market under the symbol "MDGL." The following table shows the closing high and low per share
sale prices of our common stock for the periods indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> High</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> Low<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Year Ending December&nbsp;31, 2017:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16.39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>17.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>46.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15.16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Fourth Quarter (as of December&nbsp;18, 2017)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>87.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>39.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ended December&nbsp;31, 2016:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12.68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>17.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Year Ended December&nbsp;31, 2015:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>67.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>69.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>79.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>57.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10.85</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;18, 2017, the closing price of our common stock on The Nasdaq Global Market was $84.04 per share, and there were 38 holders of record of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A5"></A>DIVIDEND POLICY  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently anticipate declaring or paying cash dividends on our capital stock in the foreseeable future. We currently intend to retain
all of our future earnings, if any, to finance the operation and expansion of our business. Any future determination relating to our dividend policy will be made at the discretion of our board of
directors and will depend on a number of factors, including future earnings, capital requirements, future prospects, contractual restrictions and covenants and other factors that our board of
directors may deem relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=63,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=781811,FOLIO='S-61',FILE='DISK128:[17ZDN1.17ZDN42401]DM42401A.;9',USER='CHE109570',CD='18-DEC-2017;21:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_do42401_1_62"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A6"></A>DESCRIPTION OF CAPITAL STOCK  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of all material characteristics of our capital stock as set forth in our restated certificate of incorporation, our
restated bylaws and our Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;A Convertible Preferred Stock. The summary does not purport to be complete and is qualified
in its entirety by reference to our certificate of incorporation and bylaws, copies of which have been filed as exhibits to our previous SEC filings. For more information, see the sections entitled
"Incorporation of Certain Documents by Reference" and "Where You Can Find More Information." </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of Common Stock  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share. The following summary of certain provisions of our
common stock does not purport to be complete. You should refer to our restated certificate of incorporation and our restated bylaws, both of which have been filed with the SEC. The summary below is
also qualified by provisions of applicable law. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;18, 2017, there were 12,495,705 shares of common stock outstanding. Holders of common stock are entitled to one vote for
each share held of record on all matters submitted to a vote of the stockholders, and do not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of
preferred stock, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of funds legally available for
dividend payments. The holders of common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights. There are no redemption or sinking fund provisions
applicable to the common stock. In the event of any liquidation, dissolution or winding-up of our affairs, holders of common stock will be entitled to share ratably in our assets that are remaining
after payment or provision for payment of all of our debts and obligations and after liquidation payments to holders of outstanding shares of preferred stock, if any. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Computershare Trust Company N.A., whose address is Meidinger Tower, 462 South
4th&nbsp;Street, Louisville, KY 40202 and whose telephone number is (502)&nbsp;301-6088. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


NASDAQ Global Market  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed for quotation on The NASDAQ Global Market under the symbol "MDGL." </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared any cash dividends on our common stock and we do not anticipate paying any cash dividends on our common stock in the
foreseeable future. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of Preferred Stock  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue 5,000,000 shares of preferred stock, par value $0.0001 per share. As of December&nbsp;15, 2017, we had 1,969,797
shares of preferred stock, designated Series&nbsp;A Convertible Preferred Stock, outstanding held by two stockholders of record. No other shares of our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=895811,FOLIO='S-62',FILE='DISK128:[17ZDN1.17ZDN42401]DO42401A.;12',USER='HYUNG',CD='19-DEC-2017;16:15' -->
<A NAME="page_do42401_1_63"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>preferred
stock were outstanding or designated. The following summary of certain provisions of our preferred stock does not purport to be complete. You should refer to our restated certificate of
incorporation, our restated bylaws and our Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;A Convertible Preferred Stock, each of which have been filed with the SEC.
The summary below is also qualified by provisions of applicable law. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in
series and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences.
Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of
shares of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares
of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control
by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of directors, without stockholder approval, we may issue shares of
preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A Convertible Preferred Stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of the Series&nbsp;A Convertible Preferred Stock is convertible into shares of the common stock at any time at the holder's option
at a one-to-one ratio, subject to adjustment. The holder, however, will be prohibited from converting shares of the Series&nbsp;A Convertible Preferred Stock into shares of our common stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock or any other class of any equity security of ours (other than an
exempted security) that is registered pursuant to Section&nbsp;12 of the Securities Exchange Act of 1934, which may be increased or decreased to any other percentage at the holder's election on
61&nbsp;days' notice delivered to the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
our liquidation, dissolution or winding-up, whether voluntary or involuntary, after the satisfaction in full of our debts and the payment of any liquidation preference owed to the
holders of shares of our capital stock ranking prior to the Series&nbsp;A Convertible Preferred Stock upon liquidation, the holders of the Series&nbsp;A Convertible Preferred Stock shall
participate </FONT><FONT SIZE=2><I>pari passu</I></FONT><FONT SIZE=2> with the holders of our common stock (on an as-if-converted-to-common-stock basis) in our net assets. Shares of the
Series&nbsp;A Convertible Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series&nbsp;A Convertible Preferred Stock will be entitled to receive
dividends before shares of any other class or series of our capital stock (other than dividends in the form of our common stock) equal to the dividend payable on each share of our common stock, on an
as-converted basis. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Provisions of our Certificate of Incorporation and Bylaws  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the board of directors' ability to issue shares of preferred stock, our restated certificate of incorporation and restated
bylaws contain other provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying,
deferring or preventing a future takeover or change in control of our company unless such takeover or change in control is approved by our board of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=117086,FOLIO='S-63',FILE='DISK128:[17ZDN1.17ZDN42401]DO42401A.;12',USER='HYUNG',CD='19-DEC-2017;16:15' -->
<A NAME="page_do42401_1_64"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly
or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Classified board of directors; removal of directors for cause.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated
bylaws provide for our board
of directors to be divided into three classes serving staggered terms. At each annual meeting of stockholders, directors elected to succeed those directors whose terms have expired are elected for a
three-year term of office. All directors elected to our classified board of directors will serve until the election and qualification of their respective successors or their earlier resignation or
removal. The board of directors is authorized to create new directorships and to fill such positions so created and is permitted to specify the class to which any such new position is assigned. The
person filling such position would serve for the term applicable to that class. The board of directors (or its remaining members, even if less than a quorum) is also empowered to fill vacancies on the
board of directors occurring for any reason for the remainder of the term of the class of directors in which the vacancy occurred. Members of the board of directors may only be removed for cause and
only by the affirmative vote of 80% of our outstanding voting stock. These provisions are likely to increase the time required for stockholders to change the composition of the board of directors. For
example, in general, at least two annual meetings will be necessary for stockholders to effect a change in a majority of the members of the board of directors. The provision for a classified board
could prevent a party who acquires control of a majority of our outstanding common stock from obtaining control of our board of directors until our second annual stockholders meeting following the
date the acquirer obtains the controlling stock interest. The classified board provision could have the effect of discouraging a potential
acquirer from making a tender offer or otherwise attempting to obtain control of us and could increase the likelihood that incumbent directors will retain their positions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advance notice provisions for stockholder proposals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated bylaws establish an advance notice procedure for
stockholder proposals to be
brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors, as well as procedures for including proposed nominations at
special meetings at which directors are to be elected. Stockholders at our annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by
or at the direction of our board or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our secretary
timely written notice, in proper form, of the stockholder's intention to bring that business before the meeting, and who has complied with the procedures and requirements set forth in the bylaws.
Although our bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or
annual meeting, our bylaws may have the effect of precluding the conduct of some business at a meeting if the proper procedures are not followed or may discourage or defer a potential acquirer from
conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of the stockholders may be called only by our board of directors
pursuant to a resolution adopted
by a majority of the total number of authorized directors. Stockholders are not permitted to call a special meeting or to require our board of directors to call a special meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=66,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=360791,FOLIO='S-64',FILE='DISK128:[17ZDN1.17ZDN42401]DO42401A.;12',USER='HYUNG',CD='19-DEC-2017;16:15' -->
<A NAME="page_do42401_1_65"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No stockholder action by written consent.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated bylaws do not permit our
stockholders to act by
written consent. As a result, any action to be effected by our stockholders must be effected at a duly called annual or special meeting of the stockholders. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Super-majority stockholder vote required for certain actions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law,
or DGCL, provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless the
corporation's certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our restated certificate of incorporation requires the affirmative vote of the holders of at
least 80% of our outstanding voting stock to amend or repeal certain provisions of our restated certificate of incorporation. This 80% stockholder vote would be in addition to any separate class vote
that might in the future be required pursuant to the terms of any preferred stock that might then be outstanding. In addition, an 80% vote is also required for any amendment to, or repeal of, our
restated bylaws by the stockholders. Our restated bylaws may be amended or repealed by a vote of a majority of the total number of authorized directors. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Provisions of Delaware Law Governing Business Combinations  </B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the "business combination" provisions of Section&nbsp;203 of the DGCL. In general, such provisions prohibit a publicly held
Delaware corporation from engaging in any "business combination" transactions with any "interested stockholder" for a period of three years after the date on which the person became an "interested
stockholder," unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> prior to such date, the board of directors approved either the "business combination" or the transaction which resulted in the "interested
stockholder" obtaining such status; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> upon consummation of the transaction which resulted in the stockholder becoming an "interested stockholder," the "interested stockholder" owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding
voting stock owned by the "interested stockholder") those shares owned by (a)&nbsp;persons who are directors and also officers and (b)&nbsp;employee stock plans in which employee participants do
not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at or subsequent to such time the "business combination" is approved by the board of directors and authorized at an annual or special meeting
of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock which is not owned by the "interested stockholder." </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"business combination" is defined to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder. In general, an "interested stockholder" is a
person who, together with affiliates and associates, owns 15% or more of a corporation's voting stock or within three years did own 15% or more of a corporation's voting stock. The statute could
prohibit or delay mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=67,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=753789,FOLIO='S-65',FILE='DISK128:[17ZDN1.17ZDN42401]DO42401A.;12',USER='HYUNG',CD='19-DEC-2017;16:15' -->
<A NAME="page_do42401_1_66"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A7"></A>UNDERWRITING  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to
certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC is the representative of the
underwriters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="108pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriters</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Number of Shares<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>790,663</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Evercore Group L.L.C.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>376,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 JMP Securities&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>150,603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roth Capital Partners,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>112,952</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 H.C. Wainwright&nbsp;&amp;&nbsp;Co.,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75,301 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,506,025 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the shares covered by the option described below unless and until this
option is exercised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have an option to buy up to 225,904 additional shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the
table above. They may exercise that option for 30&nbsp;days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion
as set forth in the table above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by the Company. Such amounts are shown assuming both no exercise
and full exercise of the underwriters' option to purchase additional shares. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="77pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paid by the Company</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>No Exercise</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Full Exercise<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Per Share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,500,005</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,625,006</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
sold by the underwriters to the public will initially be offered at the public offering price set forth on the cover of this prospectus supplement. Any shares sold by the
underwriters to securities dealers may be sold at a discount of up to $2.99 per share from the public offering price. After the initial offering of the shares, the representative may change the
offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters' right to reject any order in whole or
in part. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company, members of management, the board of directors and certain existing stockholders have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge
any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus supplement continuing through the date
90&nbsp;days after the date of this prospectus supplement, except with the prior written consent of the representative. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may include short sales, stabilizing transactions
pursuant to Regulation&nbsp;M of the Securities Act of 1933, and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares
than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A "covered short position" is a short </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=68,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1046733,FOLIO='S-66',FILE='DISK128:[17ZDN1.17ZDN42401]DO42401A.;12',USER='HYUNG',CD='19-DEC-2017;16:15' -->
<A NAME="page_do42401_1_67"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>position
that is not greater than the amount of additional shares for which the underwriters' option described above may be exercised. The underwriters may cover any covered short position by either
exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider,
among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above. "Naked"
short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such
naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of
the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock
made by the underwriters in the open market prior to the completion of the offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the
representative has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases
to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a
decline in the market price of the Company's stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result,
the price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these
activities at any time. These transactions may be effected on The Nasdaq Global Market, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relative Member State")
an offer to the public of our common shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of our common shares may be made at any time
under the following exemptions under the Prospectus Directive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive) subject to obtaining the
prior consent of the Joint Bookrunners for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> provided that no such offer of shares of our common stock shall result in a requirement for the publication by us or any Brazilian placement
agent of a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to the public" in relation to our common shares in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an investor to decide to purchase our common shares, as the same may be varied in that
Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU)
and includes any relevant implementing measure in the Relevant Member State. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=69,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=855833,FOLIO='S-67',FILE='DISK128:[17ZDN1.17ZDN42401]DO42401A.;12',USER='HYUNG',CD='19-DEC-2017;16:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq42401_1_68"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This European Economic Area selling restriction is in addition to any other selling restrictions set out below. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United Kingdom, this prospectus supplement is only addressed to and directed as qualified investors who are (i)&nbsp;investment
professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order); or (ii)&nbsp;high net worth entities and other persons
to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as "relevant persons"). Any investment or
investment activity to which this prospectus supplement relates is available only to relevant persons and will only be engaged with relevant persons. Any person who is not a relevant person should not
act or relay on this prospectus supplement or any of its contents. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
Instrument&nbsp;31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction
not subject to, the prospectus requirements of applicable securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this offering memorandum (including any amendment
thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory of these rights or consult with a
legal advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriters are not required to comply with the disclosure
requirements of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) ("Companies (Winding Up and Miscellaneous Provisions)
Ordinance") or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) ("Securities and Futures Ordinance"),
or (ii)&nbsp;to "professional investors" as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document
being a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the
possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in
Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other
than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=70,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=617934,FOLIO='S-68',FILE='DISK128:[17ZDN1.17ZDN42401]DQ42401A.;14',USER='HYUNG',CD='19-DEC-2017;16:07' -->
<A NAME="page_dq42401_1_69"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"professional
investors" in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus
supplement and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as
defined under Section&nbsp;4A of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the "SFA")) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in
Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth
in the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in
Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the
securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6&nbsp;months after that corporation has acquired the shares under Section&nbsp;275 of
the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2)&nbsp;where such transfer
arises from an offer in that corporation's securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the
transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments)
(Shares and Debentures) Regulations&nbsp;2005 of Singapore ("Regulation&nbsp;32") </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in
Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited
investor, the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferable for 6&nbsp;months after that trust has acquired the shares under Section&nbsp;275 of
the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2)&nbsp;where such transfer
arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction
(whether such amount is to be paid for in cash or by exchange of securities or other assets), (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is
by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948,
as amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any
corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except
pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=71,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=467299,FOLIO='S-69',FILE='DISK128:[17ZDN1.17ZDN42401]DQ42401A.;14',USER='HYUNG',CD='19-DEC-2017;16:07' -->
<A NAME="page_dq42401_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimates that its share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $500,000. The underwriters have
agreed to reimburse the Company for certain expenses in connection with the offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment
banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the
underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for
which
they received or will receive customary fees and expenses including $350,000 paid to JMP Securities LLC in July, 2017 in its capacity as the Company's financial advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array
of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their
customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise)
and/or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading
ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or
short positions in such assets, securities and instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=72,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=933494,FOLIO='S-70',FILE='DISK128:[17ZDN1.17ZDN42401]DQ42401A.;14',USER='HYUNG',CD='19-DEC-2017;16:07' -->
<A NAME="page_dq42401_1_71"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A8"></A>LEGAL MATTERS  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain legal matters will be passed upon for us by Stradling Yocca Carlson&nbsp;&amp; Rauth, P.C., Newport Beach, California. Certain legal
matters will be passed upon for the underwriters by Ropes&nbsp;&amp; Gray&nbsp;LLP, Boston, Massachusetts. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A9"></A>EXPERTS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements as of December&nbsp;31, 2016 and for the year ended December&nbsp;31, 2016 incorporated in this Prospectus by
reference to the Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements for the year ended December&nbsp;31, 2015, incorporated in this prospectus by reference from the Company's Annual Report on Form&nbsp;10-K for
the year ended
December&nbsp;31, 2016 has been audited by Friedman&nbsp;LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial
statements and financial statement schedule have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A10"></A>WHERE YOU CAN FIND MORE INFORMATION  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement on Form&nbsp;S-3 that we filed with the SEC registering the securities that may be
offered and sold hereunder. The registration statement, including exhibits thereto, contains additional relevant information about us and these securities that, as permitted by the rules and
regulations of the SEC, we have not included in this prospectus. A copy of the registration statement can be obtained at the address set forth below. You should read the registration statement for
further information about us and these securities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and special reports, proxy statements and other information with the SEC under the Exchange Act. You may read and copy this information at the following SEC
location: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Public
Reference Room<BR>
100&nbsp;F Street, N.E.<BR>
Washington, D.C. 20549 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may obtain information on the operation of the Public Reference Room by calling the SEC at (800)&nbsp;SEC-0330. The SEC also maintains a web site that contains reports, proxy
statements, information statements and other information about issuers, like Madrigal Pharmaceuticals,&nbsp;Inc., who file electronically with the SEC. The address of that web site is www.sec.gov. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our common stock is listed on The Nasdaq Global Market and similar information concerning us can be inspected and copied at the offices of The Nasdaq Stock Market, One
Liberty Plaza, 165 Broadway, New York, NY 10006. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=73,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=743712,FOLIO='S-71',FILE='DISK128:[17ZDN1.17ZDN42401]DQ42401A.;14',USER='HYUNG',CD='19-DEC-2017;16:07' -->
<A NAME="page_dq42401_1_72"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A11"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement on Form&nbsp;S-3 filed by us with the SEC. This prospectus does not contain all of the
information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For further information about us and the securities
offered by this prospectus, we refer you to the registration statement and its exhibits and schedules which may be obtained as described herein. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC allows us to "incorporate by reference" information into this prospectus. This means that we can disclose important information about us and our financial condition to you by
referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus. This prospectus incorporates by reference the
documents listed below that we have previously filed with the SEC:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016, as filed with the SEC on March&nbsp;31, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Definitive Proxy Statement on Schedule&nbsp;14A, as filed with the SEC on April&nbsp;28, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarter ended March&nbsp;31, 2017, as filed with the SEC on May&nbsp;11, 2017, for
the fiscal quarter ended June&nbsp;30, 2017, as filed with the SEC on August&nbsp;10, 2017, and for the fiscal quarter ended September&nbsp;30, 2017, as filed with the SEC on November&nbsp;9,
2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Current Reports on Form&nbsp;8-K, as filed with the SEC on March&nbsp;31, 2017, June&nbsp;1, 2017, June&nbsp;21, 2017, and
July&nbsp;5, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The description of our common stock set forth in the Registration Statement on Form&nbsp;8-A filed with the SEC on January&nbsp;1, 2007
(the "Form&nbsp;8-A"), as well as the description of our common stock set forth on pages&nbsp;123 through 125 of the Registration Statement on Form&nbsp;S-1, as amended (Registration
No.&nbsp;333-138894), which was originally filed with the SEC on November&nbsp;22, 2006 (which description is incorporated by reference into the description of our common stock set forth in the
Form&nbsp;8-A), and any other amendment or report filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference into this prospectus all documents filed by us with the SEC pursuant to Sections&nbsp;12(a), 13(c), 14 or 15(d) of the Exchange Act prior to the
termination of any offering of securities made by this prospectus. Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC (including without
limitation, information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form&nbsp;8-K, and any exhibits relating to such information). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained herein or in the applicable prospectus supplement or in any other subsequently filed document which also is or is deemed to be
incorporated by reference modifies or supersedes the statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this
prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=74,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=200609,FOLIO='S-72',FILE='DISK128:[17ZDN1.17ZDN42401]DQ42401A.;14',USER='HYUNG',CD='19-DEC-2017;16:07' -->
<A NAME="page_dq42401_1_73"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of the filings incorporated herein by reference, including exhibits to such documents that are specifically incorporated by reference, at no cost, by writing or
calling us at the following address or telephone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Marc
R. Schneebaum<BR>
Chief Financial Officer<BR>
Madrigal Pharmaceuticals,&nbsp;Inc.<BR>
Four Tower Bridge<BR>
200 Barr Harbor Drive, Suite&nbsp;400<BR>
West Conshohocken, Pennsylvania 19428<BR>
(484)&nbsp;380-9263 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements
contained in this prospectus as to the contents of any contract or other documents are not necessarily complete, and in each instance investors are referred to the copy of
the contract or other document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference and the exhibits and schedules thereto. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=75,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=382128,FOLIO='S-73',FILE='DISK128:[17ZDN1.17ZDN42401]DQ42401A.;14',USER='HYUNG',CD='19-DEC-2017;16:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>SYNTA PHARMACEUTICALS CORP.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$300,000,000<BR>
COMMON STOCK<BR>
PREFERRED STOCK<BR>
DEBT SECURITIES<BR>
WARRANTS<BR>
RIGHTS<BR>
PURCHASE CONTRACTS<BR>
UNITS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up to
$300,000,000 of any combination of the securities described in this prospectus, either individually or in units. We may also offer common stock or preferred stock upon conversion of or exchange for
the debt securities; common stock upon conversion of or exchange for the preferred stock; common stock, preferred stock or debt securities upon the exercise of warrants, rights or performance of
purchase contracts; or any combination of these securities upon the performance of purchase contracts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide you with the specific terms of any
offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or
amend information contained in this document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus
supplement, carefully before you invest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale,
you should refer to the section entitled "Plan of Distribution" in this prospectus and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities
with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options will be set forth in a
prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on The NASDAQ Global Market under the symbol "SNTA." On October&nbsp;15, 2015, the last reported sale price of our common stock was $2.04 per share. The
applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The NASDAQ Global Market or any securities market or other securities exchange of the
securities covered by the prospectus supplement. Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the
risks that we have described on page&nbsp;3 of this prospectus under the caption "Risk Factors." We may include specific risk factors in supplements to this prospectus under the caption "Risk
Factors." This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"> <FONT SIZE=2>
The date of this prospectus is October&nbsp;16, 2015. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=76,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=608992,FOLIO='blank',FILE='DISK123:[17ZDN3.17ZDN42403]BC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg42403_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG42403A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> TABLE OF CONTENTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG42403_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_prospectus_summary"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_prospectus_summary"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_risk_factors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_risk_factors"><FONT SIZE=2><BR>
3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIO OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2><BR>
4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_special_note_regarding_forward-looking_statements"><FONT SIZE=2><BR>
4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_use_of_proceeds"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_use_of_proceeds"><FONT SIZE=2><BR>
5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da42403_plan_of_distribution"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da42403_plan_of_distribution"><FONT SIZE=2><BR>
5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc42403_description_of_common_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc42403_description_of_common_stock"><FONT SIZE=2><BR>
7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc42403_description_of_preferred_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc42403_description_of_preferred_stock"><FONT SIZE=2><BR>
7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc42403_description_of_debt_securities"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc42403_description_of_debt_securities"><FONT SIZE=2><BR>
9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc42403_description_of_warrants"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc42403_description_of_warrants"><FONT SIZE=2><BR>
15</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de42403_description_of_rights"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF RIGHTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de42403_description_of_rights"><FONT SIZE=2><BR>
16</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de42403_description_of_purchase_contracts"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PURCHASE CONTRACTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de42403_description_of_purchase_contracts"><FONT SIZE=2><BR>
17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de42403_description_of_units"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de42403_description_of_units"><FONT SIZE=2><BR>
18</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de42403_certain_provisions_of_delaware__cer03850"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN PROVISIONS OF DELAWARE LAW AND OF THE COMPANY'S
CERTIFICATE OF INCORPORATION AND BY-LAWS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de42403_certain_provisions_of_delaware__cer03850"><FONT SIZE=2><BR>
19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg42403_legal_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg42403_legal_matters"><FONT SIZE=2><BR>
21</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg42403_experts"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg42403_experts"><FONT SIZE=2><BR>
21</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg42403_where_you_can_find_more_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg42403_where_you_can_find_more_information"><FONT SIZE=2><BR>
22</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg42403_incorporation_of_documents_by_reference"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg42403_incorporation_of_documents_by_reference"><FONT SIZE=2><BR>
22</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=77,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=339047,FOLIO='i',FILE='DISK123:[17ZDN3.17ZDN42403]BG42403A.;6',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_about_this_prospectus"> </A>
<A NAME="toc_da42403_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a "shelf"
registration process. Under this shelf registration process, we may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants, rights or purchase
contracts to purchase any of such securities, either individually or in units, in one or more offerings, with a total value of up to $300,000,000. This prospectus provides you with a general
description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific information
about the terms of that offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to
the registration statement, including its exhibits. The prospectus supplement may also add, update or change information contained or incorporated by reference in this prospectus. However, no
prospectus supplement will offer a security that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus
supplements and the documents incorporated by reference into this prospectus, includes all material information relating to the offering of securities under this prospectus. You should carefully read
this prospectus, the applicable prospectus
supplement, the information and documents incorporated herein by reference and the additional information under the heading "Where You Can Find More Information" before making an investment decision. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained or incorporated by reference in this prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not
contained or incorporated by reference in this prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby,
but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any prospectus supplement is accurate only as of the date on
the front of the document and that any information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of
delivery of this prospectus or any sale of a security. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the
accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should
not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus
supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context otherwise requires, "Synta," "the Company," "we," "us," "our" and similar terms refer to Synta Pharmaceuticals Corp. and our subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
trademarks include, without limitation, Synta Pharmaceuticals, our corporate logo and the GALAXY trial. Other service marks, trademarks and trade names contained in this prospectus
supplement, the accompanying prospectus or the documents incorporated by reference herein and therein are the property of their respective owners. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=78,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=338243,FOLIO='blank',FILE='DISK123:[17ZDN3.17ZDN42403]DA42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_da42403_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_prospectus_summary"> </A>
<A NAME="toc_da42403_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following is a summary of what we believe to be the most important aspects of our business and the offering of our
securities under this prospectus. We urge you to read this entire prospectus, including the more detailed consolidated financial statements, notes to the consolidated financial statements and other
information incorporated by reference from our other filings with the SEC or included in any applicable prospectus supplement. Investing in our securities involves risks. Therefore, carefully consider
the risk factors set forth in any prospectus supplements and in our most recent annual and quarterly filings with the SEC, as well as other information in this prospectus and any prospectus
supplements and the documents incorporated by reference herein or therein, before purchasing our securities. Each of the risk factors could adversely affect our business, operating results and
financial condition, as well as adversely affect the value of an investment in our securities.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


About Synta Pharmaceuticals Corp.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that
have the potential to change the lives of cancer patients. Our lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several large
randomized clinical trials including GALAXY-2, a pivotal Phase&nbsp;3 trial in non-small cell lung cancer (NSCLC), as well as breast cancer, ovarian cancer and acute myeloid leukemia (AML). We are
also evaluating several candidates from our proprietary Hsp90 inhibitor Drug Conjugate program (HDC Program), which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively
deliver a wide array of anti-cancer payloads. Our first clinical candidate from our HDC Program, STA-12-8666, is undergoing testing to enable the filing of an investigational new drug application
(IND). Preclinical evaluation of additional HDC candidates is ongoing. We also have an additional clinical-stage oncology candidate: elesclomol, a mitochondrial metabolism inhibitor. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the broad clinical and commercial potential of our drug candidates, together with our operational capabilities and additional competitive advantages, provide us with
multiple, sustainable growth opportunities. Our capabilities and advantages include: our intellectual property portfolio; the full ownership of all commercial rights in all geographic regions to our
programs; our ability to integrate discovery, translational, and clinical research to optimize our development programs and further strengthen our intellectual property position; our operational
experience in effectively managing
large-scale, global clinical programs; our strong network of relationships with leading investigators and medical centers; our proprietary chemical compound library and the strength of our drug
discovery platform; and the skills, talent, and degree of industry experience of our employees. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We commenced operations in July 2001. In September 2002, we acquired Principia Associates,&nbsp;Inc., which had previously acquired Shionogi
BioResearch Corp., a U.S.-based drug discovery subsidiary of the Japanese pharmaceutical company, Shionogi&nbsp;&amp;&nbsp;Co.,&nbsp;Ltd. In this acquisition, we acquired a unique chemical compound
library, an integrated set of drug discovery capabilities, and a pipeline of preclinical and research programs. Since 2002, we have been advancing these programs into later stages of development,
discovering and developing additional drug candidates and expanding our management and scientific teams and capabilities to support more advanced stages of drug development and commercialization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at 45 Hartwell Avenue, Lexington, Massachusetts 02421, and our telephone number is (781)&nbsp;274-8200. Our website address is </FONT> <FONT SIZE=2><I>www.syntapharma.com</I></FONT><FONT SIZE=2>. The
information contained on our website is not incorporated by reference into, and does not form any part of, this prospectus. We
have included our website address as a factual reference and do not intend it to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=79,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=933916,FOLIO='2',FILE='DISK123:[17ZDN3.17ZDN42403]DA42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_da42403_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>be
an active link to our website. Our annual reports on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K, and all amendments to those reports, are available
free of charge through the "Investors&#151;SEC Filings" section of our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the
SEC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Offerings Under This Prospectus  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under this prospectus, we may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants, rights or
purchase contracts to purchase any of such securities, either individually or in units, with a total value of up to $300,000,000, from time to
time at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each time we
offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities,
including, to the extent applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> designation or classification; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> aggregate principal amount or aggregate offering price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maturity, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rates and times of payment of interest or dividends, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> redemption, conversion or sinking fund terms, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting or other rights, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conversion or exercise prices, if any. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
prospectus supplement also may add, update or change information contained in this prospectus or in documents we have incorporated by reference into this prospectus. However, no
prospectus supplement will offer a security that is not registered and described in this prospectus at the time of its effectiveness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we offer securities through agents or underwriters, we will include in the applicable prospectus supplement:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the names of those agents or underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> applicable fees, discounts and commissions to be paid to them; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> details regarding over-allotment options, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the net proceeds to us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This prospectus may not be used to consummate a sale of any securities unless it is accompanied by a prospectus supplement.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_risk_factors"> </A>
<A NAME="toc_da42403_3"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our securities involves significant risk. The prospectus supplement applicable to each offering of our securities may contain a
discussion of the risks applicable to an investment in Synta. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the
heading "Risk Factors" in the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or
incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading "Risk Factors" included in our most recent </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=80,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=603134,FOLIO='3',FILE='DISK123:[17ZDN3.17ZDN42403]DA42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_da42403_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>annual
report on Form&nbsp;10-K, as revised or supplemented by our subsequent quarterly reports on Form&nbsp;10-Q or our current reports on Form&nbsp;8-K on file with the SEC, all of which are
incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have
described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_ratio_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_da42403_4"> </A>
<BR></FONT><FONT SIZE=2><B>  RATIO OF EARNINGS TO FIXED CHARGES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any time debt securities are offered pursuant to this prospectus, we will provide a table setting forth our ratio of earnings to fixed charges
on a historical basis in the applicable prospectus supplement, if required. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_da42403_5"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and
make informed investment decisions. This prospectus and the documents we have filed with the SEC that are incorporated herein by
reference contain such "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
statements in connection with any discussion of future operations or financial performance are identified by the use of words such as "may," "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe," and other words and terms of similar meaning. Such statements are based on management's expectations and are subject to certain factors, risks and uncertainties
that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not
limited to, the risk that we may be unable to develop and achieve commercial success for our drug candidates; the risk that we may be unable to discover drugs that are safer and more efficacious than
our competitors; the risk that we may be unable to establish and maintain manufacturing arrangements for our products; the possibility of delays in the research and development necessary to select
drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure
regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate
collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products; the risk that we may be unable to protect our proprietary technologies; the risk of
patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors detailed under the heading "Risk Factors" in
this prospectus as updated and supplemented by the discussion of risks and uncertainties under "Risk Factors" contained in any supplements to this prospectus and in our most recent annual report on
Form&nbsp;10-K, as revised or supplemented by our subsequent quarterly reports on Form&nbsp;10-Q or our current reports on Form&nbsp;8-K, as well as any amendments thereto, as filed with the SEC
and which are incorporated herein by reference. The information contained in this document is believed to be current as of the date of this document. We do not intend to update any of the
forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this prospectus or in any document incorporated
herein by reference might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this prospectus or the date of the
document incorporated by reference in this prospectus. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result
of new </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=81,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=255332,FOLIO='4',FILE='DISK123:[17ZDN3.17ZDN42403]DA42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_da42403_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>information,
future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary
statements contained or referred to in this section. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_use_of_proceeds"> </A>
<A NAME="toc_da42403_6"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We cannot assure you that we will receive any proceeds in connection with securities which may be offered pursuant to this prospectus. Unless
otherwise indicated in the applicable prospectus supplement, we intend to use any net proceeds from the sale of securities under this prospectus for our operations and for other general corporate
purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital
expenditures, investments, acquisitions or collaborations, repurchases and redemption of our securities, research and development and product development. We have not determined the amounts we plan to
spend on any of the areas listed above or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds, if any, we receive in connection with
securities offered pursuant to this prospectus for any purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds in short-term, investment-grade,
interest-bearing securities or apply them to the reduction of short-term indebtedness. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da42403_plan_of_distribution"> </A>
<A NAME="toc_da42403_7"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades
or a combination of these methods. We may sell the securities (1)&nbsp;through underwriters or dealers, (2)&nbsp;through agents or (3)&nbsp;directly to one or more purchasers, or through a
combination of such methods. We may distribute the securities from time to time in one or more transactions at:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a fixed price or prices, which may be changed from time to time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market prices prevailing at the time of sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prices related to the prevailing market prices; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> negotiated prices. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may directly solicit offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase the securities from time to time.
We will name in a prospectus supplement any underwriter or agent involved in the offer or sale of the securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we utilize a dealer in the sale of the securities being offered by this prospectus, we will sell the securities to the dealer, as principal. The dealer may then resell the securities
to the public at varying prices to be determined by the dealer at the time of resale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we utilize an underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the time of sale, and we
will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we,
or the purchasers of the securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the
securities to or through dealers, and the underwriter may compensate those dealers in the form of discounts, concessions or commissions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to underwritten public offerings, negotiated transactions and block trades, we will provide in the applicable prospectus supplement information regarding any compensation we
pay to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=82,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=206930,FOLIO='5',FILE='DISK123:[17ZDN3.17ZDN42403]DA42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_da42403_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>concessions
or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters
within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may
be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities
Act, or to contribute to payments they may be required to make in respect thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase
securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and the
aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when
authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all
cases be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of
the jurisdiction to which that institution is subject; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such
securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery
contracts. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of our common stock sold pursuant to the registration statement of which this prospectus is a part will be authorized for quotation and trading on The NASDAQ Global Market. The
applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The NASDAQ Global Market or any securities market or other securities exchange of the
securities covered by the prospectus supplement. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to facilitate the offering of the securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of
the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than we sold to them. In these
circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In addition, these persons may
stabilize or maintain the price of the securities by bidding for or purchasing the applicable security in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers
participating in the offering may be reclaimed if the securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or
maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
compliance with the guidelines of the Financial Industry Regulatory Authority,&nbsp;Inc., or FINRA, the maximum consideration or discount to be received by any FINRA member or
independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of their business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=83,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=648158,FOLIO='6',FILE='DISK123:[17ZDN3.17ZDN42403]DA42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc42403_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc42403_description_of_common_stock"> </A>
<A NAME="toc_dc42403_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share. On August&nbsp;3, 2015, we had 136,442,378 shares
of common stock outstanding and approximately 50 stockholders of record. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summary of certain provisions of our common stock does not purport to be complete. You should refer to our restated certificate of incorporation and our restated bylaws,
both of which are included as exhibits to the registration statement of which this prospectus is a part. The summary below is also qualified by provisions of applicable law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, and do
not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared from time to time by our board of directors out of funds legally available for dividend payments. All shares of common stock outstanding as of the date of this prospectus
and, upon issuance and sale, all shares of common stock that we may offer pursuant to this prospectus, will be fully paid and nonassessable. The holders of common stock have no preferences or rights
of conversion, exchange, pre-emption or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. In the event of any liquidation, dissolution or
winding-up of our affairs, holders of common stock will be entitled to share ratably in our assets that are remaining after payment or provision for payment of all of our debts and obligations and
after liquidation payments to holders of outstanding shares of preferred stock, if any. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


NASDAQ Global Market  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed for quotation on The NASDAQ Global Market under the symbol "SNTA." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc42403_description_of_preferred_stock"> </A>
<A NAME="toc_dc42403_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF PREFERRED STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue 5,000,000 shares of preferred stock, par value $0.0001 per share. As of August&nbsp;3, 2015, no shares of our
preferred stock were outstanding or designated. The
following summary of certain provisions of our preferred stock does not purport to be complete. You should refer to our restated certificate of incorporation and our restated bylaws, both of which are
included as exhibits to the registration statement of which this prospectus is a part. The summary below is also qualified by provisions of applicable law. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in
series and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences.
Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of
shares of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our company before any payment </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=84,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=636878,FOLIO='7',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>is
made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy
contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of directors, without stockholder
approval, we may issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will
file&nbsp;a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description will include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title and stated value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares offered, the liquidation preference, if any, per share and the purchase price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the procedures for any auction and remarketing, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the provisions for a sinking fund, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the provisions for redemption, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any listing of the preferred stock on any securities exchange or market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated)
and conversion period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated)
and exchange period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting rights, if any, of the preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the
affairs of Synta; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any material limitations on issuance of any class or series of preferred stock ranking pari passu with or senior to the series of preferred
stock as to dividend rights and rights upon liquidation, dissolution or winding up of Synta. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our preferred stock will be set forth in the applicable prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=85,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=661320,FOLIO='8',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_9"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc42403_description_of_debt_securities"> </A>
<A NAME="toc_dc42403_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEBT SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material
terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer pursuant
to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement,
the terms of any debt securities offered under such prospectus supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from the
terms described below, the terms set forth in the prospectus supplement shall control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell from time to time, in one or more offerings under this prospectus, debt securities, which may be senior or subordinated. We will issue any such senior debt securities under a
senior indenture that we will enter into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture, which we will enter
into with a trustee to be named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus is a part. We use the term
"indentures" to refer to either the senior indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture Act of 1939, as in effect on the date of
the indenture. We use the term "debenture trustee" to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by
reference to, all the provisions of the indenture applicable to a particular series of debt securities. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each indenture provides that debt securities may be issued from time to time in one or more series and may be denominated and payable in foreign
currencies or units based on or relating to foreign currencies. Neither indenture limits the amount of debt securities that may be issued
thereunder, and each indenture provides that the specific terms of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental
indenture, if any, relating to such series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will describe in each prospectus supplement the following terms relating to a series of debt securities:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title or designation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the aggregate principal amount and any limit on the amount that may be issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency or units based on or relating to currencies in which debt securities of such series are denominated and the currency or units in
which principal or interest or both will or may be payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether we will issue the series of debt securities in global form, the terms of any global securities and who the depositary will be; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the maturity date and the date or dates on which principal will be payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the date
or dates interest will be payable and the record dates for interest payment dates or the method for determining such dates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=86,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1011977,FOLIO='9',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of the subordination of any series of subordinated debt; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the place or places where payments will be payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our right, if any, to defer payment of interest and the maximum length of any such deferral period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional
redemption provisions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund provisions or otherwise, to redeem,
or at the holder's option to purchase, the series of debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether we will be restricted from incurring any additional indebtedness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple
thereof; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the
terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable
prospectus supplement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion or Exchange Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable
for our common stock or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions
pursuant to which the number of shares of
our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consolidation, Merger or Sale; No Protection in Event of a Change of Control or Highly Leveraged
Transaction  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indentures do not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of
all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders of the debt securities protection in the
event we have a change of control or in the event of a highly leveraged transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt
securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=87,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=841057,FOLIO='10',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Events of Default Under the Indenture  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following are events of default under the indentures with respect to any series of debt securities that we may
issue:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we fail to pay interest when due and our failure continues for 90&nbsp;days and the time for payment has not been extended or deferred; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we fail to pay the principal, or premium, if any, when due and the time for payment has not been extended or delayed; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we fail to observe or perform any other covenant set forth in the debt securities of such series or the applicable indentures, other than a
covenant specifically relating to and for the benefit of holders of another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice from the debenture
trustee or holders of not less than a majority in aggregate principal amount of the outstanding debt securities of the applicable series; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if specified events of bankruptcy, insolvency or reorganization occur as to us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of
default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under any bank credit agreements we may have in existence from
time to time. In addition, the occurrence of certain events of default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding
from time to time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than a majority in
principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the debenture trustee if given by the holders), declare to be due and payable immediately
the principal (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and premium and accrued and
unpaid interest, if any, on all debt securities of that series. Before a judgment or decree for payment of the money due has been obtained with respect to debt securities of any series, the holders of
a majority in principal amount of the outstanding debt securities of that series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount
of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events of default, other than the non-payment of accelerated principal, premium, if
any, and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect of principal,
premium or interest that had become due other than as a result of such acceleration). We refer you to the prospectus supplement relating to any series of debt securities that are discount securities
for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an event of default. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable
indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any
remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture trustee, with respect to the debt securities of that series, provided
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the direction so given by the holder is not in conflict with any law or the applicable indenture; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=88,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=504627,FOLIO='11',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability
or might be unduly prejudicial to the holders not involved in the proceeding. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
holder of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies
if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holder previously has given written notice to the debenture trustee of a continuing event of default with respect to that series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holders of at least a majority in aggregate principal amount of the outstanding debt securities of that series have made written request,
and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of
the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such
series represented at such meeting) other conflicting directions within 60&nbsp;days after the notice, request and offer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the applicable indenture. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Modification of Indenture; Waiver  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The debenture trustee and we may change the applicable indenture without the consent of any holders with respect to specific matters,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to fix any ambiguity, defect or inconsistency in the indenture; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to change anything that does not materially adversely affect the interests of any holder of debt securities of any series issued pursuant to
such indenture. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with the written consent of the holders of at least
a majority in aggregate principal amount of the outstanding debt securities of each series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in
principal amount of the debt securities of such series represented at such meeting) that is affected. However, the debenture trustee and we
may make the following changes only with the consent of each holder of any outstanding debt securities affected:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> extending the fixed maturity of the series of debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reducing the principal amount, reducing the rate of or extending the time of payment of interest, or any premium payable upon the redemption of
any debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reducing the principal amount of discount securities payable upon acceleration of maturity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reducing the percentage of debt securities, the holders of which are required to consent to any amendment or waiver. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series (or, at a meeting of holders of such
series at which a quorum </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=89,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=200537,FOLIO='12',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>is
present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may on behalf of the holders of all debt securities of that series waive
our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities
of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt
security of that series or in respect of a covenant or provision, which cannot be modified or amended without the consent of the holder of each outstanding debt security of the series affected;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment
default that resulted from the acceleration. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Discharge  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for obligations to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> register the transfer or exchange of debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> replace stolen, lost or mutilated debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain paying agencies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hold monies for payment in trust; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compensate and indemnify the trustee; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appoint any successor trustee. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to exercise our rights to be discharged with respect to a series, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, the
premium, if any, and interest on, the debt securities of the series on the dates payments are due. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form, Exchange, and Transfer  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide that we may issue debt securities of a series in temporary or permanent global
form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to
that series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present
the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the
office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or
exchange or in the applicable indenture, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=90,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=528629,FOLIO='13',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt
securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except
that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we elect to redeem the debt securities of any series, we will not be required to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business
15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any
debt securities we are redeeming in part. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Concerning the Debenture Trustee  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes to
perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee under such indenture must use the same degree of
care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it
by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment and Paying Agents  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise
indicate in the applicable prospectus supplement, will we make interest payments by check which we will mail to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate
the corporate trust office of the debenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable
prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt
securities of a particular series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed at the end of
two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governing Law  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the
extent that the Trust Indenture Act is applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=91,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=268931,FOLIO='14',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dc42403_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Subordination of Subordinated Debt Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to
certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of senior indebtedness we may incur. It also does not limit
us from issuing any other secured or unsecured debt. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc42403_description_of_warrants"> </A>
<A NAME="toc_dc42403_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF WARRANTS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue warrants to purchase shares of our common stock, preferred stock and/or debt securities in one or more series together with other
securities or separately, as described in the applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of
the warrants will be described in the warrant agreements and the prospectus supplement relating to the warrants. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the warrants:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the specific designation and aggregate number of, and the price at which we will issue, the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency or currency units in which the offering price, if any, and the exercise price are payable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation, amount and terms of the securities purchasable upon exercise of the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the
warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise, and
a description of that series of our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the exercise price for our debt securities, the amount of debt securities to be received upon exercise, and a description of
that series of debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously
exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms,
although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any applicable material U.S. federal income tax consequences; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or
other agents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the date from and after which the warrants and the common stock, preferred stock and/or debt securities will be separately
transferable; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=92,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1016775,FOLIO='15',FILE='DISK123:[17ZDN3.17ZDN42403]DC42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de42403_1_16"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> information with respect to book-entry procedures, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the anti-dilution provisions of the warrants, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any redemption or call provisions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the warrants may be sold separately or with other securities as parts of units; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de42403_description_of_rights"> </A>
<A NAME="toc_de42403_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF RIGHTS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue rights to our stockholders to purchase shares of our common stock, preferred stock or the other securities described in this
prospectus. We may offer rights separately or together with one or more additional rights, debt securities, preferred stock, common stock, warrants or purchase contracts, or any combination of those
securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will be issued under a separate rights
agreement to be entered into between us and a bank or trust company, as rights agent. The rights agent will act solely as our agent in connection with the certificates relating to the rights of the
series of certificates and will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners of rights. The following description
sets forth certain general terms and provisions of the rights to which any prospectus supplement may relate. The particular terms of the rights to which any prospectus supplement may relate and the
extent, if any, to which the general provisions may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent that any particular terms of the rights,
rights agreement or rights certificates described in a prospectus supplement differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that
prospectus supplement. We encourage you to read the applicable rights agreement and rights certificate for additional information before you decide whether to purchase any of our rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will provide in a prospectus supplement the following terms of the rights being issued:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date of determining the stockholders entitled to the rights distribution; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the aggregate number of shares of common stock, preferred stock or other securities purchasable upon exercise of the rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the exercise price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the aggregate number of rights issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the rights are transferrable and the date, if any, on and after which the rights may be separately transferred; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date on which the right to exercise the rights will commence, and the date on which the right to exercise the rights will expire; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the method by which holders of rights will be entitled to exercise; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=93,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=780826,FOLIO='16',FILE='DISK123:[17ZDN3.17ZDN42403]DE42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_de42403_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the conditions to the completion of the offering, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the withdrawal, termination and cancellation rights, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether there are any backstop or standby purchaser or purchasers and the terms of their commitment, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether stockholders are entitled to oversubscription rights, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any applicable U.S. federal income tax considerations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise of the rights,
as applicable. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
right will entitle the holder of rights to purchase for cash the principal amount of shares of common stock, preferred stock or other securities at the exercise price provided in
the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
may exercise rights as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly completed and duly executed at the corporate
trust office of the rights agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the shares of common stock, preferred stock or other securities,
as applicable, purchasable upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other
than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby arrangements, as described in the applicable prospectus
supplement. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rights Agent  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The rights agent for any rights we offer will be set forth in the applicable prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de42403_description_of_purchase_contracts"> </A>
<A NAME="toc_de42403_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF PURCHASE CONTRACTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific or
variable number of our debt securities, shares of common stock, preferred stock, warrants or rights, or securities of an entity unaffiliated with us, or any combination of the above, at a future date
or dates. Alternatively, the purchase contracts may obligate us to purchase from holders, and obligate holders to sell to us, a specific or variable number of our debt securities, shares of common
stock, preferred stock, warrants, rights or other property, or any combination of the above. The price of the securities or other property subject to the purchase contracts may be fixed at the time
the purchase contracts are issued or may be determined by reference to a specific formula described in the purchase contracts. We may issue purchase contracts
separately or as a part of units each consisting of a purchase contract and one or more of our other securities described in this prospectus or securities of third parties, including U.S. Treasury
securities, securing the holder's obligations under the purchase contract. The purchase contracts may require us to make periodic payments to holders or vice versa and the payments may be unsecured or
pre-funded on some basis. The purchase contracts may require holders to secure the holder's obligations in a manner specified in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will describe the terms of any purchase contracts in respect of which this prospectus is being delivered, including, to the extent applicable, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase
under the purchase contract, and the nature and amount of each of those securities, or the method of determining those amounts; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=94,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=563920,FOLIO='17',FILE='DISK123:[17ZDN3.17ZDN42403]DE42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_de42403_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the purchase contracts are to be prepaid; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance or level of the securities
subject to purchase under the purchase contract; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any acceleration, cancellation, termination or other provisions relating to the settlement of the purchase contracts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any applicable U.S. federal income tax considerations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the purchase contracts will be issued in fully registered or global form. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preceding description sets forth certain general terms and provisions of the purchase contracts to which any prospectus supplement may relate. The particular terms of the purchase
contracts to which any prospectus supplement may relate and the extent, if any, to which the general provisions may apply to the purchase contracts so offered will be described in the applicable
prospectus supplement. To the extent that any particular terms of the purchase contracts described in a prospectus supplement differ from any of the terms described above, then the terms described
above will be deemed to have been superseded by that prospectus supplement. We encourage you to read the applicable purchase contract for additional information before you decide whether to purchase
any of our purchase contracts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de42403_description_of_units"> </A>
<A NAME="toc_de42403_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF UNITS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description, together with the additional information that we include in any applicable prospectus supplements summarizes the
material terms and provisions of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus,
we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the
terms described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will incorporate by reference from reports that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental
agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to,
all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular
series of units that we may offer under this prospectus, as well as any related free writing prospectuses and the complete unit agreement and any supplemental agreements that contain the terms of the
units. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue units consisting of common stock, preferred stock, one or more debt securities, warrants, rights or purchase contacts for the
purchase of common stock, preferred stock and/or debt securities in one or more series, in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security
included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each security included in the unit. The unit agreement under which a unit is issued may provide
that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will describe in the applicable prospectus supplement the terms of the series of units being offered, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
securities may be held or transferred separately; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=95,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=507935,FOLIO='18',FILE='DISK123:[17ZDN3.17ZDN42403]DE42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_de42403_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any provisions of the governing unit agreement that differ from those described below; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
provisions described in this section, as well as those set forth in any prospectus supplement or as described under "Description of Common Stock," "Description of Preferred Stock,"
"Description of
Debt Securities," "Description of Warrants," "Description of Rights," "Description of Purchase Contracts" and "Description of Units" will apply to each unit, as applicable, and to any common stock,
preferred stock, debt security, warrant, right or purchase contract included in each unit, as applicable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unit Agent  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name and address of the unit agent for any units we offer will be set forth in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issuance in Series  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue units in such amounts and in such numerous distinct series as we determine. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Enforceability of Rights by Holders of Units  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or
trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us
under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the
consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de42403_certain_provisions_of_delaware__cer03850"> </A>
<A NAME="toc_de42403_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN PROVISIONS OF DELAWARE LAW AND OF THE COMPANY'S CERTIFICATE OF INCORPORATION AND BYLAWS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Provisions of our Certificate of Incorporation and Bylaws  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the board of directors' ability to issue shares of preferred stock, our restated certificate of incorporation and restated bylaws
contain other provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying, deferring or
preventing a future takeover or change in control of our company unless such takeover or change in control is approved by our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly
or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Classified board of directors; removal of directors for cause.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated bylaws provide
for our board of
directors to be divided into three classes serving staggered terms. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire are elected for a three-year
term of office. All directors elected to our classified board of directors will serve until the election and qualification of their respective successors or their earlier resignation or removal. The
board of directors is authorized to create new directorships and to fill such positions so created and is permitted to specify the class to which any such new position </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=96,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=561053,FOLIO='19',FILE='DISK123:[17ZDN3.17ZDN42403]DE42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_de42403_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>is
assigned. The person filling such position would serve for the term applicable to that class. The board of directors (or its remaining members, even if less than a quorum) is also empowered to fill
vacancies on the board of directors occurring for any reason for the remainder of the term of the class of directors in which the vacancy occurred. Members of the board of directors may only be
removed for cause and only by the affirmative vote of 80% of our outstanding voting stock. These provisions are likely to increase the time required for stockholders to change the composition of the
board of directors. For example, in general, at least two annual meetings will be necessary for stockholders to effect a change in a majority of the members of the board of directors. The provision
for a classified board could prevent a party who acquires control of a majority of our outstanding common stock from obtaining control of our board of directors until our second annual stockholders
meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could have the effect of discouraging a potential acquirer from making a tender offer or
otherwise attempting to obtain control of us and could increase the likelihood that incumbent directors will retain their positions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advance notice provisions for stockholder proposals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated bylaws establish an advance notice procedure for stockholder proposals
to be
brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors, as well as procedures for including proposed nominations at
special meetings at which directors are to be elected. Stockholders at our annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by
or at the direction of our board or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our secretary
timely written notice, in proper form, of the stockholder's intention to bring that business before the meeting, and who has complied with the procedures and requirements set forth in the bylaws.
Although our bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or
annual meeting, our bylaws may have the effect of precluding the conduct of some business at a meeting if the proper procedures are not followed or may discourage or defer a potential acquirer from
conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of the stockholders may be called only by our board of directors pursuant to a
resolution adopted
by a majority of the total number of authorized directors. Stockholders are not permitted to call a special meeting or to require our board of directors to call a special meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No stockholder action by written consent.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated bylaws do
not permit our stockholders to act by written consent. As a result, any action to be effected by our stockholders must be effected at a duly called annual or special meeting of the stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Super-majority stockholder vote required for certain actions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides generally that the
affirmative vote of a
majority of the shares entitled to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless the corporation's certificate of incorporation or bylaws, as
the case may be, requires a greater percentage. Our restated certificate of incorporation requires the affirmative vote of the holders of at least 80% of our outstanding voting stock to amend or
repeal certain provisions of our restated certificate of incorporation. This 80% stockholder vote would be in addition to any separate class vote that might in the future be required pursuant to the
terms of any preferred stock that might then be outstanding. In addition, an 80% vote is also required for any amendment to, or repeal of, our restated bylaws by the stockholders. Our restated bylaws
may be amended or repealed by a vote of a majority of the total number of authorized directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=97,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=912753,FOLIO='20',FILE='DISK123:[17ZDN3.17ZDN42403]DE42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg42403_1_21"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Provisions of Delaware Law Governing Business Combinations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the "business combination" provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, such
provisions prohibit a publicly held Delaware corporation from engaging in any "business combination" transactions with any "interested stockholder" for a period of three years after the date on which
the person became an "interested stockholder," unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prior to such date, the board of directors approved either the "business combination" or the transaction which resulted in the "interested
stockholder" obtaining such status; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon consummation of the transaction which resulted in the stockholder becoming an "interested stockholder," the "interested stockholder" owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding
voting stock owned by the "interested stockholder") those shares owned by (a)&nbsp;persons who are directors and also officers and (b)&nbsp;employee stock plans in which employee participants do
not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at or subsequent to such time the "business combination" is approved by the board of directors and authorized at an annual or special meeting
of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the outstanding voting stock which is not owned by the "interested stockholder." </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"business combination" is defined to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder. In general, an "interested stockholder" is a
person who, together with affiliates and associates, owns 15% or more of a corporation's voting stock or within three years did own 15% or more of a corporation's voting stock. The statute could
prohibit or delay mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations on Liability and Indemnification of Officers and Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation limits the liability of our officers and directors to the fullest extent permitted by the Delaware
General Corporation Law, and our restated certificate of incorporation and restated bylaws provide that we will indemnify our officers and directors to the fullest extent permitted by such law. We
have also entered into indemnification agreements with our officers and directors and expect to enter into a similar agreement with any new officers and directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg42403_legal_matters"> </A>
<A NAME="toc_dg42403_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts, will pass upon the validity of the issuance of the securities
offered by this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg42403_experts"> </A>
<A NAME="toc_dg42403_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2014, as set forth
in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on
Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=98,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1008285,FOLIO='21',FILE='DISK123:[17ZDN3.17ZDN42403]DG42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dg42403_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg42403_where_you_can_find_more_information"> </A>
<A NAME="toc_dg42403_3"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and file annual, quarterly
and current reports, proxy statements and other information with the SEC. You may read and copy these reports, proxy statements and other information at the SEC's public reference facilities at
100&nbsp;F Street, N.E., Room&nbsp;1580, Washington, D.C.&nbsp;20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC
at 1-800-SEC-0330 for more information about the operation of the public reference facilities. SEC filings are also available at the SEC's web site at </FONT> <FONT SIZE=2><I>http://www.sec.gov.</I></FONT><FONT SIZE=2> Our common stock is listed on
The NASDAQ Global Market, and you can read and inspect our filings at the offices of the Financial
Industry Regulatory Authority at 1735 K Street, Washington, D.C. 20006. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is only part of a registration statement on Form&nbsp;S-3 that we have filed with the SEC under the Securities Act of 1933, as amended, and therefore omits certain
information contained in the registration statement. We have also filed exhibits and schedules with the registration statement that are excluded from this prospectus, and you should refer to the
applicable exhibit or schedule for a complete description of any statement referring to any contract or other document. You may inspect a copy of the registration statement, including the exhibits and
schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of the fees prescribed by the SEC. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also maintain a website at </FONT><FONT SIZE=2><I>www.syntapharma.com</I></FONT><FONT SIZE=2>, through which you can access our SEC filings. The information set forth on our website
is not part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg42403_incorporation_of_documents_by_reference"> </A>
<A NAME="toc_dg42403_4"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" information that we file with them. Incorporation by reference allows us to disclose important
information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will
automatically update and supersede this information. We filed a registration statement on Form&nbsp;S-3 under the Securities Act of 1933, as amended, with the SEC with respect to the securities we
may offer pursuant to this prospectus. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement,
including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed
with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the
registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in "Where You Can
Find More Information." The documents we are incorporating by reference are:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014 filed on March&nbsp;12, 2015; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2015 and June&nbsp;30, 2015 filed on May&nbsp;7, 2015 and
August&nbsp;6, 2015, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Current Reports on Form&nbsp;8-K filed on February&nbsp;5, 2015, March&nbsp;6, 2015, April&nbsp;1, 2015, April&nbsp;6, 2015,
April&nbsp;27, 2015 and June&nbsp;15, 2015; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the portions of our Definitive Proxy Statement on Schedule&nbsp;14A filed on April&nbsp;30, 2015 that are deemed "filed" with the SEC under
the Exchange Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the description of our common stock contained in our Registration Statement on Form&nbsp;8-A filed on January&nbsp;26, 2007, including any
amendment or report filed for the purpose of updating such description; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=99,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=693505,FOLIO='22',FILE='DISK123:[17ZDN3.17ZDN42403]DG42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<A NAME="page_dg42403_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg42403a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all reports and other documents subsequently filed by us pursuant to Sections&nbsp;13(a), 13(c), 14 and 15(d) of the Exchange Act after the
date of this prospectus and prior to the termination or completion of the offering of securities under this prospectus shall be deemed to be incorporated by reference in this prospectus and to be a
part hereof from the date of filing such reports and other documents. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC file number for each of the documents listed above is 001-33277. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus
modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request, orally or in writing, a copy of any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost, by contacting: Investor
Relations, Synta Pharmaceuticals Corp., 45 Hartwell Avenue, Lexington, MA 02421, (781)&nbsp;274-8200. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on information contained in, or incorporated by reference into, this prospectus and any prospectus supplement. We have not authorized anyone to provide you with
information different from that contained in this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer
or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=100,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=895149,FOLIO='23',FILE='DISK123:[17ZDN3.17ZDN42403]DG42403A.;5',USER='VRIVERA',CD='15-DEC-2017;23:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg42401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>1,506,025 Shares </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g467069.jpg" ALT="LOGO" WIDTH="337" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>Common Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B><BR>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> <BR>
December&nbsp;18, 2017<BR>
<BR>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Evercore ISI  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> JMP Securities  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Roth Capital Partners  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> H.C. Wainwright&nbsp;&amp;&nbsp;Co.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>We have not authorized anyone to provide any information other than that contained or incorporated by reference in this
prospectus supplement and accompanying prospectus or any free writing prospectus that we or the underwriters provide you in connection with the offering. We take no responsibility for, and cannot
provide any assurance as to the reliability of, any other information that others may give you. We are not making an offer of these securities in any state where the offer is not permitted. You should
not assume that the information contained in or incorporated by reference in this prospectus supplement and accompanying prospectus is accurate as of any date other than the date on the front of this
prospectus supplement.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>No action is being taken in any jurisdiction outside the United States to permit a public offering of shares of our common stock or possession or distribution of
this prospectus supplement in that jurisdiction. Persons who come into possession of this prospectus supplement in jurisdictions outside the United States are required to inform themselves about and
to observe any restrictions as to this offering and the distribution of this prospectus supplement applicable to that jurisdiction.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=101,EFW="2234106",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=129443,FOLIO='blank',FILE='DISK128:[17ZDN1.17ZDN42401]HO42401A.;37',USER='CHE106812',CD='18-DEC-2017;21:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g467069.jpg
<DESCRIPTION>G467069.JPG
<TEXT>
begin 644 g467069.jpg
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M>*&V&#8W87)V@;&UMR21L[C'T1DG*#,U0D-'4F7P_\0 '0$  @(" P$
M        !@<%"  $ @,) ?_$ #X1  (# 0 !! $" P0&!PD   ,$ 0(%!@<
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M%V"I([JOR 4N$>>%A6V6L9REGZCCWYTK"?NLV5(4O.<^/">\T=Z;B.8K3-)
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M[CT.+=P18XTY$?,C,MI]:/43M"U3XCBVD8]Q@-E2_5[?JS7+P+R13>5O;5%
MA\135TM2"^U1@<SKVSPUO>WM%;+OFJS'O[3\5+V_I6?5EOU =>,7B2LY!9,7
MN[Y.9E2+WDIU-.M- MQUK[S:IDA2O:(B?>6Z5C^:U8G'^R%M!&LNY!HQ!3ZA
MXO9 UXU1)92O",.KME5/.@6%YSGPI+ELK]?0E/C.<N*3Z?S>.N@_C/E.%?JQ
MG&,_?]GG'GKG"<AM=)[>7<:)K%=?/4!QWW#J&[UX\I3F"CX:.#HE_2:I:\J6
MI)[9!Z%?FRGT+6RGPA'IQT<0#19((20"?;*#/&9-#):SZFGQ"VDD#/-J_P#F
M0ZPXVM.?U92K&<=3OZFPJZ.MQ7:9_P IS^JY85UR6I\;$JJ2KHB$CWGXEE38
M5I:OO/M XK$S\?0_^EDSF;C]OQ&E\:Z'*=46K ZWB\"NT*4RC'/M7Y"JWD-6
MBWM,6O>UOVB8]5T\R.ZMP_X32)-3V7=3[7M$<4<M>I=9Q[-INP;)C*'PW+"I
MTV-KE/22,\R:,U:IZ*/, =;-C@#6'6E.5'&_$YZ_;+)1&\0KV8 AY:0RCMN5
M>/,?'QG]&Z4"+4)0<1]6/NMAF1-;;S]DDN?KZF9W#.S)5^=/)O6V[F-@-ZNA
MUU<BM;U5#Q*9"W6]NN*8S0)"KX,;<@AYWY J1K<Y,SR2FA(.,KORD5*O"98:
MSRM=B'MHUZ%8BI+3%BMYC2/2[8;3MS9N9HQ66DMY=>Q7[+7H9I65)R]AL&'$
M'0ZI7MLI;SAO ]SQ?T^Y7.XY^D3ZSI.A>6^W552)< LIFI+AN$<C>Q@V#>1R
M8']X>-8)!W+(;7^NI%T8OU%Z_2[0.8=Y#F><0;^G);>%1@FLK<8C4.2"([)Z
MFI!8$;^[IAJ>A!B^R*3>^G.-?Q"/#_=%EBZ=M*!NG'*9F210@9V[OP]BUO@T
MMQ3+0TA=H!QI^O,^]EI*I:S5V(@V4N86;*!H2M>+Z&'V"F&21GFGQWVFWF'V
M7$.LO,NH2XTZTZVI3;C3C:DK;<0I2'$*2M"E)5C.40^\;VM:KP2E*-M32DM.
M2.CMFS)]577[,8N:E]>W86->FQXA%A<::=FZW8H<:3?ALRJ7IJ/)A9 *0D)5
MLD-]J^WX?OD98]U<*2:#<94R9G./5\*UK%''N.DEKU^="QEGHP;YCN,J>1 C
MR$K6(]O+BU"PL'%#?E;::3UM^2?''&5XG,\F>-V7IP&FJ):.5H7L4R!27N"M
MJW+-SBN!L<*LA,=JM[' =9BP)^1-3QCY,[:W=:GB[R:JA'0JIV?S=;.'00-
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M#CGSSV62$'(6OWDD)SGIC<#V3/BRO9YSV"?6OOX.8&Y5&X$'.%H9Y'%#GO\
MBL5O]@-0,R.;!^-Z7'\YM^\+CR'Q2GE>>)?2W@Y%,#H-%H06U?L/I%0T *L@
M /\ )#:OP+F%]KU^WW'>E_A$>\>I*9QG*?M_^6,_[,+\Y_5_FQG^?KG9[@)Y
M4]M3GW?=GRT @?9,-LW9=BIUXVA34VRI["AKG,RA+%UAI*20(!*E2\++,K=E
M(*4$GJW(D&1;KD68R0'CHG__ -_+_NZK'LO=+X&L<E;MQ*V3L2#KMMHQT9%F
M62^QT>UJ4^XNM^[)T\6ZFN%PL9:*NZL<.738D0@'U5UR'CI,V5CY$,75\/\
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36>L]'1T='6>L]'1T='6>L]?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g819290.jpg
<DESCRIPTION>G819290.JPG
<TEXT>
begin 644 g819290.jpg
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ME5%>(S/QR*L. KRWZQ)Q ?=6C;L*W40C86UQ0-;EJY#(G,U*J$Q*4AC;WM<
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M7W&=''(Q'(@U$,448&6,LJ89YJ=HC[2WLK608J.&H4F$M[8F2HRAJ#S!G'C
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MM-YK*1V_>,?9+">./,OET*9%57F-CW.>,;1$V*L7Y9('RM'F:@9R6R'-0GF
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MC#"]MLSC4VT&SF$8[<89/A,^)V$%Y+A5RSM<63RKF;:5Y+>W<O&>!+6\1_\
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MUSHLF3P6_P!T/CCPT-J-JBT;FL>MZ.1^JY<J75[,WAZ]*8R2S0B 8 )@!A&
M0#-=\ ((]"",.P#[H&]""(0-ZV'>M@%L&_Z.]ZP HLL(0%AT   Z   /Z(
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M50CD/<%X%'JYI,R7Z65#Q\XJ<E4=[(9PW.KHI63=[C_(&GYL=Q;W*G=8[.:
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M3V*U/#7/&FO#Y_(C*U9I3J33>PYBXN#9"]M"9,\3Z4K['=&<+8IL4":;"?B
MS'R"#GS9"#A_17)]BJ*1$OW(9!00(/4<_?$==+8[(;]/CY;:ALV6*FI[(AT?
M@Z-X6OLYD2*.R):F8&)<J88T^.2EO:5/Z..'-MEY &4(,4+%$6[D90$CNRMW
M8,P9)2U/BFO9DSQ6Q6!F<FM.E3O[&G;IC IO7\U;M:2SZ%2%4\^!X\)I$F5*
M5.?.K\-L_P JMO[^C_&SLA@"8$0!A", P["((M:$$01:V$01:WUZWH6M[UO6
M]=6];WK?O9"871J='B,0ACX-<21#&(0QB%Q[JS8A#&+8AB%O<8Z]B$+>Q"WO
MW]BWO>_?WBJC3_6)'-DH/IY67_\ O^ZIC^&V?Y5;?W]'^-CPVS_*K;^_H_QL
MAMY-+H[^PSQ(\WJK/5C'DTNCO[#/$CS>JL]6,KPZ_5_'T]SPNR3I/[ ^L]/<
M\)D^&V?Y5;?W]'^-CPVS_*K;^_H_QLAMY-+H[^PSQ(\WJK/5C'DTNCO[#/$C
MS>JL]6,<.OU?Q]/<\&2=)_8'UGI[GA,GPVS_ "JV_OZ/\;'AMG^56W]_1_C9
M#;R:71W]AGB1YO56>K&/)I='?V&>)'F]59ZL8X=?J_CZ>YX,DZ3^P/K/3W/"
M9/AMG^56W]_1_C8\-L_RJV_OZ/\ &R&WDTNCO[#/$CS>JL]6,>32Z._L,\2/
M-ZJSU8QPZ_5_'T]SP9)TG]@?6>GN>$R?#;/\JMO[^C_&QX;9_E5M_?T?XV0V
M\FET=_89XD>;U5GJQCR:71W]AGB1YO56>K&.'7ZOX^GN>#).D_L#ZST]SPF3
MX;9_E5M_?T?XV/#;/\JMO[^C_&R&WDTNCO[#/$CS>JL]6,>32Z._L,\2/-ZJ
MSU8QPZ_5_'T]SP9)TG]@?6>GN>$R?#;/\JMO[^C_ !L>&V?Y5;?W]'^-D-O)
MI='?V&>)'F]59ZL8\FET=_89XD>;U5GJQCAU^K^/I[G@R3I/[ ^L]/<\)D^&
MV?Y5;?W]'^-CPVS_ "JV_OZ/\;(;>32Z._L,\2/-ZJSU8QY-+H[^PSQ(\WJK
M/5C'#K]7\?3W/!DG2?V!]9Z>YX3)\-L_RJV_OZ/\;'AMG^56W]_1_C9#;R:7
M1W]AGB1YO56>K&/)I='?V&>)'F]59ZL8X=?J_CZ>YX,DZ3^P/K/3W/"9/AMG
M^56W]_1_C8\-L_RJV_OZ/\;(;>32Z._L,\2/-ZJSU8QY-+H[^PSQ(\WJK/5C
M'#K]7\?3W/!DG2?V!]9Z>YX3)\-L_P JMO[^C_&QX;9_E5M_?T?XV0V\FET=
M_89XD>;U5GJQCR:71W]AGB1YO56>K&.'7ZOX^GN>#).D_L#ZST]SPF3X;9_E
M5M_?T?XV/#;/\JMO[^C_ !LAMY-+H[^PSQ(\WJK/5C'DTNCO[#/$CS>JL]6,
M<.OU?Q]/<\&2=)_8'UGI[GA,GPVS_*K;^_H_QL>&V?Y5;?W]'^-D-O)I='?V
M&>)'F]59ZL8\FET=_89XD>;U5GJQCAU^K^/I[G@R3I/[ ^L]/<\)D^&V?Y5;
M?W]'^-CPVS_*K;^_H_QLAMY-+H[^PSQ(\WJK/5C'DTNCO[#/$CS>JL]6,<.O
MU?Q]/<\&2=)_8'UGI[GA,GPVS_*K;^_H_P ;'AMG^56W]_1_C9#;R:71W]AG
MB1YO56>K&/)I='?V&>)'F]59ZL8X=?J_CZ>YX,DZ3^P/K/3W/"9/AMG^56W]
M_1_C8\-L_P JMO[^C_&R&WDTNCO[#/$CS>JL]6,>32Z._L,\2/-ZJSU8QPZ_
M5_'T]SP9)TG]@?6>GN>$R?#;/\JMO[^C_&QX;9_E5M_?T?XV0V\FET=_89XD
M>;U5GJQCR:71W]AGB1YO56>K&.'7ZOX^GN>#).D_L#ZST]SPF3X;9_E5M_?T
M?XV/#;/\JMO[^C_&R&WDTNCO[#/$CS>JL]6,>32Z._L,\2/-ZJSU8QPZ_5_'
MT]SP9)TG]@?6>GN>$R?#;/\ *K;^_H_QL>&V?Y5;?W]'^-D-O)I='?V&>)'F
M]59ZL8\FET=_89XD>;U5GJQCAU^K^/I[G@R3I/[ ^L]/<\)D^&V?Y5;?W]'^
M-CPVS_*K;^_H_P ;(;>32Z._L,\2/-ZJSU8QY-+H[^PSQ(\WJK/5C'#K]7\?
M3W/!DG2?V!]9Z>YX3)\-L_RJV_OZ/\;'AMG^56W]_1_C9#;R:71W]AGB1YO5
M6>K&/)I='?V&>)'F]59ZL8X=?J_CZ>YX,DZ3^P/K/3W/"9/AMG^56W]_1_C8
M\-L_RJV_OZ/\;(;>32Z._L,\2/-ZJSU8QY-+H[^PSQ(\WJK/5C'#K]7\?3W/
M!DG2?V!]9Z>YX3)\-L_RJV_OZ/\ &QX;9_E5M_?T?XV0V\FET=_89XD>;U5G
MJQCR:71W]AGB1YO56>K&.'7ZOX^GN>#).D_L#ZST]SPF3X;9_E5M_?T?XV/#
M;/\ *K;^_H_QLAMY-+H[^PSQ(\WJK/5C'DTNCO[#/$CS>JL]6,<.OU?Q]/<\
M&2=)_8'UGI[GA,GPVS_*K;^_H_QL>&V?Y5;?W]'^-D-O)I='?V&>)'F]59ZL
M8\FET=_89XD>;U5GJQCAU^K^/I[G@R3I/[ ^L]/<\/L^0SLU&;B6P.C9OJ\-
M=?\ YBB#U=>FWJ_24:Z^OJW\'7D;/"3;\IMGVD@_F<^:O?H[> K/N+Z;.%/%
M5![(\+]_]AT-6J7OO>M-_>^^>QHZ5W?<=\'W/=]UW/=;ZNKKWD?/$&X-=CGC
M%_HC7_\ L>=%8:O%(L@"/+Y6(/\ K'\P4^?K[*U-R(=^^;R@^3GE$A'XB^<S
M#]G[.,J/"3;\IMGVD@_F<>$VW7P.;;K^YS0:W^O^I3_5OW]?JWK6_AUK(K^(
M-P:['/&+_1&O_P#8\>(-P:['/&+_ $1K_P#V/)>;]%?:/P5'R@_*3>Z3Z[T]
MQQE5IU;P[T(+JWA$'>A!$%U1!$$6M]T$01!5:V$01:T(.P[UO0M:%K>A:Z\>
M%D'7L7A9O[H6];$+PLB[H6PB[L.Q;]E=8A!'_3UO>][T/^EK>A>_D5?$&X-=
MCGC%_HC7_P#L>/$&X-=CGC%_HC7_ /L>,WZ*^T?@IE!^4F]TGUWI[CC*L3LA
M'W/=NZ 7>^KO?=.R(7>^H6Q:T7W2K?<:T,0AZT#JUH8A"U_2%O>]GA-N^5&W
MKZ]BZ_"B'K[K?7O8NOV3U]UO>][V+X=[W[^\BOX@W!KL<\8O]$:__P!CQX@W
M!KL<\8O]$:__ -CQF_,OMGX*90=.7W2=7_C>GZ.;C*CPDV_*;9]I(/YG'A)M
M^4VS[20?S.17\0;@UV.>,7^B-?\ ^QX\0;@UV.>,7^B-?_['C-^BOM'X*90?
ME)O=)]=Z>XXRH\)-ORFV?:2#^9QX2;?E-L^TD'\SD5_$&X-=CGC%_HC7_P#L
M>/$&X-=CGC%_HC7_ /L>,WZ*^T?@IE!^4F]TGUWI[CC*CPDV_*;9]I(/YG'A
M)M^4VS[20?S.17\0;@UV.>,7^B-?_P"QX\0;@UV.>,7^B-?_ .QXS?HK[1^"
MF4'Y2;W2?7>GN.,J/"3;\IMGVD@_F<>$FWY3;/M)!_,Y%?Q!N#78YXQ?Z(U_
M_L>/$&X-=CGC%_HC7_\ L>,WZ*^T?@IE!^4F]TGUWI[CC*CPDV_*;9]I(/YG
M'A)M^4VS[20?S.17\0;@UV.>,7^B-?\ ^QX\0;@UV.>,7^B-?_['C-^BOM'X
M*90?E)O=)]=Z>XXWQB#H6NK?]H(O\0BT+7T[UU;_ &96%*^BDX[RVLZ?K$U?
M(&5+5<3OZ!.$HCS3!FR96##N2%-V33T_:)@]@BYIAP@I;$+F+4:G*TF%+XE&
M5KT@>4)"I"HL\,'HL AB%H.@ZZ]B%U=R#7]8Q=>]:T &NL0][WK6@ZWO>]:U
MUYYGJ^Z6.Z(I87(6U9DURN7U#R(B3O8_!*,VM'R*)J!G;:VY!1OC@T)&2YCX
MZ[FR.!VO7%DU/RSG<T/+E:F(QY;/=L" ;6T)&[.1K=U.V*=$S'Z_*8Y16O(*
M953=;(^SH\FV:GI3B[76A1&QZ[BE<2B':KF,4\A@)FA$0J/3EIE3BV.DK:K&
M3*'(IR,AR]7!#,27UT-\6>(IR==JVF2U^FUSPZY$C$FE4'H=OE:.;WTG:&^P
M)6\WX75Y=LOIQ&O;6^15K>Y*-B9W*8/K<XH7^-A8F)EZE^Z5GD+'$]RQ=PI?
MC![J'&A+R>EENDCY/2-%7,MB/%J)<?9!)F&GY2IJ,3PMLB2+KT U*6B9L#$U
MULI8T"64J'-3)"1-_?6SS_OE6BO0ISK./PFFPH>9L(KZ3P2UI2Q\C4LHXQ5.
MDLXI[=F]SK)UA\+42+3=+HP:WMQ\L=HPZ(V5S#IWTN<&AM4K-#OT5<<E[O8D
MIL*_[0F,YNY9:95W3P3!7<8DLMCTXH>%T-#&Z*E1".L<:K]RJELK2"R^+O:.
M./8G>4I9!N4MSFTOY;<T9QK?@HPQB?I[;LFUIU=MH.3C83C/I),V2OF1KG6I
MW6%>4Z4U*X?"XLPQQC8XY ZV:$+>VLJ0K;FY.LD=W]2Y'NA92.!\VZ2;DG)C
MK)B%>0FH:YE['<-'DUV;+'^<R,,ZI5\YMPGC7-I7'Y&TUX[U!8C/(&25QA:*
M15984B7UHX395"YO'XW.6%L7.5\&NOJ]_P#6+Z-;WU?],4JJB4=' CD]\.(F
M*1)J=XI-L&X?HVBDZNBU;(VJ22/C7<MX7 F0B,=(2MD=7(VZ0S*)*$KY6K^T
M.3V@<)0@T)D="4KZ.7YE22IKY<:O-H7D*X=->/Z&HYVSGF%$JVA^K6QWJ?5B
M^M(1=8EB-T26=:3))"MC":D.31(],6:2:XC3R9QBE1 A/#6 0EFXPL:=^DCL
MCXM!GX8D%V+8S_;%JPHE(H>Y^V8L#8 D>T;?)%IJ+P66AUL\!05/?B!'%&=-
M'.!]*-$T4R][0AG)2EIY&LVHU,X_$7N.IDG):_U_(*9>Q4*MB-T2)M?W R.L
M^@[[V9'"RBW4"]>'V7N;&,4JJ.5='"EAW'WCU57'][0L-GU))>&<;>N1KK'X
M&3;[_5'%=_:"8^;(5RB(.D>F#NPQ-N"E0Q]U9@,B_>U)2$+(I-1*D63J1X7+
MZ<LVD#2)".00&BZYY#N!,@<MLK1)9Y>?*ZV6N?62^'PV&QV.P>&Q&-)6-Y]K
MD?C+>WM!0[ "W(FTHN*"7.5AV,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&
M,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&,4IC&
M82OJ^89QUAS9/K TO)B:F8Q>)NKH@)TI\ @E"TQ 2^KDH=^R#VIM." US"B
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M4&*(Y/8Y&)*B3;WK1R56N9TR5>C&4O0'*4)Q2D?-,IE&Z^:2GR8N6V5M4/\
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M*4QC&*592J2IER90C6IR%:-60<F5)51):A,I3*"Q$GIU!!H1E'$'%#&4<48
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MG;^UZ0_-Z0_8#Q_(X]KTA^;TA^P'C^1QXK<_F\_N9/AI]L+#\]M/UB+X^O\
M;S&NHQG;^UZ0_-Z0_8#Q_(X]KTA^;TA^P'C^1QXK<_F\_N9/AI]L+#\]M/UB
M+X^O]O,:ZC&=O[7I#\WI#]@/'\CG I:'=&5L]8T.Z(C0@@V>M:G%&1H8][T
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M\:2W<J(B)!9V]I:6[&,9WU>/4QC&*4QC&*4QC&*4QC&*4QC&*5&7D3^E$?\
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MY;I11K#.)5'I'R@FS\1!"[B>VP-*5!R6>Z-B$=97*,T^I11NQW+;,\%FRRX
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M0Y*C=SAM.WX9"%<]IBS'*,N%?43)[M<JCC9%)^Z"X)BW)DTWVA;26W@N??\
MC35Z(AY9[5C-3E!M&329[(;H8[+71K9V]78B0;H\@@\(R#0GD$* F)M'Z2F!
M/)+."8ETJT%5I*9HS0TVE00JM$"+TJ"%1HS6L=3ZF:@M9=&'.T*KKFQG&%+C
M'.'KIS"H[*E<77G'HE1REB/>VY:8W;/5-C8J4$D""E4*VUN5*$YJA C-(R7O
M>Q;V(6]B$+>Q"%O>][$(6][$+>]^_O>][WO>]^_O>][W[^9 I#,2200H )S
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M\47]0/HSDQBE<?>2OBB_J!]&.\E?%%_4#Z,Y,8I7'WDKXHOZ@?1CO)7Q1?U
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M]%A7(;#&H]E&;IX[DK$+^.A(IQ;IDG&*+\.I[QN\&AGIDS'+2SS9/*6J5%$
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)%[M>SJ'JK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g343675.jpg
<DESCRIPTION>G343675.JPG
<TEXT>
begin 644 g343675.jpg
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M-6Z">3FJ0,XD3+E<:TKIK9:J!B?S!,XIX*LY%E,)FU&Y8SU 3$,&[%C&8.(
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M=S)!LNUG*4:Y2Z62)45.7>62/D[(O+&9$%L,R-J"R12M&P"6C0N0LHN<5#M
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MSPV_)[R0R3N9'$:+%'C?8L<\V\,  DYYJQ;N\ALHUEFW]UY$A4(I=FDDSNJ
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M<)*B=*CLC<\]@7R00+LRR^$IGFXJAMTPY,3)DB45#-TDF.2.7>6MQ6_QRO\
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MZ5FANXH14B^O\J+\@N=#>:VTG@A.4=@2VD+F;2<"2V3B,N$B88@MU90+&!R
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MG2T1GPPW.TY$1P41]1^_6V254)5,(JV5*$QRZ@E*H)Y,,@"Y A9YF<!RD_\
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M*[&=KVO>]NGH[MKV_+>W1>]K6OVK]K\G%?M7M>_-=<1*V->\6.ERH)*0VM#
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M7/$(JWG":%RRS$8X@F6(2:I"Y99M'/+$L8RR;>6&:)V/@1@C 08X(F H(V&
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M/:RNJ8WE)R&YL<W>[PXD9)&,  YQQ('&N;C5F_HD#!7IY^.Z> / <>)(XD
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MMIK<CAOJ4@-YOOQW2&]1WZ<++9)'(_)[!<%7,S_=[[<<?R4SPR,NI.VD<O1
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MR,J068N/)@O-#2#>)00H*@NI*$%<+2:RD6\Z0>"Q=[SD:0]CBTX*Z9L1EMK
MT^PT&777B4AIJ1[K6"U6%'T8NYD%C&>;@-N.&+S$W'FY"E@+8N&;74H)Y,P2
M)EPQU*D%%W"-MZ430;D3("G$""7.--Q2*]@BA1B.9B/L_ &#QS>A%;2&L\U5
MZ1"(X V [AHZ,2P@-<BYLD:Z,K&6J[U5 :ZMM9Y;OQ6R&-%\@JR$^A4*58->
MNPB1B33444\C1]'C)94B.T1=+9KX7$L)C1>@"G@F(XBM<[DC+),F,,:LFA*-
M>C(X,Z>4[8H"4U(QK#&PR>!.84B3K 2:^8ZE[=<M)D?/ED-I+VKAELMIGP2
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MCW]]=\%9IOMJ.1-RQ8APDGO7+ \C*QTM?%HGE).)N?+G>)OFE B75^HQCA;
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M>B:62GS@.\F*_P J0_!2\Y"B1_.J)7\=1@[XXY@H:H[V.M*J( )<00NDGB8
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M^G62E*5CYK'NB?/"^G3FL>Z)\\+Z=9*4I6/FL>Z)\\+Z=:VES,0M'R\,7',
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M64JQVE09MOC$;2<:+'THBNE+<X;6,&G-(;8BJ6537<=YH$%F]B78U65,)QI
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M?\+/ &]A+VM^#?CJ%.O>D[JA>5D20U5^M==(I2>X20B6F)"V4.C9K20830A
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M5[V@:;;VO>U[1')5[7M>]KVO9EK=[7M>W%>U[?DO:]KV_)6WJU!L'^(6;?\
MNBDK_P!%K=:_5O\ NK4_^GWO_P :6MSLY_XAT+_K.E__ #H*Z0X!@QS '^G,
M?[ '_P"TF.]8?^]K+U08[^8_B3'WM>(!_L /^P!_\K"LM?D@KO@=\W,/[1Z/
MCK^D5HX\GO$YS_97I^*LW5!COYC^),?>TZH,=_,?Q)C[VL-*KOOXS>D>VJ<G
M'Y-/17LK-U08[^8_B3'WM.J#'?S'\28^]K#2F^_C-Z1[:<G'Y-/17LK-U08[
M^8_B3'WM.J#'?S'\28^]K#2F^_C-Z1[:<G'Y-/17LK-U08[^8_B3'WM.J#'?
MS'\28^]K#2F^_C-Z1[:<G'Y-/17LK-U08[^8_B3'WM.J#'?S'\28^]K#2F^_
MC-Z1[:<G'Y-/17LK-U08[^8_B3'WM.J#'?S'\28^]K#2F^_C-Z1[:<G'Y-/1
M7LK-U08[^8_B3'WM.J#'?S'\28^]K#2F^_C-Z1[:<G'Y-/17LK-U08[^8_B3
M'WM.J#'?S'\28^]K#2F^_C-Z1[:<G'Y-/17LK-U08[^8_B3'WM.J#'?S'\28
M^]K#2F^_C-Z1[:<G'Y-/17LK-U08[^8_B3'WM.J#'?S'\28^]K#2F^_C-Z1[
M:<G'Y-/17LKF][Y7OEE?+++*_'?++*^65[]V^65[Y7O_ 'WO>_\ ?7OFJZG&
MQW&BN]H+:@W'.W% !50UQ*'N74$Q0+WOS9@N)Q9896RPRS!,%QL!2IPJ*.3.
M CE1Q@<_04JL4LL,L<\,DD4T,B2Q31.T<L4L;!XY(Y$(=)$<!T=2&5@&4@@&
MK9[>"Z@FM;F"&XM;F&2WN+:>))K>>WF1HIH)H9%:.6&6-FCDBD5DD1F1U*D@
M]LW0W>5#VJ:@K><]D]OS2TB(&;F0@! P"3G3L>2!9Y-8L(+D/[GBC7P#6TNW
M.B-U0'"!R%&3CB<:%L+KHMQTY'VT7RU'%&)];3I 35LCDT3#<"%,K8BV9%L4
M*$"!$$,;)4R5,AKIPZ,( 8+*Y8R*GFRPY<<0._=9AQ3DE9BYCJDP("0UY,/-
M\D8>2 A'<E!+35G/'+G02X^5N(,3,*P0YLB$,=+IAT4PFEE-4+E U$S^@?<,
M[INH;=:5<Z9K5M<R:OH44(GUA86]Q:C!(=R!IY541PZH IY:$X%RBM=0@8GC
MB_&3^5MW!=&[D6T5CKNR]]8P[-;77%TUGLS)=)[Z:'=P*LMU':VTCFXN]!+.
M#;78#&QDD33KHDFTGNMETI2O>J^/Z4I2E*4I2E*4I2E*4I2E*5K&8_Q=.#]F
M?S8C6SJUC,?XNG!^S/YL1J>U_K-O^/A_W%J.;[E+^+?_ $FH.TI2NIK1UG*@
M=5&BA6V7(N;-%BMA+6Y7-W,CA@6SY/\ O<BXG*XOR\7%^6JPLYHV*<<':W3P
MSGVRT5N3!MTP<9%0'$UAG$Y"4'23LPEQ,S8JC!7258JV6T83VF6!S?[C=:2[
M5L\H*KCNWS+?61"IM-LXQRS#SP$#RRP$#SQ$#SQOQ98"896SPSQO^3+#*ULL
M;_DO:UZTVQX09+):1AA!DPU]EE947I8:#=7B10P38JNL2"++*<EM^X6.'*36
M;)!Y6<S)',X=7(.)PDEXB#ED4B+E:P8\ 2 58$@XPV5*GAQX88'CX>;PU<I
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M_P#I-5_NEM([S;:ZTG 7%-H3D2S:,KE@#(Q,8PGG@^:,@A&RV6!@MGGAT6&
MSQ%P[>&5KUI6/=582BUU$7JRFVK)SA3BZ@5*&S3J750 ,%4*"$3N.1(\9%+"
M7$+"YX89987R"RO;/"]LK6O4B*5GW^S>S^J:C8ZOJ6B:5?ZII9C;3=1N["VN
M+VP:*;W1$;2YEC::W,<_PR&)U*R]^,-QK,TG;;;'0=&U;9W1-J-?TG0->69-
M;T;3M6O;/3-72XMO<<ZZC8V\T=O>+-:?\M(+B.0/!\$V4X5E S$"' %"MQC!
M#@B@VY-\^,8,7#,*W(MTY\8F.-N1;IR_U;=-ZT0VHNAUT:]9PNA&07] K\:C
MY0PP"3RS<:2YVK*JRZU9S71G4WSN(8X"BHNY?Q25= .!CIO*+XIIS$R0#'MO
MPC<*Q\A<>^.(%CY&X^667)QQ ZJ!Y_+/+CMR<+!<N^67';DXVO?CMQ<=4Y1H
MP]JS",UGBXEW8YK."-36A!=G1V@JRFR(\-%UR=ULIM2,Z8V0DX@WWT5O%IXH
M"]4YRDSR6S48@17T,H@K69E8'V[G!7O=[(<<V< ;I.<GP@<!@[Q ' #-<THS
MGOMT@KCCC))(!^3.<^ 9J12?J[KTMI;5<B]/3^E=2D>1H_7$23WK,$>.A7EX
MFU(JE2+FG"Z4I)+42FDYHY6(I?DPIR@VV,AE'DZ<EY\/D1W"NL,\XB7UL/Z.
MPQ#0[;'0UN2G.9:+DB188N;R=B&9P:Q*$D1X-Z+F>E)[6:+03%-'2$Y]N'W5
M5W"179(?1T5--/)]+XB,F!@5[QXRM@V;);:=]VKL4JR"H1UJ>LN!I713MF07
M3&*)OBG.I*:Q9<:F<3L%Z)2H?ATJ6*Y#E%-'RD<19.I9AL/)>R'U_$@<\/6[
M2"EE7W+Q9S=V/X->94PS:VY"FID, WR]69L484W++,:MMZ+HS561&$J2DWF@
MS&9%K24Q#[V83,164 MK6..)%7!Y)@V'(Y^8 $G/'B>&?[0.!QYZEW&.<2 +
MWH)STD 8 QP'FX$#/ G M,0]4H!=!QGR(TW0Y5UK7*^ZR26:[_1%F/WI<39I
M4VQ1G((K)B0=/*ON/,*NXQ40TVG2FIF396%!NG U$0LGJ2?\O%W!Z0C%1ELB
M(3LE]836<A1BV&VVUUT,K!MIC<A65$:88E3<4YJ1NU13AEEN]'$L*Y%$V<=S
MY3%=6 D=P.Y0Q2%1(A>V1]K4K.-4EQ8[5-J7RF&IY>!6>R&LXDK78\ACR6L6
MVS V"3FPAVB@B6(-:ZUBYK2^90EANLP&-5*#<,U\^*,=EEJ(S)V:3CC=5DQX
M[".VTBZBICMEX.9G4MN))0MB2TJ(X0*:BH"D "CQ@O!Q^MK*<HL]IED=-5$=
M$(*JNF'%Q-'63-ZE&*_!8X<Y  7F7!'3P'>^*0?[6*M.\H/P@\P!Y_#D<W#P
M @?TAC P#4X2[*12DB')1+9J@#M/QXGQ<:'!4QPDX5HICO5GP4+W3@K887/8
MKZT?%S/9#97$*"!E.9QQ#Y>6KG7K/$SU+.TDXDQ;-DWQ*^4SN0N7<9Y.ZL>V
M<28PB+F7,$, #B>CBQ]C<ADG$C((X:GE=8+*!<U;#'#?U*G(!YP#QSQ /'I^
M.HLD<Q(\'.>;HJ C:X/*-V>CG4MN3'L0F#G6[%#5NH@..(@RH2)"H;N3F"FC
M,<&$ 8K6D@%LOITM=TMQT,!?;3Z*J6#E=B0IR"GICQ)>6R^#HUVCIT,9QL@2
M1&X39F<7J!UHI[G0PVR_G+#)4V4CIU/D;WG^^ZZ@D8&@KJS?8KL8<?.W!(;9
M!TLI516^02L9X4JSDH^'>#AQ'F/.3\OAZ?#FKN4?QCQY_/S8S\6!CH\&*CC)
M.LC.E!ZW=JX\952DE7RC7*1(U:[Q)I$:2]>'7..\(RQD=&&;R@OF VPOCX#&
M 6@Z6:"ZTXDFHCS#<*21!*5)#//,3/,03*^8@N>8@F>73EF()E?///+M?A9Y
MY7ROQ6M;CO?BM:OS2KPH!)  )XD]/M^DD\Y-6DDXR2<<WF]N'R #P4I2E5JE
M*4I2E67<JW<R\3/T:<JW<R\3/T:@!V*S@[? _@WI[?P0PZ?M5.Q6<';X'\&]
M/;^"&'3]JKD.'2>H=M='B/QG^;7UE3_Y5NYEXF?HTY5NYEXF?HU #L5G!V^!
M_!O3V_@AAT_:J=BLX.WP/X-Z>W\$,.G[53ATGJ';3$?C/\VOK*G_ ,JW<R\3
M/T:<JW<R\3/T:@!V*S@[? _@WI[?P0PZ?M5.Q6<';X'\&]/;^"&'3]JIPZ3U
M#MIB/QG^;7UE3_Y5NYEXF?HTY5NYEXF?HU #L5G!V^!_!O3V_@AAT_:J=BLX
M.WP/X-Z>W\$,.G[53ATGJ';3$?C/\VOK*G_RK=S+Q,_1IRK=S+Q,_1J '8K.
M#M\#^#>GM_!##I^U4[%9P=O@?P;T]OX(8=/VJG#I/4.VF(_&?YM?65/_ )5N
MYEXF?HTY5NYEXF?HU #L5G!V^!_!O3V_@AAT_:J=BLX.WP/X-Z>W\$,.G[53
MATGJ';3$?C/\VOK*G_RK=S+Q,_1IRK=S+Q,_1J '8K.#M\#^#>GM_!##I^U4
M[%9P=O@?P;T]OX(8=/VJG#I/4.VF(_&?YM?65/\ Y5NYEXF?HTY5NYEXF?HU
M #L5G!V^!_!O3V_@AAT_:J=BLX.WP/X-Z>W\$,.G[53ATGJ';3$?C/\ -KZR
MI_\ *MW,O$S]&G*MW,O$S]&H =BLX.WP/X-Z>W\$,.G[53L5G!V^!_!O3V_@
MAAT_:J<.D]0[:8C\9_FU]94_^5;N9>)GZ-.5;N9>)GZ-0 [%9P=O@?P;T]OX
M(8=/VJG8K.#M\#^#>GM_!##I^U4X=)ZAVTQ'XS_-KZRI_P#*MW,O$S]&G*MW
M,O$S]&H =BLX.WP/X-Z>W\$,.G[53L5G!V^!_!O3V_@AAT_:J<.D]0[:8C\9
M_FU]94_^5;N9>)GZ-.5;N9>)GZ-0 [%9P=O@?P;T]OX(8=/VJG8K.#M\#^#>
MGM_!##I^U4X=)ZAVTQ'XS_-KZRI_\JW<R\3/T:<JW<R\3/T:@!V*S@[? _@W
MI[?P0PZ?M5.Q6<';X'\&]/;^"&'3]JIPZ3U#MIB/QG^;7UE3_P"5;N9>)GZ-
M.5;N9>)GZ-0 [%9P=O@?P;T]OX(8=/VJG8K.#M\#^#>GM_!##I^U4X=)ZAVT
MQ'XS_-KZRI_\JW<R\3/T:<JW<R\3/T:@!V*S@[? _@WI[?P0PZ?M5.Q6<';X
M'\&]/;^"&'3]JIPZ3U#MIB/QG^;7UE3_ .5;N9>)GZ-.5;N9>)GZ-0 [%9P=
MO@?P;T]OX(8=/VJG8K.#M\#^#>GM_!##I^U4X=)ZAVTQ'XS_ #:^LJ?_ "K=
MS+Q,_1IRK=S+Q,_1J '8K.#M\#^#>GM_!##I^U4[%9P=O@?P;T]OX(8=/VJG
M#I/4.VF(_&?YM?65/_E6[F7B9^C3E6[F7B9^C4 .Q6<';X'\&]/;^"&'3]JI
MV*S@[? _@WI[?P0PZ?M5.'2>H=M,1^,_S:^LJ?\ RK=S+Q,_1IRK=S+Q,_1J
M '8K.#M\#^#>GM_!##I^U4[%9P=O@?P;T]OX(8=/VJG#I/4.VF(_&?YM?65/
M_E6[F7B9^C3E6[F7B9^C4 .Q6<';X'\&]/;^"&'3]JIV*S@[? _@WI[?P0PZ
M?M5.'2>H=M,1^,_S:^LJ?_*MW,O$S]&G*MW,O$S]&H =BLX.WP/X-Z>W\$,.
MG[53L5G!V^!_!O3V_@AAT_:J<.D]0[:8C\9_FU]94_\ E6[F7B9^C3E6[F7B
M9^C4 .Q6<';X'\&]/;^"&'3]JIV*S@[? _@WI[?P0PZ?M5.'2>H=M,1^,_S:
M^LJ?_*MW,O$S]&G*MW,O$S]&H =BLX.WP/X-Z>W\$,.G[53L5G!V^!_!O3V_
M@AAT_:J<.D]0[:8C\9_FU]94_P#E6[F7B9^C3E6[F7B9^C4 .Q6<';X'\&]/
M;^"&'3]JIV*S@[? _@WI[?P0PZ?M5.'2>H=M,1^,_P VOK*G_P JW<R\3/T:
M<JW<R\3/T:@!V*S@[? _@WI[?P0PZ?M5.Q6<';X'\&]/;^"&'3]JIPZ3U#MI
MB/QG^;7UE3_Y5NYEXF?HTY5NYEXF?HU #L5G!V^!_!O3V_@AAT_:J=BLX.WP
M/X-Z>W\$,.G[53ATGJ';3$?C/\VOK*G_ ,JW<R\3/T:<JW<R\3/T:@!V*S@[
M? _@WI[?P0PZ?M5.Q6<';X'\&]/;^"&'3]JIPZ3U#MIB/QG^;7UE3_Y5NYEX
MF?HTY5NYEXF?HU #L5G!V^!_!O3V_@AAT_:J=BLX.WP/X-Z>W\$,.G[53ATG
MJ';3$?C/\VOK*G_RK=S+Q,_1IRK=S+Q,_1J '8K.#M\#^#>GM_!##I^U4[%9
MP=O@?P;T]OX(8=/VJG#I/4.VF(_&?YM?65/_ )5NYEXF?HTY5NYEXF?HU #L
M5G!V^!_!O3V_@AAT_:J=BLX.WP/X-Z>W\$,.G[53ATGJ';3$?C/\VOK*G_RK
M=S+Q,_1IRK=S+Q,_1J '8K.#M\#^#>GM_!##I^U4[%9P=O@?P;T]OX(8=/VJ
MG#I/4.VF(_&?YM?65/\ Y5NYEXF?HTY5NYEXF?HU #L5G!V^!_!O3V_@AAT_
M:J=BLX.WP/X-Z>W\$,.G[53ATGJ';3$?C/\ -KZRI_\ *MW,O$S]&G*MW,O$
MS]&H =BLX.WP/X-Z>W\$,.G[53L5G!V^!_!O3V_@AAT_:J<.D]0[:8C\9_FU
M]94_^5;N9>)GZ-:TE_',6/%_ (,43._N;Q88!"9YWXE4E>_%CCC?*_%:U[WX
MK=%K<=ZB7V*S@[? _@WI[?P0PZ?M5? 2AP7W![I+'6SY/4*#PS('4'-YXM.X
M=\><4B@67X81T,2WX&>5OP<\>WQ7X\;WM>:V_K$&,D\M%@$8!.^N 3DX&?#4
M<HCY*3+OCDWSB-2<;I\'*C/Q9'QU[CJ,Y^A'/X0Q]W3J,Y^AG/X0Q]W4+NQW
MZ)^"9"GT</?U>G8[]$_!,A3Z.'OZO73Y?Q4],^K^/V/#2X@\I-\S'YO[QYSU
M>>IH]1G/T,Y_"&/NZXZC-_H1O^$,?=5"_L=^B?@F0I]'#W]7IV._1/P3(4^C
MA[^KTR_BIZ9]7\?L>#$'E)OF8_-_>/.>KSU-'J,YQ<GJ,YR>/CY/4ICD\?%>
MW'R>;XN/BO>W'Q<?%>]N/BO7ZZF/<=[]2G^._%QWZG-<=^+'D6O>_(X[WMA^
M!:]_]S\#_5Z*A9V._1/P3(4^CA[^KT['?HGX)D*?1P]_5Z9?Q4],^K^/V/!B
M#RDWS,?F_O'G/5YZFCU(<M:^-B9VV-^3QXV*F;8WY%^/#CQL'Q7Y%[WOCQVO
MR;WO>W%>G49S]".=S_YH8[7<_P!G4+NQWZ)^"9"GT</?U>G8[]$_!,A3Z.'O
MZO3+^*GIGU?Q^QX,0>4F^9C\W]X\YZO/4T>HSGZ&<_A#'W=.HSGZ&<_A#'W=
M0N['?HGX)D*?1P]_5Z=COT3\$R%/HX>_J],OXJ>F?5_'['@Q!Y2;YF/S?WCS
MGJ\]31ZC.?H9S^$,?=TZC.?H9S^$,?=U"[L=^B?@F0I]'#W]7IV._1/P3(4^
MCA[^KTR_BIZ9]7\?L>#$'E)OF8_-_>/.>KSU-'J,Y^AG/X0Q]W3J,Y^AG/X0
MQ]W4+NQWZ)^"9"GT</?U>G8[]$_!,A3Z.'OZO3+^*GIGU?Q^QX,0>4F^9C\W
M]X\YZO/4T>HSGZ&<_A#'W=.HSGZ&<_A#'W=0N['?HGX)D*?1P]_5Z=COT3\$
MR%/HX>_J],OXJ>F?5_'['@Q!Y2;YF/S?WCSGJ\]31ZC.?H9S^$,?=TZC.?H9
MS^$,?=U"[L=^B?@F0I]'#W]7IV._1/P3(4^CA[^KTR_BIZ9]7\?L>#$'E)OF
M8_-_>/.>KSU?S2E*Y&MW2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E/\ _OWUJZ()DC^<V:6?4<+@
M2TB#'3Z4;#RQZG4T5:2C&9530UQ.SRR'2U8B-AQBE1^@4N(7/%!#)$T6,BP/
M=6T=Q#://"EU<Q3S6]NTBK-/%:M MS)%&2'D2!KFW$K*"(S-'O$;ZYRX["]E
ML[G48K2YDL+*>TMKR]2&1K6UN+Y;I[*"XG53'#+=I97C6Z2,K3"VG,8;DGQM
M&E*5/6)2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2M8S'^+IP?LS^;$:V=6L9C_%TX/V9_-B-3VO\
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M]RD ;V##/D1!.4"E.M*!RSNC+5L.3GC?)+5,3"6/EB!VV8>F%@3LP$.28V7
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M>\;O^/8C9;0=]E28%L-;0TRY(P75]@'8U7U-*F4!Q&N3)'Y-=K):B\\#1,L
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MXFV9P;L%)TI;735'[LC23H=9[)@&!G6WF/*1>(Q%8ZY7E)VR*"YG<DJD5/\
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M<[IFZ5WJZFR4@F1U>4HK9;7<#R=:\H(,=M9S+ZUC@QR(F"$K)*D82ET!3 Q
MR!G#:UK6M:W1:W:M^2UOR6MW+6[5K?DMT5S2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*5Z-S-U+=S;<#47 1#"*YT16;RN7"'&*BCI:T0
M,)J@"$:+YACEA!2AH;# <#/ 8'+*P@6>.>..5O>4JUT21'CD57CD5D=' 971
M@5964Y#*RD@@C!!(-7Q2R0R1S0N\4L3I+%+&Q1XY(V#HZ,I#*Z, RL""K $'
M(JMW'@H=+\<<<;,-TVQPQQPQM_:8^;\6.&-L<;<=U?COQ6M;IOTWKGL46F'_
M . W3Y3'S_5ZLAI7%_8V[GOWD[*_D+3?-_=_,.H5ZC]G/NT?A7[HGYXZ_P#M
M]5O=BCTOMQ<;#=/%QVX__E+?-^.U[VZ.A8M_RO:_]]=5U2(W#7E-+( #"W"7
M5)+(%0<!31D;FU8P1(E00@\1#!HT+R02X(0> A@T/E@&'AF,)CC?OA7_ /C;
M_E>U5#:%<'F6BY7%GJ;$L Y)I]75U5BL\Y@$8*1P2.J1T8JMJ6'^D!-/PX5&
MQS!O:^8#2+"\P5R$6A#!HIXUW5.XW;;0ZIL9I>QV@Z3H-O)+K,NO:I8Z;;VE
MO:V<0TD0O<^YDA-S.=^=+"TWP\TID(:*!+FXA^G_ .3W_*@O]B= [J&O]TW:
M_:3;*\AMMF(-C]GM8UV_U*\U#5)FV@-S%8F_FNET^S"QVLFKZB(S';P) I2X
MNY+*TN/5\'9P=P43!H\YSDD!#RH.%@>93+/!AC 1F7,!7YM55@KWS!'D R +
MEC;&U\P6@ )D6+Y9K8AHR4N.[7:I:W%T6I7NNR6R6B[%:+;:'H=OR-M"-^:9
M]UKJ^NF55EO+R4*O*W$NZH)PL<4:QP0)%!%'&GR/W1^Z/M3W4]J;[:W:V^-W
M?W1Y*VMH]Y+#2=/C=VMM+TNV9W%M96P=BJ[SRSS/+=W4L]W<3SR*4I735PE*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*UC,?XNG!^S/YL1K9U:QF/\73@_9G\V(U/:_P!9M_Q\/^XM1S?<
MI?Q;_P"DU!VE*5U-:.E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2K,
M*5CYX+OH?CX^>G/!=]#\?'SUQ]=!62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G
M@N^A^/CYZ<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/
MGISP7?0_'Q\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#
M\?'STI62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9
M*5CYX+OH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G@N^
MA^/CYZ<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/GIS
MP7?0_'Q\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#\?'
MSTI62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9*5C
MYX+OH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G@N^A^/
MCYZ<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/GISP7?
M0_'Q\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#\?'STI
M62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9*5CYX+
MOH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/GISP7?0_'Q\]*5DI6/G@N^A^/CYZ
M<\%WT/Q\?/2E9*5CYX+OH?CX^>G/!=]#\?'STI62E8^>"[Z'X^/GISP7?0_'
MQ\]*5DI6/G@N^A^/CYZ<\%WT/Q\?/2E9*UC,?XNG!^S/YL1K97/!=]#\?'SU
MK*8A0KQTX.(0._\ ]&?[^/ZV(_WU/:_UFW_'P_[BU'-]RE_%O_I-0@I7XYP/
MOF'C8^>G.!]\P\;'SUU-:.OW2OQS@??,/&Q\].<#[YAXV/GI2OW2OQS@??,/
M&Q\].<#[YAXV/GI2OW2OQS@??,/&Q\].<#[YAXV/GI2OW2OQS@??,/&Q\].<
M#[YAXV/GI2OW2OQS@??,/&Q\].<#[YAXV/GI2OW2OQS@??,/&Q\].<#[YAXV
M/GI2OW2OQS@??,/&Q\].<#[YAXV/GI2OW2OQS@??,/&Q\].<#[YAXV/GI2NN
M=UUFT7A)3YY89#]8J==9M%X24^>6&0_6*E*X^NL'@^3ZNG76;1>$E/GEAD/U
MBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9M%X24^>6&0_6*G76;1>$E/GEAD/UBI
M2E!X/D^KIUUFT7A)3YY89#]8J==9M%X24^>6&0_6*E*4'@^3ZNG76;1>$E/G
MEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9M%X24^>6&0_6*G76;1>$E/GEA
MD/UBI2E!X/D^KIUUFT7A)3YY89#]8J==9M%X24^>6&0_6*E*4'@^3ZNG76;1
M>$E/GEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9M%X24^>6&0_6*G76;1>$
ME/GEAD/UBI2E!X/D^KIUUFT7A)3YY89#]8J==9M%X24^>6&0_6*E*4'@^3ZN
MG76;1>$E/GEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9M%X24^>6&0_6*G7
M6;1>$E/GEAD/UBI2E!X/D^KIUUFT7A)3YY89#]8J==9M%X24^>6&0_6*E*4'
M@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9M%X24^>6&0
M_6*G76;1>$E/GEAD/UBI2E!X/D^KIUUFT7A)3YY89#]8J==9M%X24^>6&0_6
M*E*4'@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9M%X24
M^>6&0_6*G76;1>$E/GEAD/UBI2E!X/D^KIUUFT7A)3YY89#]8J==9M%X24^>
M6&0_6*E*4'@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/JZ==9
MM%X24^>6&0_6*G76;1>$E/GEAD/UBI2E!X/D^KIUUFT7A)3YY89#]8J==9M%
MX24^>6&0_6*E*4'@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3YY89#]8J4I0>#Y/
MJZ==9M%X24^>6&0_6*G76;1>$E/GEAD/UBI2E!X/D^KIUUFT7A)3YY89#]8J
M==9M%X24^>6&0_6*E*4'@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3YY89#]8J4I
M0>#Y/JZ==9M%X24^>6&0_6*G76;1>$E/GEAD/UBI2E!X/D^KIUUFT7A)3YY8
M9#]8J==9M%X24^>6&0_6*E*4'@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3YY89#
M]8J4I0>#Y/JZ==9M%X24^>6&0_6*G76;1>$E/GEAD/UBI2E!X/D^KIUUFT7A
M)3YY89#]8J==9M%X24^>6&0_6*E*4'@^3ZNG76;1>$E/GEAD/UBIUUFT7A)3
MYY89#]8J4I0>#Y/JZ==9M%X24^>6&0_6*G76;1>$E/GEAD/UBI2E!X/D^KIU
MUFT7A)3YY89#]8J^<=FU>T-T _:^R,]WM?J;CM>89#O:_P#TL#\EW%2E2P?=
MX?QL?^M:LD^Y2?BG_P!M:TOUU&SWA'3SY7Y"]8:==1L]X1T\^5^0O6&E*Z.M
M4/!\GU=.NHV>\(Z>?*_(7K#3KJ-GO".GGROR%ZPTI2@\'R?5TZZC9[PCIY\K
M\A>L-.NHV>\(Z>?*_(7K#2E*#P?)]73KJ-GO".GGROR%ZPTZZC9[PCIY\K\A
M>L-*4H/!\GU=.NHV>\(Z>?*_(7K#3KJ-GO".GGROR%ZPTI2@\'R?5TZZC9[P
MCIY\K\A>L-.NHV>\(Z>?*_(7K#2E*#P?)]73KJ-GO".GGROR%ZPTZZC9[PCI
MY\K\A>L-*4H/!\GU=.NHV>\(Z>?*_(7K#3KJ-GO".GGROR%ZPTI2@\'R?5TZ
AZC9[PCIY\K\A>L-.NHV>\(Z>?*_(7K#2E*#P?)]77__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g72021.jpg
<DESCRIPTION>G72021.JPG
<TEXT>
begin 644 g72021.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ]1$E32S$R.#I;,3=:1$XQ+C$W6D1.
M-#(T,#$N3U544%5473(X-#(T7S%?3$E024137S1#7T)!4BY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" $V E4# 2(  A$! Q$!_\0 '@ !  ,! 0 # 0$           <("08* 00%
M P+_Q !M$   !0,! 0<+# L*"@@$!P " P0%!@ !!P@1"1(3%!=6EQ46&"$Q
M45>2EM76-E)56'%UE;31TM37(C(W07)T=[&RL[8*(S,T-3AA=H&1&20E)B='
M<X6UQ45&4V63H;?P0F*4IU1C9X:FP>'_Q  > 0$  00# 0$
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MLO>VWM=K;W^YM[VV_:MM[M^Y7S7G1U>9%RD7--T"U(H,\9@B,TT':H-$F+<
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MQW\^#;> RUE*J,YZLR&= I<W'!^8DZ)( (U!V_Q4;O C, 4&_!E9/&8+:,P
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M*!7,WYH;[!!"'>V%??;;6M>%^P:U9^!I7Y;XX]+:M[QVYV,LE=HV.VZCQ
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M54_J#*H8'N6]RWYJUE?_ .5_>?\ IDQ^S?W/5_TZ/^%O+U;FO_/3PU[L\_\
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M-3YBO(2AEMKGC9:9Z.Q!?$A#F!<X*-XS*F0>4#A)&XX:L;FK++NWF=BUZ<\
MY(:-U2S/EB- 99CCK6%JT5,6H!L>9'%L@XE;L=8FQM)HR^Q&=M#RV'1L4(=1
M'O#40$\+8:>8H0KTBQ$XJDBC4?4G34:VO2+-]D1'>BJU:T5N1FBMUH4=E6Y'
MPYF]R>,DRQB, *YD''?W0O6,GH#4JVFQR2R%]0=[=YZ42(:4LCQJQHS\RHH;
M*_M48R^W:/NSSU-RV&_^;PM[>P1=4[6%LO8(KVXEMM86S8*]K7#MM:][VVVV
M]VU0Y:U[WL$-KB$*]@A"&UQ"$(5]@0A#:U[B$*][6M:UKWO>]K6M>]ZH/I?F
MF2LEYWD$SR62ZWGDNW.W<S)O.&X:!4C CGDQCN>GB7G78P!X!E6KW0PPY:C+
M(($4.P4HPV E+**_%UDYE>#\?NN/DS#FO$L:<\^Z?L/Y0S&YQE7"(\'$N3,N
M-$+R ZXVR&D>C%(>JK:H*C1LI((9U+"T2@UW2GI5@"#"=6W^GK#=1MI"RH['
M^3.^L*NZ1"[6J2$I'RYS]VT_!%C]O.5!5$+[+*+ISJ^E#T#6U^2"1%"ZX:U0
MMM).VGWM251+,$,543)5,LLLQ[FLK,7DD6,LTRY;[<S4BMVPV;FPFXK7L((3
M2BC+&DB%:][!.*O>UC2A7L87>]K&!#?9:HN/_@#_ /8'?JAU%$LPW@+3[J3B
MT<Q<W$8>?)MC.1)!8AAC6M31&=M,+ZAJU,YDS9<A8E;Y+"#EQ#6CG"E4W.TH
MM)%3"\+Y$H"D*12N?_ '_P"P._5#K!-6K0UYPU:6S-6LPF>&2U3-*5E$TU>3
M\&)K,4B+-!*JRP69HVV*LT<Z30Q3 Z#U&S?T*FEV"A6NZ>:U&U#IVJ)JT",:
M-&] 6F]&I6()I*EVM))4N4JMB,N)(UGIRU+EGVLX ^X3A7\DN-_V,9:E0I(E
M(.4J"4Q!1ZTPLU8<4246<J,)) F*,4F@ $P\9:<HL@L9HAB 26 H-[%@"&T5
MX ^X3A7\DN-_V,9:ERO2'2_>W3OF-3[O'GY[>H??_7/IC4_OL^*4I5=EGS"+
M=//N]1/\E31^U4MK.4/=M[MOSUMWK1TBY8SWE%BF$%.B!;0W0=OCR@+^^+6Q
M9=P3/C\X&W+(3LSB :;B[DFL$VYP!W,L:&Y5K L(50[;FQJ,M>U[J<:[+=N_
M^=CI][_]K59+%>9II&6-R"Y(('@1F05;-=*\2M*BLJ@$$^(._K_?_O8Y9731
M:]\%XWM:U[WNSK+6M:VV][W?G>UK6M;MWO>_:M:W;O?M6J>!IE(0&7$E4A"$
ML=Q"$F."$-K!OVQ7$7:P;6[][VM;N[:B^!8O7P?&#9B>>)FAR5-K*[QF3HD9
MYK@RN"5V/<^/(@G&IT1RE&L;'2Z518:=.,033B][;985\8,.:2-.N-];^Z-N
MN+M,^-5$DTU8ET;9&TUQA"Q.!J>'Y.<<&9SE-[PUO"Y#LA<9G,(W&;.UDP!G
M.BM.CL/?&A!>M1RU([%S5^\E>)Z\\SJJQ(ZN6NK7V9VFCX;/,A)V8!0Q]0!W
M#'>EJ4=%$<"S1V*E=6;O&5D"4Q,2B+&YD)C1N*C8EB!^>]8MMC1%7M>Q@BS%
M5BK]HVZ6Q@@W56*O^^72V%]C=38%R+"^QN9M[5<C._4B^?BQ/QQ-6"ZN 8HB
MFY_8?UP+\0R#,637S#D;U.YMUOQ[-L6Q9J+Q_DT*!@DDA<(K*9^CD0W )$M6
M/^-&K!S8EO 6YL9^3=RABD+D!-;>6;&\/#'<_><'PZ%*?P>]L'><.H2'6!O0
M_8AWEC+!WH=@0[-Z&V]M:M,ZYI2:=79HYWL(TFHTW9XHH2MB@(TF C2U8E52
M9E*"S'6F*<)#"%D4Y*3H_6WU;4ZB2UHZSQMH5Y%CL2V0U;4W:2N6D>G6A9P(
M&5S5DM0"0/&)BT;#*SU#>:_4^S^_0OB"BIDJ&\U^I]G]^A?$%%:UL^X2?F'U
MADL^E?A#I?S@_9296NO25N.W\VV;_EJD/['PBO-K7I*W'?\ FVS?\M4B_8^$
M5LOL(^,"O]$ZG]2',#]F_P#$1>_:CIO[:SFJZYJ;'+@NJ+<A7\#O^!XZC3*N
M"X3><)P?&"C.#X3@R]_O-F^W@-]MWH=BOOTJ;F>,>>''=Q,I:68_N@D[C['N
M>^I-5JH3PO&H9#KI@V7]3&,\?')E<!:5$0;3HU@["&I=!D<B),RA&R.:!UQH
MW7$L;E:,Q<;8@(S]@OW/=)LBR/ N:[9+U!(L^/J#)<?)3JD^C>1:454+;3HB
M Q)&G)YE>$,!O^<EF]#QDR?NL( M2=MM,4EE'D(4E[]T?W0IFT X]A+LV88R
M'J.S'EI\F3#B/"&.7)JCSE*C,;8VD^7\COSY+Y"*['$HC!L<0]]DC^[#1O+E
M<H@DEN8E^^5'(OMZ!=T/@FNPK*K6Q0"88RFN(D&!)%)(S*5:-X1N<+U*8.BN
M=\2S6+2)O 0G=F"01J1+FLP"A$VNJ!YC;H2O;DY9B01C&8N_NEJ?XW81:=FU
M+@MOF&HG'V+=3NI>$9S.U(9!TR23$&'L+(\<\M,?QU(,5/;%,\D9!R0ED+$D
M8L=%K MP ,RJ1'W %(H.(T4W$"V$H[I[U'8:PGAQLQ,1ITUQ:A,)Y%=VC*+Y
MFM/FW(K$&'291G-=E*2K7)_E4CG$/ED/(EA+JXJC8M)F9UB"*R5J9$*%+0O=
ME,7:O]2&JK".!IWI4W-3-FCR4GS=GP.3JJSZ^XMF\ZSBJBN,W9O8F]\CS$GR
MW%,C\(@R0FB<(P>O?H_D>#-[PZY9.:1L$83&:3[BOCF18TT6D-"])HZ:(0Y9
M:R8\8:B^A>1)9S@:'8LLN;&5MC*7)(&=I=\F39%*F67J)Y-9:)TF*^0*SV^2
M.9C@UB1HF,UMI2]]EKW[W;[5KWO_ '6[=_<MVZI'K.U<272J1@HQAP//,KH<
MPZ@L'88D$U9UT99\?8=:LM9KQMB8R5Y$<71^3RJYYEY_OX8S1&(2D3^_(+-S
M\JBS.8<]E,9=RE9/9[W1/(V*LJYA-BF"X[+=,ND_*&!,0:J,GO>1WR-Y';95
MGY/C9W+7X6QTW8[DD>GK!B")YBQI+,E*)7/H,L7HWI\:XLF.<(O<;SJNI6I$
M2<Q6M5)T24H5@FJ59Y2<@N]S;$AWYQPP%AL(RX0 WPK;X0@AM;?"M:F,KOIM
M9W!*QS=W/E#XXM[KES-H$,86$, &6.B1YGGI2@UH/0LB-^.&YC_?UMGMZ>"P
M&]I !$5OBKV2JING&T 96><28M]1)WN398S/U4$LF2L]&:G0YBG86TQ"R+WH
MYF:0F)3 &#.9VY#=QL,"A6-2,03;V/Z\(GSGCWPVU_2Z8SHZ5SG7A$^<\>^&
MVOZ73KPB?.>/?#;7]+IC/VEO\35_BQ_ZH=8QYDT*Z2M0<S,R%F#"<>F$M<&%
MHBTE<NKDXC2?($485=US)$LK,<,E<;CN7HHTGC. W1O*+1+V9*B5+&HI'9H6
M*D!VO:J714:52 ,ECXA"3G!"&STV7N(5RQ6L&UK*KWO>][VM:UN[>]4XMW+>
MY:M<==S303:6\,LD3\;HYQNR-Q/H>XW4@[;@>'EN!ZQFS.SVO#8CU=)XHYD#
MT6"R(KJ& M@'9@0#L2-_D)'D3E=,N81Q&[0'-!+ACR,*",MX[BV,LDIK(1IT
MLPQ]$2'9CB\.=$B,],F*8&%EE<B:FM"VE(+)$+NJ3@'O I[$9^OND;3?)<K)
M<VO>*65?DI*\Q&2B>A.TM3M+G*8 C W0272*#(I$FQ[*YA#$)*1+%I9*8H\R
M)C+;FF[>YDC9VH:/57)?J%D?XH1\>253BM#=27KL%Z$PV[,1>D8W[N>5.4;R
M%71N+CDC+#$K*=U811@@A%VE)T'INGSZ18$U&G,$U0R():T,@22*O$T;J'0\
M7C,\Q1AL4,LG$CFV\%2V(1B$1-(S1)D0L#6LFDKE2I"WA-"0?(IL[O,NECP9
M8XTX=UK_ "9Y=7MQ'8=BS%R\\9191=PEABRIVRO_ ".U^^@OB9]036K]49GN
M2.[,[N$9F8EF9F4%F9B222222222<E!T<B1Z%7CC541))T1$ 5459"%55  5
M5      &PRLF:/52@]XDWQQ;42 ^W#^$'\]JEO-'JI0>\2;XXMJ) ?;!_"M^
M>U8M/[N_Z?\ _F2KZ9]X-*^:)_BV>O#0-_,[T^?D[;?CCA5OJI-H1DL=0Z0L
M )EK\RI%)6/6X)J=2ZH$YY8K+7"UPF%&J & %;[X1!M>W<O:U]MJMMUX1/G/
M'OAMK^EUZ-=*?!?IKZ T?^'5L_/]VH?&7VA_MQU9_P"->O@_^<Z.E<YUX1/G
M/'OAMK^ETZ\(GSGCWPVU_2ZO^8+G1U])R;D+NWKFIR3%+&YR1JF]<D.M<1*I
M&M3F)52<T-KAN(L].<849:U[7N =[6O:_;K\GKPB?.>/?#;7]+IUX1/G/'OA
MMK^ETQF1,AW+S03C16\Q"&Z;HHU1618K<\6/,:')\G.$;6XYE**[0^PRT<<Y
MXM84C$L;$:9"4G0-J4]N3$E@;%**]M]?[F&=&6EW3U(WJ98<PM%(7,'^/=:3
MI+0*Y3)I0;%+K N)L822&<2*4.[/'53B62X.#*R+&UN=%R5$K<TRQ0@1&)[Q
M90<$#E)[*6Y:D7I^IB,OAT2DA63P@#%-QE\*G,,+WX;"#<0-]OK6$&][;!6O
M>.1=R_N7_-6C^H+5K^5M3A](F[HV74Q=XX0J-ME*;\=AL/#;;PS?735*H=&T
MF<UXC,*J.)"@+AVWW8$^O_#QVVW.9$1_1'I4P!E!7(,,X88L>.<7,=66/"8Y
M%D$UN9FES;[(5S<WQ]XF3I'$Z,Y(H.(+("T;Q($RXD5DQE@"!]_,^G[#N>&U
MB3Y6A"63'PI:XO<,>TCS)XA+8@Z+V\:!S51:;P5\C$RC]GA#8")\2-3\E0/B
M0HA.[I5I:9-8FS.0/5M*??@_]417$J?XLI_%S_U0ZTG>OWFU.Q:-RT;,<\Z1
MV#8F,\:=Y*.$<I?O$79W'%6 V=AMLQWE)H^F::NC4*:T*8J3U*,DU;T:$P32
M&"NQDEB*&.1RT:'DREMT4[[J-J%8^Q[",50]F@6.8NT0Z',!1Y;4P,A R$2<
M:Q2:N<%9IAQAZQP<W5P4*7)X>'-4M=WES4J7)U7+%R@Y0/ZF4/4*^?[O_P")
M):[T/<M[EOS5P64/4*^?[O\ ^)):UU9DDF$\LLCRRREY))9&9Y))')9W=V)9
MW=B69F)9B2223DJ^G(8:VJZ'7KQ10007].A@@AC6*&&*.Q"D<442!4CCC0!4
M1%"JH"J  !E1:V2W&7[K.:OR<Q7]JUU8VUL)N.CFVM>5<SFN3@B;RC,=Q<!9
MBY6G2%C&&5++B" :@PL(A!L(-Q6#>][6O:]]FVVW)^R3XQ>F/G5O^&W3_AE;
M[*G^K]VE?1ND?YGT//192N<Z\(GSGCWPVU_2Z=>$3YSQ[X;:_I=3ZSPISHME
MN];^ZU0QJ#Q2HS9B.68S1O*>.J))9FL6[J4!CD2DZE/S8\BN-$2J1&'<,!O$
MG#O5)7!B-L;??6!< I%Z\(GSGCWPVU_2Z=>$3YSQ[X;:_I=<64.K*PW5@01Y
M>!\#XCQSDK%&5U.S*P93Y[%2"#L? ^(]>9$_X*Z2^&=B\AG+THK]?'>@1FTY
MY/49J=7R.3*;/6/5F)$3ZGC+@TO+7$3Y,W3A<S$JE3\Y);-*][;$JY8G(1)U
M*I:F1&*%9Q",@@K5_KPB?.>/?#;7]+J(\LO3.ZH6<#8[-CB,E<I&:!"O2+!E
M $DWH1F!3'&W  0OL;"%:UKB[5K[>U6-=2UH8M#U!XU*L(HQN'?R:>%6!!;8
M@@G<?E_-F5=+6YYM?TR.5PR&9R1P0>*P2LIW"@@AE!&Q'C^3PS(7-&YO:>\V
M9R@>69%#F1&V,[MG*=Y 9X^NG<+E4WS#EF&89Q\S97;9] )C%9##99&8=B,$
M:='"/+6U3)F)WNWKC# 7<KKXPU&:#=(4F!BV"N&"8HBB6*\6GXW@S)%G*805
M,U8Y>'90O>\?N!T%D\;72N$R!R("[R.+3)7(660O1JU[>D:YW<G):KU8JK^;
M/54W^\*;XZNK0W4.IZA'ID9BNV8C6DB6%H9I(FC!:3?9HV5MRLCH23N4/#?B
M ,DAT5H^ERZ^PFH59ULU[#S)8A2>-V18BOM)5= %9%<   . WF 1G[D715I6
MRQ(02N?84B[W( 1)@@07%(Y3&+WO"HH2O3QF*C10R41ML,8H^F='%,T-YJ$9
M*!*M4)4]@$&<';GCXZP0\X<2BC*UQN+Q<),>CD=8T*=L96)B9TY2!J:&EN2
M+2H6YN1$$I4B5.6 HDDH  A[5[WN'5595ZII![[+/UE:CUJY;GK5XI[5B:**
M3\%%+/+)'%^#*_@T=F5/:@#VH'@ /+)3] 4*-74]3GK4ZM>:Q3!GFAKQ12S?
MSF-OPCHBL_MB6/(G=CN?'QSFU/\ %E7XJI_4&50P/<M[EOS5?-3_ !95^*J?
MU!E4,#W+>Y;\U87?_P"5_>?^F2H[-_<]7_3H_5M9>K<UOYZ>&O=GG_IU*:]8
MP>Y;W+?FKR8[G"K2(=9>'52U2G1I2KSJQBE4>4G(+W^/9.6#?G'# 6#?C$$
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M?IGQID24L>/$D@Q;@*.Y7C\7F"N QU*U-3BHD"MD1%O,M?)(.X1K$ZTP=?\
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M.*1ZE>1%W)V5;4JJ-R23L !N23\IST-Z>=I-$T"1SR>32-)D=O <G>C79CL
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MG]O(_>693+*>\D9^)<@>T3EPC4 <450=SNQ4I2J3._%*4IC%*4IC%*4IC%?
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M_P#-MF_Y:I%^Q\(K9?81\8%?Z)U3ZD.8'[-_XB+W[4=-_;6<UFI2E3<SQCS
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M0#R]\,L3&85?NDG)NHW!<0QQ),.NF6L-XE<\<:@I/,LPZ=<,MDTETCU-19-
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MQD \O8_ QGSHWOY[IR]C\#&?.C>_GNI^W@/6A\6WR4W@/6A\6WR4QD \O8_
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MTSO3S#D68LG13,L3<6F?SX&0I49,)UFC$&9,R-0Y@XHX\RRIW@TM9'57%(+
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MQ=P;S(#Y23'TCIV+N#>9 ?*28^D=,9/V^MWA>(/YM-];O"\0?S:@'L7<&\R
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MQ=P;S(#Y23'TCIV+N#>9 ?*28^D=,9/V^MWA>(/YM-];O"\0?S:@'L7<&\R
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MQ=P;S(#Y23'TCIV+N#>9 ?*28^D=,9/V^MWA>(/YM-];O"\0?S:@'L7<&\R
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MR]MEZX2>YR?H-]4YV0^ZQ?K$^L,R:+_@R_P _HVKE9WZD7S\6)^.)JZL%[W
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M9Y1%R]+<"#,8V'"^:G9^&&28OC8C<O(I=@QKQ7%U*S(@51J<MY@+[G5_8W1
MWFQUKF40C8YX)>R*$T:?ZA;L]MY.\&[?"')_[NM S9_Y;*TML@U.[+?YTX([
MEO\ J#D3ZR:R1W6I/E4B!8:OD5XQ\Y)A3N16;2X7')*QGE*;145S1KC7Z52
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M7V/2AWB$8=)+$@J Q60N,?:%SY&@JR[$J@Q]W5(S7!ELI*M8I19L4I;'EVL
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MFDB4-6,D$IDV+R2W!7-&A(06VB=?W(/NL>/)UF7&, ;].VI%'B;/6?L@::<
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@DI2F,4I2F,4I2F,4I2F,4I2F,4I2F,4I2F,4I2F,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g837899.jpg
<DESCRIPTION>G837899.JPG
<TEXT>
begin 644 g837899.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!#1$E32S$R.#I;,3=:1$XQ+C$W6D1.
M-#(T,#$N3U544%5473(X-#(T7S%?34%$4DE'04Q?1E!/7S1#7T)!4BY%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" %I JP# 2(  A$! Q$!_\0 'P   0,$ P$               <(
M"0$%!@H" P0+_\0 ;A    8! P("!04'"!(.!P8' 0(#! 4&!P ($1(A$S$)
M%")!4146,F%Q%R.!D:&QT0H8-U)VDK/!)#,T-CE"5%58<G1UE;*TMN'P)28G
M-4-3<W=XEJ*UTM,X8F."D\+Q&45(5H.4*$1&9&6DI?_$ !X!  (" P$! 0$
M           " 0,$!0<&" D*_\0 7Q$  @$"! ,$!@0'"@D'"@<  0(1 R$
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M^5XW^K2?O_\ 1H^5XW^K2?O_ /1HUCPY<_+]I^!P8]ASG\42AV H%,!A#DO
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MHA[&$VG5I-P9KU2*H(&49LW:I3>ID,'AJAW'0RM C7($&-@=0O8_D"!IZWL
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M_/ESWN%B@S/=TM*C%YVP?(P8AE%UX5&4=MV#Z0:2*[5O).D$5DP.\2;E A5
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M@PE68Y&ZQN-[8_Q_*14);V; SB%?SK()")36*8@<.FY2F$Z9BB(<\>R80$>
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M3U<SA&F.H]))E,ULQU&3]H0$E">R4Q(TM>08*PH!$AR1!,S%I!YFUQ@U4P%
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M"RI%"+@(B)R 0A9AY$2!)LL$QW1SV([TS$R"28@ -&P(/B0=]H%[\H  D3>
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MMTOU1B,.SFW:J,,=[>KC&JXQK4@T*Y@X&6BU"2T7.UML!P,W79N52N$E!45
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M$_M=/?GGGR[#FM](/H;-../9""Q+PY[H"D@GNB#JA01>\'8XUJ_N>_IL ?\
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M!#</@IPX2:H9KQ6JJNNFT132OU9,LJY4,!$FR"82)CK+*''H(0@"8QOH@(B
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MQ7X4'@>.0#3SJ[,)V&OP<^BB=NE-P\9+I(*B J(IR;%!Z1)02@ "=,BX$.(
M "8HB  &L8G#G+=*@D4Y@2.G+',F ^R8Y02X,(>?(>7GQ\0'3/) *D;K?J&(
M'P()^9PJ[GR/AM?]7SMC/R^0?8'EY>6JZ/+1JS$8-&H_LZ^D$H6!MXNVS9U8
M\=9-F+1N9;RIZK>Z]"'?T: <19U"G;61^0AO43G\,3"<QB 4AR&[\ZY[??2
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ML?RQ7# TR#8[B!<ZE N.H,1O<BVHD95,]RK^9?WQ-NH.YYW\,;+)0X#S*4"
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M+7-6,V+7<<SM?RM!2L&9!26(HHS,@649,S*$/X*A>HI1 !(8-2%AR0#<F$1
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M6](9FZCYSJF(HK:56Z1!'I;RJO/'FDG[ARZ19&*L98[UP^731_DU-T3PTT@
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M#QR" E*( ( (<\#YAS[A^O3TMZGC48Q[D^>7EB'_ !/S!]Y\?GIACGI+/_0
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MPKASV<-O/L'67D/M]K6L.:]W@PD,:[VP3I& Z8FEWQC)*@ %$Q#"J(@;^EY
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M2--Z"UC,$HKJK0X!4F 2MHDB=Q&/E?BWHYQ3@O&^*\#7+Y^K6RF;KY!F7(U
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MAT.EP09!#""8-X-IOB$O)UBQ9N"MFU[)F1<M2.TJ^.+G)0M#P;D9XR@;-+Y
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MN#&'S[E+W$1[ZL4AC/*\4FL>8Q/1;D"!#*@XK-A=5Y4Q2!R())."@<5>W)
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MFR*AR#QW*<YN>W/NUE"J"(E$XI%,)0'CJ]P#Y\"//2'O'CCL'U:[RE*7GI
MY\^-<A ! 0'N AP(?$!TQ+$&23((O)L>LDR/#:+<L)I69@3,S GESC>POX##
M0L;+7$-S^:SRU"EXNGR,'6&]<NBKA%2.G'<:N\,Z;IM0,"S7PDUBG(L8@@J
M@0>![E=R"*11Y*0H#SU<@' \_'_7[?/7,  .. X  X /< <<>7EY:KI$0(I4
M1&HL!$ 29V_.DX:P]D!9%PH #'FQB))W),DF23?!HT:-/B,&L9G/YOA/[L_^
M4=9-K&9S^;X3^[/_ )1U!V]Z_>,&,E'S+]O\0ZKJ@^9?M_B'5= W;S_4,&#1
MHT:G!@U%=Z8>JQ=EV7VMU).WS4:I;JA:&2L?)^I/4W\:]$S<D?%G16;VN34
MP_)E;73.60?>$4HE$H"$J.HKO22/=E75C*,W=Y>G<; HXD96BLXZ8E8YF^EH
M=!V["2!%F!F9YB-%-96*<.B^*FY33!L/6 :KJ>P8$W',#F.MO=BRD8J*;V,F
M!)CW?;C-/16)T]399C.0IX9J48S+NP2<HKN AE:[D1S/.9,XRRSB!5X+$Q!G
M)"_(+5$I$B,"IF(  (:6JXX2F9G=3B;.T8X01B*?2[15+,BM).R&<&E 7"+]
M7BTS>J.%4E%QZW"H<I!P(=P#2&^BYSG7<^[9#VJE&R#(4.O9+R#3*;:LFR+V
M6M-VK]9EO56EG7>2!"N1;R!%#&9I"*A4$DP(!S>Z1@?I)^R7N!Q23X#A4HEY
M#J,/T3%#N(CR)N//2@%D0$:8(/B"#Y#G(,7,G2(P$E6-]Y$SN&%[G:Q]VQPS
MG#R-@4W.;CUGU[M\]&LT:JT:56=B4&$#"J+M$UDSUU^FF11VU(4#$6/U' 3*
M&$1YXX><B)A('6;J. B!QX$H=0>8% 0 > \@'W\<\CSSILN.738V?L\$3FY:
M14:MZ@1PR?,U4FD,)H\HD:Q:Q_9=HF#DZJB?8IC '(\=W.)CU%YX#N/("'O#
M@.!$/<(AYA[M%$0#O[53<S,.;\^7B=Y&YQ#WT_FJ/@J_W];R9!!QK+?JM/\
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M\0:^X;Z2T0#8!O%$1X#];]DKN/[GW>OAY./Y<I_;?Q!IZ>S>:_<V%.R^;_\
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M[()@/PY A \OS:J=LW5+TJ((J%$0$2J)D.41+W*(@8! 1*/T>>>GW<:[@
M  . #L'U!\-:148,S,P)(46! &DSS)W^SE:V-P2"  "(G<S,QX#I]N*ZH(<@
M(?$!#SX]WQ[\?;JNJ&XZ3<CP' \C\ X[CJW"XBAW6[4MS&1,\2.9\?;U)3:W
MBQCC1K7I2-:PL--LUY]%PL SS\)UZWCF)2)JI(E4,4JA@[%5*82\2)XJBI:#
MQO1XN<NXY.EXZN13*1R&"#!L2YKHMB@K8#MHXZC%$'Q^5NAJHHEU#[!Q+J/+
M?)2\WY[R93=KD'C^P&V[9BJCY3+&5XVPDCVU>=Q#@7;"']41,230/(^JIHF6
M0,0#BOR(#TCJ0G#N/HW%>+:+C>&9N6412JW'5UDR=R*TLY31CTBI%!62<'.N
MZ'L)A44,)N!Z>Y0U0OML(T@3WH6YD&Y'O(# &((,&]K>P@)!VA1 (6!<GKN.
MG,P<)9ES<'(8VMT=2H6@3%PEI6/2?LCL2.00$RKTC54%3IH*)E(BF8RQQ$Y>
M"DYYXTV#[KMOK._W,$*E@K)UCAT<'T:09W."CC.*Y(O%5$%'D2S>*) @=VS.
M8R:A4UC'#I'DG'(!)LHP8J."/3LVIWB*1D479FZ1G221OI)I.#$%4A#>\I3
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M7^#$OT:<]HU=HJ?RI_J+\_WGPA-2?D?\1\/V'X^&&OFW"V<0X# &7 ^LL8B
M_CX\OCJL9FF7L=KJD#+8>R35DI%^8B4U*L2C%MA(B<_,BJDD/@)J"0"%,<Q
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M$]8.8"$X* >\<T=X^H;Q6&6=TNJN5J[)KS=>47@XY4\1,N>?6)&*,=#E@^7
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M'[F=OLL2O+Q^9:"LE<*;)Y#K9D["T*>;IT(F)Y>S,P64*!XF-3 0='*4HIF
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M0J]HM%*L64JA#6NDU;Y\6Z E)=)H_KU2*) -8I))0I/5HX/$)]_.?I'J#@@
M/&K.TW.X <SY:TTR]1W$XM00RD#/Y>;\$QV8H*H6HSD1!LC'G;G*X*"JA5U$
M1\;PO# 3 :Q,$K/YRR#:V\S,CX8C2QV!//8[;S\"#APG ? /Q!HX#X!^(-(8
MAN&PDOCB&S']TZH(XJG'S.-@[\XEBM("4D9*2&(9-FKYQX:*POY'EDUX 04<
M!TDY\]*B6Q0*CU*-">B#/')4C(Q_RJQ!\KXR0+HHILO']:.99 06(8"]1DQ
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M/L;WG'SRCY1NMN&J/J8G98RQOJH@_AB6&"E+ WCR"I'IST0HDNU2= F8!,8
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M3*+DV@Y1K>-)JHTV2Q_(J3595GSS]+FEE%)J%=%*/AF8/^OI,10H@/ &YY*
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MZ;MEYA^AA'(FW\V.9YG8[B^([-NJ^6M9O&XFV_ZM[8=/HTUC[INY+^Q\8?\
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MB<YC&.@L91,_(]11Y'2%PQ( <3 GLZG*+P5-S8@Z@";@\L6'V1W1,SW707
M'.UB!87B.APU#T$V)J#CCT<&!)FKTL]6L%SAIF2N3Q_\KC89N2;VF<9MG<JO
M-JK2"ITV"*"*!3B4A4"D!, *.ID$1$4P$3";D3<")>@> ,(  E]W !QS[_/W
MZ:BTO^X:-;I,HW;E",6+8!(V:,[C%M6R!.1-PBW00(BB41$3="90 !$>>XCK
MUADW<D(=]OK#G]WL>'Y/"[:855&X>^_<>Y($G:\FY,<YM)Q6REC,K<V[ZGI
MWY _ 6Y2Z?1IK'W3=R7]CXP_Z_1__E:/NF[DO['QA_U^C_\ RM3VR=*G^[?]
MGC]_0XCLVZK_ %E\/'Q^9$NGT::Q]TW<E_8^,/\ K]'_ /E:/NF[DO['QA_U
M^C__ "M';)TJ?[M_V>/W]#@[-NJ_UE\/'Q^9$NGT::Q]TW<E_8^,/^OT?_Y6
ML8M>;L^4^"DK7,;?4/DJ$*FZFSMKFS5=)1I%2$658H ("]5;D,*A@(4H&#L
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M!!_@HL)G ,HD7XCP81_[?E #=-OK3&XWB#[H=EX@>11*/';N<>0^'/ ^>CQ
MX'D2_ ?;$?M]_P"3CN/;47F/_225W(4!8;8SQ[/5N#KJDBDZ7MC<T.Y>JQ"R
MC>6]1:+K"L\(P51. JI )3E IPY P<^G;SZ2C'&Z9*<4PVU8SJU=>.&3IB_?
M)Q+]TL@H*2R[1DY5!5P@B< +UE#VN>P<@(CE#(Y[26]0J:5T@F2 I82 ?JN[
M-]XV/3$>IDQ_SAP<2)OGLI/+_37!L9%A:3O#&,U;DZKLS],GD?)^8*!F)>@9
M1VRXNJ%4N5"Q_+7*O*SS&=?H/FTFX8F228'0,[;%.J)S"":9C*%$ 3X9'=<G
M[Z,/R>\S>9@/%V8;"WJ.\.(:0N'8VL/XE3/&(LQ5M[ Q=L*S3:JJR*F-)=W'
MS1W70H1L03BHJ'28Q=BV4W*V!G!6&QR>*A5AZHV57EG"RS=82(M@ZE#%!4#&
M!,#$ZR@';R$H\@ Z;M</2?MJ777]PD-O^4G56CPB4V\K$PYWB<K\KJ DBXBR
M$7 5HML/=VN'25$H=73P':K*Y?.YIP%X>[&0NDTJ@OW1,A@22(D@J3N-)@AS
M0S*CN9A/9T2*M$C2MU4!K%1,"[0(F1(Q#SDF.])#C3<OM9QA>-Q6<(AG7*]B
M68QI8XF!D[-6\LY#N\L1_EBI9@3;HIME$ZBS5")8KOC+H(-P%3H( <ZE2]&9
M6]RT_F?>;F7<5D3+;I@MG&4Q_B7$UR3.PH]4I,)$1)ALM0:JE(9TUL$@+E5-
MP4!12,9=(.1$HDS>C^DYI62,D4+%==QS9SW&]KR(UL[^,'Y.(1DCXSU0\N*Q
MTVAB%Y(IW*(" @/ \!IWLUF2_03$9*2H3,C4CLK,QFL@1T8!.8 $0*F;RZN_
M]MYCSR.J,UEJN396S>3T$*K ]DTJ 1# [ RHOIL1 "["QJ+U!I.:]'T!-V7,
M91:M@M]8K-I;K"C:(4Q$ WH^-K^=\82>_G=)/T"(&/C\[;B[KCS$LIA^+?9N
MGWL<O/'K$C4<AS"!I9$)5VBFYB2HF605(NV\,2%3(&HS;S^OBSKLQWXXNMTE
MNIO-$L^+L0;AJVI.QDT.1:7DMI?@'(-!K,FV314=(13%$BZT @H!3$03.""?
M3R&YV3)^2%"IJDHS02JD(HF8THB4PD.4#%ZO;[")3!U!SV'MSH2R-D4H"BCC
MV-3(H<QCII/VI"',H/MG.0@E(<3]Q.8P#U!SR(ZH7-$&1D8NL$4:ALI4B+B!
M TM<D@F]XQ/9(+>M>CL[&,QEE(D 2"M92)FYDF9,Q $2>XQ])I0?H7JS/R-D
M' DUDG#S3(;JW%.S=2MC8XR=FJ$9D 7)DRHD6FD4_7&[Y?I*^23(8JJA0$8?
M<K;4=[CC$^W"6?'N%FQ6CZ7Q:Y!MVB,=F1FZ?4$\B6TK6S/K8"822-5(9%68
M(N8I68M)5J<%# ;@)\=\>\S;_2H6%P[N'Q2?*=JEY&+M,#AZC*N)VU)+PC[Q
MXBU))13ALXB$&2R9C&6%=/I#L8#IFZ1==3MV#^WP$-,0>/G+9@]@6<B#"0>%
M3DT"BD7AJH@94XBJB4/"4ZC"<%"B CI:XJY<+4S7#GT,H*-V55F<7!( L$B-
M)5V,")!#:LO*<(XCF%&:R='5#&6#4C3W4C3)),B1[  LP))&G6+R?=-[^.-H
M2RM)BL]XVR&3>_G^U-Z;0:8O%'R['1\^D>F-'LVR;>N1"RXII?)"8$/$V+H*
M+D#G[ADCZJ;V\2Y'](UG?'3?<U#YFS;AC:9:WS&4:+RSRLXZ>MH9#-,KC&/*
M16(<Y7JAE3E*P10("#8SHQ?#.F)0V.9'=_+MY)"+=XT!) R0/$G,C)QR:1%D
ME>4C$(HN/!R*  I'*4% , B3@P!JV1^]E]*7BW4=OBF:*\I$5'/)*QOC$:UN
M2>S()&1AX6264$7:X@IRJ0H%+][/R(@'.LE<NX)*Y%NL"C5 @O3;3[5B-, ]
M"PDSC%_!>=B/6$.J=1.9RY,3J)DKU $#O>2EIUNX.+W39;6VGOX^'SIG/"^)
M-[#B6V@Y0SM"2T9D^:9EQ5(ODE<K)MD"KI4P+P0S<+&].H/B)B@!"$(FF&0X
M6SQZ2I64R])8PLVYNT9Y>X'S5/[BJCG.KI06*\29<@Y)1"B-<,KKL_D]<ZT<
M6/\ D!%4B*#]JX<+N2\F,4-C3(^\UGAI"L?/V @81>V"5"OQ3:80<*',/3RB
M ( !$AZC@!@+P03<@(CJW2VXYKDJ%DZ5+8H5G:_<(=\A-)ED%&3:18>$)3L"
MOVRR+@[@Z8 4#D5!0@>R4P ' QV#@$KD:A.D:9IU0) B00T@&>]I%@+"!!D9
M+,F)S%/26@D5Z),:E=H4Z0Q $P2):X8DDXUOL"YYW+3U#WA,*+NMW#6VT;9=
MNV%MU#M#,[R*A732^Q";BP94Q>TEX\ZJ25:LQ47T4W6=< 3PT42I'$W4*LQ^
M1LNY(@O13;M+#;+:MFG>1O::9=H]1*\,Z?XMV^VZMD"7Q T;@1-1S5FJ!'3J
M:<J(>K$(NDJ'A@;DSP,?,]C:^/,XX8Q]M-M$K#9H;OHG.]6+9K >RRD=5G'J
MS2$E)IW*(N6L,81_V)C6CQ-1VB8YSD.(\Z>Z:Z8BK$7C;*3;!5=":P!1S5S&
M\/%RP.Y?'<$,4DP<P4;" J";)^:)(#<YUDA<JG((&5$_M#>,O5U3^#H,@QH?
MNG0%)]@;0'$ &>[([QP]/)5C.C-M<&"7H"94:5/US0"Q(:25"@-#$Z1*N8!Y
M'@ \_B'XQ\^._P ?+G0!3]A H?'N/'?G[/+3!\=;Q)[*-<9VFMXGE&\=(M_%
M;MYUV6+D&9BCTF)+HK*B#901#DA.H1'J*(#YZRA'<O;%W1F7W-C-W).>HCF6
M3)R!0Y-X8@IP?D $2F 1 P<=NX:QR:H,>J5?]VW6/R/=MO:V,?\ !M8F.UHB
MPMVU$P;3LQL.M_"</1^^>\H>?N,8?S#_ */LT>W^U#D?+VQ'^,/XOM#3(7.Z
M6RLXL\R\QJ_29IN5&WB)N2F(4$P 3**B*G!$B_2,<?9Z>1$0UC7Z]IF:MSEJ
M:UIK)1-;*E\L.&$HFL5DJJH5(J0])PZCBH<I #W"8.^K!1K$_P 4?S[-AT_F
MGX<I$[F;OP-FH_A:1ML*U$]+>U'3GTP_X/%#N <_9P/X.P_9Y_BUR RP]A+Y
M_5Q^749Q?2"NA?,HP^%;>1^]>QZ1&Y>@Y4XV4 !:S2IRN!*#,PB F'GL0!Y+
MV -*W8MT=BJL,O.R>.W+INBF=5!M'.B++O44BF44.W+X@&4,4A3"!0'D3%$!
MXY'4/2K42/WG5$]*;>'51Y 7-K>-?X)S1))JT02+37I'5MM#$2.9, 2)YR]G
MD_P#\)C!^'CGGCGW_AT#U\#[(<?VX^7V<C_'I@<#O)E;'3DK\ACLL=43IO#.
MG<U-H1S]D1D8QE@6:*J=?44B:AA*41-P7IXYU6+WH?.".CI.N5%G/,Y4RI8\
M\?,IB94B9!.0H%,<HE44#@" <0X-Q]NH[.MRR=3_ '3[V&VCSCYE?P;7Y5J4
M].VI<HYZHD=/"TX?STF^ =N>?:#M_K[_ (: *?L(% ?_ 'O]&HQ('TB<1+3/
MS3<X_?P%Q.\D&):Y,N :K%(Q4, O/7#G,BHDY*'WHI1$3#V#2BO-Y4BRDFT"
M- 66L;L@JI0Z+TG)61>DRKPZ@G "IHI""AA$P<%Y[Z;L<[SR-4?_  VM\5%O
MGQ$CAV8,16IB8B:U*>5C!,&_N@WM)?Q[?[4/WX^[S]^CV^_)?^T8?X_R=]1W
M2F^>&@9Z(J\[#Q<58K(10:M#.)A,'<VJF'28C</$X,8P^R0._4(\!R(Z[KOO
M</CBO(VJV4!TPC'*OJI1]?*8X.R_\"!>OD#&.!B%X\Q[>_1V-:1^\ZD&(^K?
M:W\SYGSF[\#9NT5*1-H K49-P !WQ)(Z<Q$\\2%<=/'(<@(<@'<.X\?E[>6N
M8'\@XX[@'G_H]VF48KW:.\D6.AQAL=3$/$7]@[>Q\LX6*";+U4R/ .4^LP\.
M2K%,GP ]BCIZH&()NW(#\/=Y\?G_  :@,K%J8DZ(#;@R #!L.1&WNQ@YG*9C
M)U!3S":'(D"0W.#<$B0;$=?=CL-W 0'C@0'SXX\O?SR''QY[:\@=(CR'D/M&
M$2_2Y[ )O+GX%$0X'C@!UZQ\A\O(?/R_#]7QTPZA[/+33=\.6]W3C<)DJP5;
M)N/ZQ2V>!I-5H>A59Y7RO"*S46F0OC).7/K)5/(IQ.7A4Z@ 75B!8-X@2MIE
MI%CTL2;](C&*W+S'..8^-P,/H>N$VC-RZ5Z@2;H*+*"0.3@FF43GZ0]X])1X
M#W]@U!B7TJ6Y93!-WW9,]D2[K;A0+3=6\N^1R"4^0W&/*'.R4/8;XPK@0WJ2
MC=JE%NGPLU'9#F2  Z@X,8)QY<%1BY$$4C++>IN!21*'4950$C"1,I?Z83F
M"@'OYXUJZUOT;V1WGHRLVNI*>W,PF8C6_,^3(C#;:PI)QEED$;Q/S$+41K*;
M94[RMVIH9 CA@+M$%VZX% @=7:IS! '@2 =/=$ZC/0 "1OMMBZF$(;4+R #<
MQ/@"(\#?G YC8:A-QV%)BM8ALJ^1*Q7VF;X.#G,;,+)+,8N8LB,[&M99BT9,
MW2Q3K.D$'9$5DR 8H. ,D50Y@#E+-V>]K#FU&A7&P62S5*8R!5ZZVL\=B(;?
M!QMWLC!]((QS92+BG+CUPY71UA%J8K<Q%A*/AB(<#J _<=A/<[=LHV.R6:L6
MB K^;-NFWRIX5JM;QBK;5*588>%9-KQ68I\U4 ,43<;-B#PTDN)"@@!A!0R8
M=.D-W';4'L5B3=!BG.6T;.FYC>;=;3A^2P]E^!A92;"STB&"L)P2<5;8IPC&
MU)ICLK1ZWLL(NBD=Z=!9PZ\8RP#JM:DF(CV=@>869)A3/+>#,@B2'[)0%8MJ
M!-UM82)\;;&+GETQML0&7:)+4M&XR%D@ZZV:P<%*6=O+S,>0U/7L,6REFT99
M%%'!21[XJ3Y(I2N?",H' E#I,7GTRV9\30%LK= G,DTB%O5R9@[JM5D[)$,I
M^P,C#]Y<Q,8JX(Y>(KA_,XI$,"XATI H)1 -9C</5\J4?'^_+ 3[;CFN[W[<
M5;\(V&A%J$#+S-8GJZC7JQ&2CU:V,UR-8IQ67#-=K,-1%,$B(B)2J\'$JZUO
M%D!4<P7:I[G-HN5\\Y\M62,-RN%,E0#"6<UM"B0-8@V\0>,O#&19,Z*QQL]0
ME"61JOTF?*J@LY1<E.4VH%1H4D28O,V("F(!-R3$1N#U[H:2[ZK;@#3)!BX_
MFB3)/+;GB?A7+>+DK^EBI;(-0)DQPP&2;T=2=BD[8M'E*4XKHPPK>M*)]!RJ
M 0B9E!(8%/#Z>3 V7.&^W"^(+]C?%L=9:KD#(=\R]6<2RM)KMO@SVRG.[$V>
M. F9>%375>>KL2M@%VW%(BI 43Z^GN!8!V^U[=G(9RO%$LSZ[1>=;'NDF<E5
MF]P^- ?MHFF_)\F6IS;;,RIRLHJK1\0X81$C!F1,5=V4IA;"<@GUY:MMLA$,
M@[(ZTELQS 7>)B7>6K>-PF>WD/,#!.6BRLVE.Y(D;RH\5A9V"M316'^3HU%$
MB3,43^KMVHB(JR'DM%M/.\BP,2T#E!M[A8$[-1I,ZMB1J W N2.4[1<?;C8Y
MS[NEJVWR_8)I]M8%)&9LNCZF)VU_+,HB'J2K&(DI8[V56>G3(LDX+'F132(J
MF8QU"B/L@.E64S7B-&B)94-DZD)8U53Y0O"EEB0JI@!55N9)&7]8!JHL55!5
M/PP4,H!TCE$GL#PPW?U@8<]9XV$QTWC:2R'C^E9_=W&X':J*$BJZ2/J=A28R
M5C*FJF*T3ZPX226;J"*:YU$R&*(#QJ%"W[6=SE(MLVK7*5;J3M9H&]#+$^]I
M:]&<9$@C5>P1QU:W<ZS1A4,ZF*RDHJ\31CP.5JS=+!UI]9^K4LQ4M>;F 9L
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M6@T 2C9$A#""1J,](0GRJ0"=8KB;H]G6CX9Q+UY6D]D0$8*!-.L]/0:2&!K
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MW@+%>BF BX(D"JA%A !,(CI<\D4K&>1ZO9*-)M7CN4D ;MYVV5:47AWK*OM
M,59I!RI5FKA=\O\ REPDDJF*A@$.HP#R-L8V3*+1Q037#$;>)<VNLV&5?N8:
M166C(H(<%B,(IV8X=:DQ.'3(X<BIR0OB"1(>P:;SN'O5=C\+U>:R'&V&MS?K
MZDA$5FEN$VKZ1M"#D5HN)7,'2L5!Z)4T%U0(8J8*"8X<ASJQ1FLY5HD-W^T$
M&BUBX8M 178:4-,C2" 3[4B!A#FLIE58$G3I/M<K+8G<V:9/QG"YU;$>'Y2R
M42:D(5*T6C&RR2M81E53N73*+8(%19(RBYE#=+XY$ %01%415 QS&$>^O+G+
M,](BC.H"\X_;2]7?",Y.'6!-9G7X<70( LU3Z>M99!T?L5$ ,82@(]A[4'->
M+Z5'8L7M5/E*W9KW&Q/RA68YPD:7"6D"H$.,C*<B4Z2!%A\8W " %.8"\FU[
M9G'4KD&VV%SDIO65L<,R-F6'7,"DJ$G7&BO"[TN0BKG,A*H.ERE(T,D'!C#U
MF !-SI$"^MBIGEJ%0&"G60TAR!V80]XACJ$1W02&<_5EGS+>JJ,F2"8DD'3!
M )+3L(MM,P( PL.,$*O\_P#%$I!FDDS2"*JD.W<(F9QXUPR+8[,[=#J$H&\(
M2=BD 1\C&]^I,@ /A[S?XPZBVQG.HRN2L1-$?E$R%5E)RHIN9".48$<BU*V,
M4\44P 52-$"<D, &*!1* &XU*2'E^$WYQUSC.B.*\4'(9I1<@V-.E$[7(WL+
MVQZS/_Q+@YWG(;GG]8WV=.LDR9Q71HT:7&JQ9++.1M8KTY8YA<S6)@8E_,2;
MDI1.9!A&ME7;M8"!R)A301.;I#N/' :9_@+?UMDW%8+H^X2F9&C8;'&2+#8:
MC4'%O%. D):R5B;>P$E%LV#D15=+F?L%NA-(AQ42,0X![0!IV5YBU9RF6N&0
M01=+2U>EXU)LX !0<*/6*[<B*P&["DJ90"* /82F$-:RFS;97<; []&4TRUM
MNFH.#VP6?=189Z"F6)8^NT[(DI?'KRD6][# )6SY1^T'UZ*6=E71.FKU^&<#
M=ZG:">1A2O,2-9B)!)L (8  F025BQ54J23!#";@#3$[F8,BUC.TCG.S%[HJ
M77:4]O&X&7H6&(\M^EZ76W+^Y1LO'S9&;@B48_;NT$N6C]\F?J<1HD!5D/!7
M!R\E$;&_WHXU;Y_Q?AYDDVEX#*&,+-DJ&S RE8Y6F-FD X.W/%@]ZA.*[TR9
MA(<JA4BGY(?V_9U EB3;_9\3VEQ9MUVVJ;S32Y;+FZQ:E8CDUXR4FZ@O9; 9
MXWR@A699^@VD:]:X@I&J4L03# HI^.BFF<I.+UM4VQR^:L5X&J$9C20H6!K+
MMXW>4V3F4WZ3^,Q7.OLFS,M3X]63\4%6CA$4D" BDL*:2)C DKT!JGM&( $%
M@5!V$BUVAK7VMX!AN;3207),%29!$ Z28'.1$$&+D #ILQR&1<>1SV09R5OK
MC%]"ULUOE4G;YHFYBZH*G26;=B?^9HH3\$!R8Y2'$>"@(CK#(?<=@.R428RO
M"94I$K0*TZ5CYJWLY1%Q&0[Q,Q"J,EE@3]8265ZR]*)4NI8#=213E[AK'8/Q
MQN(W9[)<H[M9W%3N>R+;,CT#&MHQ' S$@#S)&V#;9*OZG*5JLR*ZA 55O3J&
M3LSAFF86<FH<Y%%S&,4!7;-U&O65['BW<!MUVJ7?;[@+%>:*M:LZT>1I#-";
MS<U@8 T;$S1\.-%4XQ^QQ\JL@@IXZGB3()G<J J!.2L699D 7( DGV1O*L?9
M(BY Z$&P7LEL))N 3W0)(4Q!@WF!O'29&-@MSG3"[.CQ>5GN2J8SH$V=-O%7
M)Q+,TH>0.LJ*2;5L_7 BJC@QR&3]3$ 4 Y3$Z.2\!B$=N"JT/4++DG*TO0L<
MT:.LYX:$M)[9'R<9/Q"P(_([]VY21*O&2;SQ $(94IUT4S%4-[/<(*:[LGEL
MP1F )*]8AO\ ;L/9#](#(YMG\76V.^:\10:K&0<Z6)LR-.8/@;0-3E)=5&0<
M0:AP(=55$2D*(\ZN-IP#D>FVB#R3D+;A;<E8(Q[OARW;;3AN-C$YX\K 3\"R
MC:#ER(J3E4L;.5^!*1PR+#.?O(**%411X*80C6TKRF-0(@6TP3<R!<@"X$$D
MB^)[)+C5XCQN1IF(U2(N8DQ"SB5O;[Z0;"N>(;<)<RR$95,>8"RH;&#W(;Z9
M:/*O:'(13.2"4B'K<AE1( O"-#M_#,KXQ1#@P>3E)W/^$(#'\7E.>R=3V&.9
M\Z*,3:'<@D,')J+B<$R-E"IJ'55,)#]1?!ZD^DWB 4 $=:MV)-LF:*A1&66:
M9M=N6 \$USTA=LS98=O\S7BV>8LE!E:F\BHN\.*(B<&,C&)RRZ3DL(X4,5J7
M@0+][*.E2D=NMN@:-1,G6.@;D'D7<LU9+R-0H>)HT%8JSC(LX@=NV@KCAMTK
MX<94[6=(H1BB)C*0K10PB0%#AJ.T*D@+( ,$S.\3*G3!&WB1#<L-V*&"6TW
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MO6; "K0[YX >*\7(8@@9,W6'LCS&!N4S3ND;YTKZ^$9]&@X,D;-7&$,_M2Z
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M I3G J:28D$HD 0Z$P$. XUOURZ,$)J/%-"*ZA4KBL#IIB=*Z%:F2T%5AG!
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MWO<35'D=1S(SSPM]?5N&2D'168$3;K>,B912/%T<W#L7A0,T\!0IC+ ?I$!
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MAP)B&$H#SVY[ZF: 0\N0YY-V]_F.O%<7*GC'$V5556S.L(GLJ&IHP5;"PF!
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MX2FEW)GDTX5=."G2?RY'*@KNB%7.NAR'8H$  =Z0O ]1N.H0XX+W*4O?CC\
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M8GLK) CFY6648,1F"W4&[9HS4C2J"8(@Z:0*"7LH(\ .J&+=H!/=F"-)%R)
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M$=8,K?Z0UAX6P+V^N-H2RN&R$#++S#,L?-G<E$[5*)='6!)V=P4!,F5 QC'
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M@A=0#K8*!'E@+9QEBV.,A,"9EN^-+KANZ2,5)NVB8%5R-)-@2>)%?H LF9"
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M@+!)D?V3&\(Q;D52,T8/5RN+&XD4D#H.%^1% X&.("8. 37:I3-N^UK>(SW
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MWCF_8-$R/*_Y07ISF1,6]\3GR&6\:QD]8JT]ND,C8JFUC)"RPI%SKR,(PEQ
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MXHW\X]-_<O7_ /NEKIL&_:@3&5-J^5L<P5I^9$W<V#2"C+:!3J%@'*[U$Q)
MP)\''PDDC@8"CR'7P)@#3GZ-_./3>/\ \KU__NEKI&]U;8'F$KDT&<2K2;M)
M%!2?7\/PH5(RG"KT14$$RB(<EZE! I1-W'W:ORQ(S62*[BO2(V.S+R((-^4&
M>>+<N)S"#_2">4=\=+_"_2]L:N>)+7 UR,B=OF7487<!#8A<JP@HL95I(P=E
ML<>JF#.T2D%("<47SDR*A ,L51(A@  /U".G_N;0O+,:GNCP30IJ'R'0I9K
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ML5<J/@F[%Y#D<JI01H'":92@M+M<PKDA5=8-1895UZBQ*JT3#2)48QAF"O\
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M^S^BN%$Q#^ROC/\ =]4/^_X_7W8L<_L;8W_<#3?^X8_7PG<0_LKXS_=]4/\
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MG*4=4LJU^I6>"4KZ418ZNX@VB<&ZE70."LG4-/-&_"RAF:8F,(&*!0 I!*8
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M)(J"*X)'( #W#6E%7/GC8K?@2@4[-0656T5#25*=#,5JW:$Z)2G494>DKN
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M))HDBFF7(6HB/1J,M32')*YO*9K0K9$HF:TZ+C2O? [3M000\:V<%J;Q45&
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M14.X"<8.'2ST#,WKLJA2)$43(W4*!NLP'$W "4-:_)?U--Z8]4 /^M,ER=0
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MX:> <>2\@ CP/(?6' ]P^H?CI"-R$6YG<72D,S:L7CN1D(INV:R1A*S<KE=
MH5%<>!#PS]/F/;X\]@TZ5^P?+YFX-*HK"+058;S%@0)F,9&0OG<MR^OID\A
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M:QJ5UFH1770&+ ,=KD:CK_P-F<I^%F6J[U"P".3K(2GIT!$,*>S!.D Q?<6
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M!<WJECJ9!3D&"%,$DB#!O, B\VN#AJMXLMG=T['^(F3V-=R8'A9<P/2],O\
M.-QZL19B3J #<)*E P&$O &*( ?RTOK^A))WVO2>29<96-K,6NAD-]** 7Y
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MA[0\P@ZL3HS2O-W<(Y4KE;I]K@U6K**:/VS0L8Y(0XN3*J=":!5%U6Y-S)Y
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M#Y^TK+JD,SG595^PUHJYXNP,VZQO6"A)MW!O'*50YCB7D*2'.DZA81I)$,0
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MB#=L)3=(E*36Q5M#:,HW&#*+C&H1<4W;-48M@JX2$Y(P%#F*FJ'7["R@<&.
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MT==<ZP[R_9IA]QUBR?&Y ;M<BKYGB6GJ:-[930,@3;K+%.HHHB+01]95.H!
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MU#LBCRY(D8#<=-+W-8!R1/SU7HF6:5:Y^N,%9>7BX673<.&\0V4!-S($,(>
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MH%.!#% $AXV&TVJ)!7629M_&<AU+J%332.Z.7@I ='Z?$6$A  I3*B?@.P"
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M1T!\1_)^C1ZEE?Y&G_43_P .#UK,_P#6*W^]?E$?C>'S)Q@/W,J7P'^Q7_\
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M #R/"8F/R4>>>X=P'@0]VN]3!V*5/#!:G-%BHI&3234.Z,FFF8! 4R$,L
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M;,T37(!TCD%!P5ZV,)!1.B)0+\%(25O  "J1=28-F-B2P8]9$[@ &0]0(UK
MF3$&3O,;@'IM D",2%) FB5,H 5(A2)I%(  0I2E+P0")E]E,@  %   "@
M <>6O2 @// @/'GP(#Q]OPTT"Y;X-K="IC?(4]EB"/7GUPDJ'&&B4G<U,S=O
MA3F+,0D1"Q:3F2D%HDA%%9$6K8Z3--)1190H &BU[Y=K%2KU M,IEN#=5_)2
M1Y"IR<$B_FT%XEJY!H\G)8(U!=2'A(YWU-Y"4E4VK5FJFH58Y13,(7*X&Q!!
MN+@<P/("3L+^Z^*M#'\5IVVG8"WG$V]P'1X'(#Y" _Z//\6J 8H\<" \\\<"
M'?CSX^/'OTPS=#Z03;=MEI;R;LN4*VM:)/',UD.EPC$[N=1G(=NQ<.(F764A
MTG:3& E'J2;-O*N546RRAC$34$_ :6+:-F>9W#;:\(9OL$$SK<SE3'D%=9""
M8*F79QBDTB9<J;9P?[XHD9+P3E$_)N#ASQQW8-)BTQ,\MP+&;S,CI8&^%*D"
M2(!,"9&'):-&C3XC!HT:-&#'28O*G/!OHC]@]NWN^/U^?Q]W4*9@'N ^&(!R
M \C[0&YY$/AQV$1[>7GKUZH8> 'MS]0^7?MWU!AA'0B;<P0<2#<'F(CW?W8C
M,M>WS=/:;]NM+,9+:RN(LJ8EM%.Q;3FRYXUY6;#-Q"[%%]\H)@51!0#*'*#D
MI^4>KJ  #N$7F./1?;UZQ!QLQ?;$RN;.K5+'..;/B1"^ONC->*Z*Y\8E)?3K
MA4K:(=+*',X>R2P@#XH"B8Q^>-;-X' #<=''EW O;ZO?YA]G;R'MKT:QJ.42
M@*X1G^O=W;40Q!<ZB!(VDF!M!ZF<;+.<6KYY:2U$H**"4J8-.F4)[&FM)2T-
M=BJB6%SO;$(N!L%;O<(7W%=U=X;@"UHA,KU0^.Z1DEN:/Q?7K9-*2=-?K(RP
M>I3)81H)&KQK'J&.8_B&2 IAYUFERVJ;HKQN-86F;F%F40IAK*5.O>3*I=WE
M?9W)6S0PLJ-7XVA)JG-"2,$Y$H.[&0_'6F+M,>H0)J8;1J5RRJJH&8*NPL;D
M0>0WY&Q VB\X35V9BQ"ZB""8.Q\R9B^YN8)N,0!Y V(;XI>WX!''.47M+;U'
M;E.8[R)>']S<34DVED(Y9G$U^$8JJ =^_G"<%D+0H3ANJX%4RGL".EDHVSO<
MU+^CK;;=<GV61C\SQMR2G8&8KE]>M9$6,5;6TPQ";M34X^.5VT*X4?,2JF(L
M*O@&,;@"A,QHT_8J-B1:)M/F3$DCE/1?R1B#6<P(6 00 (NID3UZ7Y>^8)9C
M:%OM#,%SMU!NIZ1*S*[1O;,C-[RJ^^Z-4PC03@JM'UMZ4[>LN*8^*HX&22;)
M#(>.( (\=TMS\AZ3G;?A%J\7NUHR_8YB1?MHV"IBC1Y;GE]<F(E3G'RSZL5%
MA42N3(#-1RJ94A235$_(&$=;%FNA0@&'DP /2/L=1 .)5./9.01^CQR("(=_
M/O\ !>P V=_(W!$R08 )!%MQ!C<QAA6:1*H0.H$[1OTYP-MXWQKW,=L'I-:Q
M/8:W"5B^P,/9+)AR3E=X%,7E/6IBTY&<-&;JL-:LH?Q8]K\T2)N/7$VR:"4B
MN;U8A3B' /']%7>MQ.1L3Y4L^X)AD..,MF*PL*&PR8"!K$2OQX%2=.$#-T&W
M^PSJ1\4\44R?0FWZ4R&. #J4S@  W'('[<B !R?CL CSR @/(]A\@U5(>2!P
MF*7G[ @ "'';R#L'/GV[:E:?>!!(@<[@$WM!%Y-]6H@ "0(&%:H64J56YW N
M(@QSMR']F!(PF3*80$!'D>!#I$.X]A#W<?FUV:-&K\58-&C1HP8-&C1HP8-&
MC1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP
M8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C
M1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8-&C1HP8Q>[QCV:IMJB(WP
MAD)2O2\>Q!8W2B+MVP70;^*8.Y4_%4)UF]Q>1U KBWT=.::KMEV14*1HE&99
M!P=DW-5LOAF\BS &$;D!_8%VJD=)H)@>16DR/VIGR?68"F_EW\K[3^3TH6$A
M)>8.4IR1<<\D#D.;H(8C1NHN8IC?TI1 @@(^X.^H'-M/IC;9F;:KNQRQD#!Z
M6-<S;=8')M]JN/)*0<!$94QE49N7C8&\5ERL4CEY&+&9-&TNY:E5;MGCD"@<
M ,4-55 #()(!"@P0"(8D1XMW@+>!B<6TRX'= -QO.YMR(Z_KV!Q:IG9[G^KX
M[H$'$X6^4,MP>%'E"I>1Z]=X!:NQ4NI<'<RA3\JTJ:9FC)VKMDG!79G[$Q1<
MIF,W,;Q2=\9S7L5W8Y,I6Z&EN<=XVEK3;K'MKS1$* _CHG'&;YK%T9"-K9CB
M;BT$DE*\)EVK@(D9'QX<56C<X@"(E.5RF[KTF>3]ON!=KF2<;X)+E6[YKBJI
MD?(M1:2+M)KCO#"#&&ELIW<JC9)5RN>LQDT#AH18I&ZIVZA5E2EUDVZ?TE$1
MC*8VK5/'LUCRDQVZJ(:VN(SYFE\O%83JD"K&+2)8<)9%9%K*7Z942*VB8!9X
MW!8!55ZS"3O2M-%@@L=FB1, *8Y218R=(4S&+2]4V*H)+$F_(@FTD@2)L+[Q
M>2VUEM*W,9HMNZO.CW"-?V[CFBEX:QE4,4-K-7WDF\4HL@"L[DBX.H%LG"!(
MPA0.VJ@)%]=]12;@82< 8<8JFR?<Q68ZG[3E<'TZ6:0.Z6$SZ[WM?.:'-+&J
MK"02FAE",G#8+HME5LJF:MM045/&&C#%ZSI-^3&=))[_ '<)B?%;&XY\Q/C2
M 46W*4S#D+D*MWQ*2Q1DG&-O3<J-,NUB94$$XL$DTT4W<([<+@DN98@./O8@
M#B+MO;A(K>-MNVQT)>D7N)S77,CS]@FX*UL)25K/S*9E=-E4V,<X<D]4=" @
M=900+W ""/(",@*6F3)T@Q&PCV;B-($M!:/YQ(&(U5 !98N09MW0IN2;P!L2
M9.^V('-PE4-7,3Q&'6&,\.9(ED?2304C&YEBIZ$F;S9E9VP3LI-.U*^5)6[-
M[U&,G"T1,*R)!8(,DECME_5_#3!X.R2A7-_OJWC+R*M9M^V78M.3S7;)#5Q0
MBKIED#(L6>S7EDI(>VU5DHQHU/"+%!50&3I]TF%/@2C(UF7(FQ#:[E-A<LAP
MF/JQEZR"O,N)2&JT?(6N/9.CIM'EWL+=D3QX=@=1=-HXLZR13=3@$SKB*G>[
MV;='LCVM3T!C,]AI%$>9+.UO+F+J<.V,R]7N+I-NVN]Y<1A02BV-C=.$449J
M;X%Z<Q0*<Y!T* "=14E2!(,Z8@CX1!FX$Q,D@9V*@*'@S$[,3 ;8&" +0!N8
MCFJF.<CS6Y/;BM<T\?V#&DU>:W:HMO4+4Y0/,1CE,SR-:BX=-P!OX+TR95T5
MBE* )J$$>^H;%/1V9_Q?B[T>5@HM8AV$EM19Y*=9-Q+09&(9J2]AO,FYD2VR
M&=RJ!HB7L#H%/"D',B155)1R8S<13ZBA*E*>D'VA06?8[;$[R_7V.2GRL='M
MV[82?-9K-R;;UV)J;NUI*_(K.S2K02N&, JL5\Y1.4Y$A P:O$9OSVJ2]\S!
MCF+R]7G5JV_H.%<OL4ER^!2%T3$*G&3;H%122F7@G(6/BCB5V^$>44QU+ &0
MS@2H!,6O:8,P>\1)/.YDX12RF0O/4%()M  $D@D1R%Y'(2,11U/8/F+ %GVL
MYV@,,H9C;4]7+SW)6%+A>(V>F:%.Y88*%:6>BOYM-2M@_*LLFQL;=FW*5-L*
M@LN +UDMVU':)NRVL5[;9DV4V^U9[,U"T[ADK3A>A72%1-1(G*4G,/ZI(L))
MP4D1)I*BY;$G&;!0HM_&4./(D$-3@X-W&8HW%Q4G,8PL@29ZZ])'6."D&ZD1
M9Z\[63%9L2;@')O7X\'B/*K072:97"8&.F(](\+SJ5IAELQ@&0;$R 1,['?8
MS!D\SB36<$AE$FS2"#%[03;?<7VZ8UGL";--W^%IW">Y"[[?JAD&=A;1GYU<
M-O[*UP"B5!7R3/&E:W;:;(R":D(\E5T$BPDTX(F#M./>+&Y.0#D+?;;LGW3Q
MV0;;E5;$D&$1N P$\P^[P9BN=KL55<,.7KM^#N/65DDACW#*Q(/_ %^:EZVW
M9@5YXOLF5(4P[(FC4F@"" Q$[0!:6#'XD6V(N)()&([9I!(618F]Q:!O'OC&
MM^^V'YUV_162JK4=OE=W(PV9MIU4P[6 LUPAG+O$%KKL:X:O*HN^M2)U%:4L
MNX3F&[N,.GU2:(%\/I #!,?L>Q5=<';2=NN(LAD9(W;'F+*S6+4A&./6V#:9
MCVABN6C-T4!3<-&IC> FHF/08J11)[/'#L=&G6GIV8\MXOL3,1<QOXF9M"O4
M9P 0-Y)O>! M,"UK;[[S)HT:-68KP:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&
MC1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P
M:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C
M1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:-&C1@P:
M-&C1@P:-&C1@P:-&C1@P:-&C1@QC=QCG,O4[+%,@ZG<E!2C%J4>.!7=,ED4@
M'GD/IG+Y]OCVUK7W;T7&Z)[Z-;'->QY'5NN;X<01^8JE",I&70>UBU8JRO=9
M:1L>/K(].KZF_;/X=9D^BS*&$(N0 Q"%X[%V=-< ^A^ W\>E*R9\ ((D&"3?
MJ+F1SY[897*Q'(SX[1ORQ ^7T;&6L[YD-,9ANUHQ)BW&.SRF;5,9Q>/)9FK)
M6Q&STQ-'*U@L'K9%TT093)DXQFD"! ?,VH??" 4##AD9MCW;87VE8:P)<-N6
M.-YN'\%R-OH5APM:UH,MSO==8V)^\QCEJHVJ92?LXJ6BX9VBQDX)%L515,79
M4%$Q'I'85]X_8'YS:H;^E_M@_CTG9@%1)M?D 8C<"T$DR!$SX##=JQ@&"H((
M7H1N01!!,F\R)MC6 IGHN,WV'#%WK$_BMC2L0Y=W<8JR_7MH<M>U+?$X0QO7
MFKQ&WE1LKI5 QGTVY6%W\V&!$V,?XQBMDP.!BED%E/1Y5O'_ *07:YN'P'B:
MHTRCT:AY-K639V-=';/BA.-"H5U@RBW"JHK NH E>.D0*<$P#Q!$0Y&7D?(O
M]O\ QCJH_2+_ .]^;4]F)F3/=O:1 @P8GO")N22 22<':OR,>U,3?4((-[@
M6!G$'OI%MK68,NYMK][QAA)Y)V9K0G%7I>:Z5=6<1+1DJX?1[QQ5\O4V9;K0
MMHQPX]64$0 GCD,B@!#@8>!L]9V_[PMO.6,Q2#' V.=S*^[EGC(UQO<K.Q<!
M7L82U8A&\+8(.2K;V->@K1HTOC258C8E1)-1^FB(E3.!1+.U_3_^[_'J@_2_
M 7_'#4&D)8ZCWIL;@ F2.1C>!, F=YF>U.D+I4@0+S-M)WF1=>5C8$$ 8U?&
M_H^]VU9H4EZ/2,P=2+'B:U;@HG/J^]MS88]E(0,6G/-+&[8+U S96<=9 @E6
MIZ_ /$9HK<L*KX8$*F80!7)ST96;;!A3>956<=$4^XY&WG1.XBI3<*\CTK)E
MNG4Z.!*-AK1+>&<&4@\6*)F"3T5$&JQ4S'1,553G8G_IQ^T/\4VN0>9OM_B#
M04@S)]D](M!VVF=[1;88.U;H+$&X)OW9W.QT[>)Q$_Z/C;'?J-E;/FYS*]1M
M-&ON;6=4K1H6UVUA8YQY"5(7#E"7L*,*V:PS:76<.3-DSH(@MZH0"&$"B'$L
M.N)?Z;^V'^+7+3HN@:02?/?",Q8EC GD-AY23]^^#1HT:;"X-&C1HP8-&C1H
)P8-&C1HP8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g715173.jpg
<DESCRIPTION>G715173.JPG
<TEXT>
begin 644 g715173.jpg
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M25$)24A)Y/I]KD>GYN/[#KA3: 3S*<!!/("D>./4#[)_Q^[3I>%9$MV$U?\
MK>-J].^W/-\IB(Z?+I D#V62/'IOO5T4[#N&$1@>P/3E@N[M7N]&L-W,FGX]
M?Y#EF!8/E.12YV!;87V5,OL7LS#J=QI3+#TQB4_&#I^TVPX$I/A($P)_5!B=
M=)7$<I+E:T)20I Y!"AX')8/VONU'9' >[/?J/NV@X5]Z0.%DH2DG@<JYY\
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MYX]#H^KJ[N[?HK//'/'8? ^\^@Y^')Y.CW'C_P#/>E__ $\?3_/]N3WG0?\
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M .;YWZ7Y>GJ_=ZXQ?X30?Y#O[/\ PT?A-!_D._L_\-93ZL@?S9K]A/[M'U9
M_FS7["?W:/<^._SOI?T!Z?Y_MR>\\/\ YOG?I?EZ>K]WKC%_A-!_D._L_P##
M1^$T'^0[^S_PUE/JR!_-FOV$_NT?5D#^;-?L)_=H]SX[_.^E_0'I_G^W)[SP
M_P#F^=^E^7IZOW>N,7^$T'^0[^S_ ,-'X30?Y#O[/_#64^K('\V:_83^[1]6
M0/YLU^PG]VCW/CO\[Z7] >G^?[<GO/#_ .;YWZ7Y>GJ_=ZXQ?X30?Y#O[/\
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MF>*U+7=HA"=[T!U+@<2E0R$7I"Z>H%=C== VVJ(2<2W)M]VJ&9#=EL6L7/\
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M\XU?I[(SIW9]FKLMN#M2UDTC=5&99NYG,6U,9-:XPB4$L.M/-=D;CM2AM78
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M3]*Y"$-,):<+Y64^Y+;@<[2@ZH&Q#H$W-W5ZGMI^I;<'I\PG;' 'L[RB]G[
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M-5OAE?>SS]7RW_NQY$_E#]/]ATLL4\UTQ1]?I*!S\_MJ Y_, -)GZLGI!5]
MLAX(!,<D D$ D>?0_O\ 32MQ:%+:@N1Y#;["@[[U:G&.TN\*)"2?ASZ@GY_K
M,Z>734XRL#:]FQ>U^G_SA+NK*;*X]+X]+X[?,%1(]#^?_ :&O1?YA_:-=G:K
MNX#+@3\>!^?R//K\2#^D\<:Y*"D>&U^GGA/KZ'YC[_T_#Y9+F#.6SNDNVP(^
M?[?@^"5F+L>;L55&[MOB7_3#_P"+,E_]]C_W7=2GU%GIC]Y]79+WMEL?3(_
M(\GP[]KG[^?((Y!''PU*;7*=4WU&:_\ 6GW ?JQAY_\ &S^9^!@T:-&H,18-
M=3_\0]_1.?W%:[==3_\ $/?T3G]Q6HL_^)S?ZDOPPZ'UX_UH_B82N*_D._T3
M/^.E?I(8K^0[_1,_XZ5^LOP#_9>1\\S_ ,W%WQ/_ %W-^67_ .N&#1HT:V<4
M,&C1HT8,(5K<K I&?2=K6LGJG=P85(C)).*)=)MH]&MYN.BR<9*.U,9;SK:$
MK[^25#Q\=1XW(ZZ.D7:-[%G,YWCQ*HF9X]>0\::CL3K.QN%8H\N/>(;8JX,N
M7[NJD(4R^7VTI;<20@$>=0BSO;C?7(/:OY-?;9Y.Y@5"YTD(JI&066.)MJB5
M=O9% 3&3&?6E21-BH)="?"D!HJ2#QJ$.PVQ?4!.Z@.BV-[Z+19)BF*]60S3,
M\GP6#D-#:2[+)W_J]QAF<P\W%?M4J$IGAMI8!5V* \&A/JYDB)E\SG$D!OI0
M"-R#5N"20=40=VK\.D@Q)RS3^+A-C:)JC*6Z0EM\-?"2D;J<7=CEGM ND'!H
M6 S\IWGH*E&Z%._D.$QW8%X[87-)#?,23:BOCUCTR)!8D@L./S68Z$N!0Y/D
MB4N(9ABV?8[59?AE[59-C5Y&$NHO*>4W-KYT51*?>,R&B4J"5I4A:20I"P4*
M"5<C50N].?;5]/?7=M+==0IJTU%ET;VV'Q;\X W:4%WE$#/$V%O55D>' D-4
MLV7$*W6(C;#"93,D1@H(4I(]_1,QN%L[T8=06X#V(YQ4XODFX6Y6X>QNW-!%
M;7E^/;>V_P!&141J2EDNA%6[)G-3;2/6N.)2PEPK"$]P!FCFSOXJ:C)D!4A
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MY#G5/6Y;4RL:NXN.VF$Y'2N4N:,9#8I;735;E6^I:4.W8=;^@NEXLK2I16M
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MF7N',G6.%KW(QG>7,;#+HEY45-<S!MHN./SBRQ726%^]D06VUMM*6E [BE(
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M6ZHT]1FCVE^()_=C&SY$LV<H["E=NQ@T:-&J^(L&NI_^(>_HG/[BM=NNI_\
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M 7O5TAV[<<[8?F1 @RT%N7"B2FU.-NJ;D1V7T*=9X]TZ4NH4DN-<#W:R.Y'
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MRHMHX3(0GL:6VH-IYNIT:TOHF3_);L[N]-UM7?[J*[W6.JSSB;Q1L-;!LI?
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M/>S_ -7KO[9F_B8O==_PO]EROUX^%J[4K5QW!"2HI'J0$J/''QYXX ^>JO\
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MD7&0Q213=.Y7%5BWF@GGW ))/VO'J/S#GR/U'U]1H8>04$EA7([CP%I'(!X
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ML7MG*Q"^G9?NKCN_<#*HR9]GME<;;X]*M(M-,;*6HTJ%:N,@NS6>>SE#7<%
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MLUM=N-1[7;LW5CLON0=M[# =K<2W!V7K47L#\)-TH-]%>S_-H$:7*^M;%YI
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M&C!@T:-&C!@T:-&C!@T:-&DEP_)_#!A%1_\ 65S_ 'U?W%Z6ND5'_P!97/\
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M*5-@#[)![2///.J7B71Y_0D<SJ/#>HR7-=$6>3F0"4F$1J4([%VL1.+VQK^
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M/]WW5YQY\]:NU;#L_+Y;;^F'+2E':D<)\@^!XY\GGQXY/S/RX^&NIY("%?9
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MNI)B0K4@_G52>8[ EWL%XC<K,BQ)01F7$=E/EVVWWIJGA,23X'_#D\?J]-'
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MZGQ#A/Y<VES&+\+'(%18+ \\%28CI3R 1R.>.0?!UI-YD&D9IFJD--)+V69
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M5J+/_B<W^I+\,.A]>/\ 6C^)A*XK^0[_ $3/^.E?I(8K^0[_ $3/^.E?K+\
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MC1@P:-&C1@P:-&C1@P:-&C1@P:-&C22X?D_A@PBH_P#K*Y_OJ_N+TM=(J/\
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M(';KR4VWN#8[5U=)1XEC]53TDY5I45T*JALQ:VS4EU"K"&TEKM8FE#SJ3)0
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MVG.?S\>.3J26F2V8QV;CT*X8F$*4Y)0M)3^202M1X\J\<GP>?3X?'3VZYO/
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M:Q1R+8O--P1-?=^L&BIQH$)XT@\W]EW=OYGC.SVWE&[BW3S%R;!,FLIS.=Y
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M;CM7._;R'$SL0'#$L<\_C$?U=WZOG^G2QTPVQVZ%/N5$NWJB!906ZU]IIP6
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MG^?QUSHT8,&O-+B19K*XTQAJ5'6 5L/-I=0HI/*24J!!((\<_'7IT:,&. D
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MWP#Q4=UJ7>_=/[23HR.P6/8AE=\[MQNJFXJ,VR.=0T;54(CY?D.*AN NRE(
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MR)RX>85,361W$O?1XB)"0VMP-ELA/(@[(Z@^H3;3=_JGPUCJNL*J%NGUG4F
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MTPG((V++:7CC-ICE7);I/<H]VTBM2N/Q$90CA(8:[6> GEO[*>*Y/9U^T W
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M66(]\77T>VNWN,S:VRQS",4H)]/1-8O4S*:AK*V16XVPH*8H83L2,TJ-4,J
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M9C/L@M&L/7D$R;>5SS28,(Q905&5%]Z4^[Y*@HIYTUZOIVD@M!0Y=4.FFZ4
M> OBA*<#TG5'.U\?PANW87=6W87Y]\3_ '^G?8F5C&-X6_M%MZ]BF'R?I>,4
M#N*U*ZVBD]ZG%OUL<QNV.ZZXI2WUI\R%DJ?]X?.EUE&#8=FF-R,/RW&J7(<8
ME1T17J*TKXTJM7'92$,M(BK;]VVEEM*4->Z""V@!*2$^-5&1.OWJ6P;%'-U-
MX]L=KVMO\SQ_-IVU]5AEY<2\J7=4&0.4M) R-,MA$-,2R;"),R5%</T8!:0.
M> 'AZ)^J3JAW2WQWIV.ZE\"VEQRSVZP;;;/L=R#:O(K6VAVU?N$U,?37V$*X
M8CRXS]8(XCJD):#4AUMQ;9+2VEKFR\W)G]6-70C +&B(G<I*YHMV,,GTV?"+
MF21(6V9EMDR,M._,9H2KNE7B?F([4[88$CW6#;?X9B30?3(+>-X[4T[:92&O
M<?2?=U\5A E*9_%NR. ^ZDD.K7R==%5L[M51Y?9;@5&W>&UN<7#KC]IE<+'J
MR/?3GWNWWS\BQ;CB2IY[L27G>\+=*05DG5*$GVCN\>#8_P#65/MU0P,&8W'W
M/B9AN+E3]_?UM:_C>1L5C5%%AT;4B<PB3&6B0Y<OM_5< @MN*'DZG]U3]5&?
M[:;=;"-[)X]A67[K]2^6X[@NW)RJYDP,"A6M[1+O%6]I.AMJGR:QAEOAAF*T
M9$GWB.U(((TV/49*OP5* 30B-,DB$4YD+$[;(\5A9]-U$&(O\8L;UE5$U.MO
M:("[W]5VO;$ILGV2V@S3*:;-<LVSPO(LOQ]0<ILDM\>K9UO *7 XGW4]^.M\
M^[<_&LI=4M+3@"VPE?G2Q7B.*N+4XO&Z)3BX\J&IPU,'O,6<"F9&*PP%>XE
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M[;\:(&^3$O\ A,R1;27 VBR4V% ?^5]?LC[AZ? GU'!Y+;-292FBPTEUM]'
M4ZE)X0E*B2>?M<=QY!'@>?'!XUNR9?\ \F2V5RVVGWMGU)[D17YCJI,E+%#2
MH81QRI:NXN)X2 3WJ5P.T<J/ TD87_)=>GNP83*KNJ'<:;'6I:6Y4&HQ^0R2
MVHMNMA^.^M"BA0*5H[R4J!"AR//[">RW[H3\G/0>S7@7A?BN5XI'KO">AZ;)
ME[CHI9F1F9V1EPBZI>\BSA*5J2AIN[NM_P":+\J?Y,O:OVB_*;[:^UGLSUO0
MG@WM5XKUN>1ZK/S,KK<GINJF/\$O33]QF1C$<N<<W4%B&S'2[F(GF)8-E$AT
M/0G2&&TE960\P5*[N#^0.WD @A/! \ZW\^E-ET],6Q*NTD1\!JT/)''*5.\^
M[)'/E(Y224\]GQXU%=7_ "678Q2%H_YS>ZR0ZD(<4BDITK4@*2KL!]\>$GM"
M2/3M\ >3J[G:KHNPG;S!L2VOK]P[&X5M]21Z9;A;JDV:V>TJB/6,5CN=BJ4C
MA3?>$AP#N03X.O,ORT_E:]D?;SI?"<GP8ZN,NBS\S,F9O3YG3CJCE:8@J/Q9
M8-*L1Y*#I/R/^P?BWL)+Q/,\5ZG+S7K#+,LR\^74,89;G-2D9.53)S5XH956
MS.4;N"./   /!//YC]WD_+Q]YUV-(5[YLD)_+3X[A_*^'GGGX\>G.IJ?\U>C
M_P#KHN/_ );7[]<)Z5Z1*DJ&56_*2E0_$L^J3R/0_ Z\$_?K)=]%/F1KRY0O
M;]6WECV\ZR!RR>.WH7R^B?;C\UGVQ!=/M*M\TMDK3]$Q8JY(3P!3,)(Y(\#D
M@<'Y\\#5;JQ[Q:?(*3P.23P%$<GMX\\$_'T/PX&M_3JZ_P"32;6=6?4)FN_U
MAU0;C89;YDFK^FT%7B^.38<4U\9$9*DO2>'RF0AM*^%< *'*"1XU'(_\D9VC
M*N__ )Y.[(5ZE*<(Q4H)_M\^/0@CX<:^VO8S]T)^3CP;V9\'\.ZOQKQ$S^FZ
M3I,G-RX^$]5,A+*Z?)RYPC(R*E&$H(2+N(*<&/DKVC_);[7>)^-^(=;D]-D2
MR\_/S\R&;](Z6/O(SSI9D95+/)#*,A-0,=Q\L:2Q3V$H^R2GU'*O'W'P//Y_
M/KS\.>?7T"/TJ4#^K^S[M;JDW_DG^PD&SBU5AUS;A0;:Q*1"JY./X/%GR^>0
MGZ)!>=3*?!*2E);0ON(("B>1K+'_ )(WM,%$IZR=UR#_ "\*Q0GG@#U ]/'I
MKIC]TO\ DNE*1'QWQ!TJ5'PKK&MXH49&VW:BD^QPW\C_ +:A%ET66*"WU72T
M_59)?4;G)MZ^=NDDM+G([>WT\]I[O[2./S?]FNLEQ/)5\B>.!Z#R?'/GQK=P
M_P#HC6T:N5+ZR-U^0./LX5B@  Y\GGX@D_<./SZ\D3_DD^RM@CWU=UJ[FSF&
MW7&778F)8=+:#K9"765.,.+0EUM7A:%'N2?"D@^C)?NE?R9:J_?SQ('<?WIZ
MS5L0\\A=K\K[[#AT?R0>V>U]%D( ;]3T@WMR_2/.^V^]\8TJ9(<^B5AX^TY'
M6XGQS]GO/KSQP?N/D^>/!UX%>]2 5$)!(')  \_,\G@_+Y_=K=[>_P"20;/O
M1XC0ZQ-V4+C(6A2QA>*'O"E%0[1P.P#GCC[7/KSYTE[3_DH/3W2/QXMUUU;@
M4TF4GOCLV6/X+ >D-E8;[F43'FRXGWBDHY0DCN(23R=)+]TM^3'F/COB6FH&
MI\(ZN.Y& I>3RRM%LWX+K#,K\C_MI&(2Z+ISX\Q?])Z1VEFRE%*ZEKX9&U--
MWZ:5C:U!QLJ4@I"OM $$D?#QYY!\\^/'@^FMB3V*[G.S^\<=E(^UG,9?>?R0
MD)=)[CR %#X ^OCCX<VDC_DCFSKC276NLS=N0TH)6@MX=B!;=2>"%)6VDA25
M)]%))!'GDCUL,Z-/8([=='^#Y;A=+O[G68-9?D";V9/M<>I(3\?L20B,VB/R
ME24\D%S[)5SY'' '!?E%_+S[!>T/LWU'A70=9UW7Y^=+)D2S>AS\AB0S\J<\
MNIY<(L=&6MJ-R X7'=>P'Y.O:+P+VCR/$/$(0Z;)R<J:YD,W)G&3+*S81C65
MF9DV3*>YHK3RF(B $!7<.0" .?/)^_M].#\?0_HYUR >" %\D_=QP3Z'P?/[
M_!\ZMY/LP\, X&YF2^OQK*T?#CU'R]>.//IXUQ_W,/$  /X3LE('Q-76\^O/
M'(^'@>/@/'GU/SG'VT\'R<O*R\G)S:_A&1."Z%8,=[;);W0!IW]/H(C.LO7+
M7(9JN]6PKGC8V/GQQCS>S-!%7N<KT2Y8UA2 >>.T2DJ"N?(5S\#Z\_(:M/U&
M3IQZ::?IVC9+'JLDL\A&22H\EY5@RTR(ZH_O. TEI2A]KWAY_) X\)U)O7FO
MBG5PZWQ#J>IRXI#-D2CL@ 1B%.][6W3W[XFFC)1LHIW[ =[<&C1HU0PW!KJ?
M_B'OZ)S^XK7;KJD'AAXG_HG/[BM19_\ $YO]27X8=#Z\?ZT?Q,)7%?R'?Z)G
M_'2OTD,5_BW3\VFN/O\ 4_V:5^LOP!/WKR-^\_\ S<7?$_\ 7<WY9?\ ZXX-
M&C1K9Q0P:-&C1@P:-&C1@QP0?@?7Y_ <<>-0*Q7IGZA:/K[W!ZF+7J5NKWIV
MRG:2MPW'NG"3"8378QFD69$=DY/'EHKT%3+D=AY+:#8./*=?)<:"1XGMHTB#
M5]FSYG[<\_>X44OU*?E8[>7'W6<./GCCG[R/3QP.?3Q^GSZGG6M7D'3_ -3&
MS74+U5]56U6PUAEFZ>Z._;6UT;[3';9[19;&:KE9@VE$AEMR)0&;*E%R0H^X
M<0A2FE#GG95/I\3^;UUQVCX@'R#Y \D>A/C@GQZ^H^!U'FY7O=/Q,=+>W?A!
MI.X>=_/?$F5F>ZU?#&1(I);E=^;Y\^>^-4_9KI9W=V&Z7[78K-^F3/+O#+OJ
MBW=R> WC/O5VE5/NH$AVER9^OJYC4IVOM9@!CSEI7&;=6"H)*2=.'5[*=6^3
MX![/B3%V^W<K6MG8*:CK1K+R>*^_SC;,Y7,=Q#':%*YJG;^YIY3<.TG/00P]
M]5LKCK=<'.MFOM2>04)*0>1R ?/SX//YP=?78 " $^?0=HX ^ X '(Y\_IU#
M]&W;G8\ZHDG[Y+6_D7MR7B9ZI0N$;'5]:5*\[#L[WS0AMM3KF;J=(&^>]T:A
MK\_Q'<ZSHJ#.^J3(*R)%R5VI<K47>.1F-N2##>0ZIE<EEI4%HE:F7DK[P.3K
M![+=,?45L!1W5G"P?=E55-Z>]G[S/:@7Z[NYO<[QS*'A<1\>^DR"I%\*E$94
MBM2M"WF@YX\G6R@$@#C@?'X?/U_7KY(''E((X'CM!\? <?,'D\<< :3Z(<>\
MEP!0'&_GMO>QVVYWP?2Y56B%=S?SOO?IY\&-:F?M+O?UF=0606^7[.;]X5T_
M7'4WC5M(ILMF.89;3\:IMM;EV->*A1YCLB-1_A":^-,B%?,ETGA"O)#E]'_1
MANEL;N#TF9LWB&XU1=M9SO/7[OR[S*)=Q!AX+.B6?X&0I<:4\OAA3XBKCE">
MYON22>.=;!26PD$ )X[B1P../3CD^>3Z@D\G@\#QXU]$<<?J' '()]3\@/GX
M^.G'3 ZF3>K4@;7=]UVYXKGBML(]5)BP(1(L=-#R:6.ZC;3_ ''<'&N?U^;(
M=96;]7UU88AC,FUPW(*C 8NQ.:P7;AYS ,@J94=[,77$50,*N,J/[P+>N6UM
M.H*0@^3PV<GV:66L]3&5[UR]G[^VSICJ6O\ .T;@U-R]'581W]OGX43(H4=3
MR(_,B\4H?;;24K6%=J01K9\*4G@E*21Z$@'C\WCQ^C7''GP ./7QP#X^R1Y]
M1\3QZ>-)/I(SE)9R-2NU#OS;O=N_D;T6JK'K)PA&,80*AH9-JGP^I1\/'"JU
MVQK>8?LWG;;NU3?5[LGU [IY2[A.+Q=H)^ 6,DPL#OXEU:R;5.838-E!8J+-
M3BH\F;-LDR&'X*A'1^6.,E285OPC?JSRK#.GS=/;;=V=,W5Q*\S%!EV6*V:K
M#'W8>,W-C:R)LFHDU[KP8>CNQ 4L.%2BE)&MC'L3]DJ0@E(\?9!X^?;R.1Y]
M/31V@DD(2"1R%$#DD_, <^/S\^O&F?0H?#4Y18["%+O;:/IMV-C"O6YCJU1B
MDMV-R(\]HJE/YQO;O9C72B;5T6)=/.Z^9T6U^_6S6ZNS&$8_G^Y6XF6VTVGQ
M?<3=#;B2;N=25L6QG2!=5V76K3L<64",Q'3$L&6.]'A0LH]G1_"GG73)#WLW
M@-GC^Z/4?.NMU;:D>>2\W@T3)1[C&J.IBJ[V([%35QXTIIKN<"UR IQ2@>!-
M//MO<.W0Q6SPK.J*+D&+7!B_6M+,#@BV"8<EJ8RU)2RXVIUH/LM+4V5%#G;V
MK2I)(*FK($*J@0JFMALP*ZKAQ8%?#C-I:BQ841E,>)%C-I\(:C1VFV4( "4(
M2E*? \2Y>00GO2,=GAU<.QL?#WM>XE-QYF>YD--4LE>_PU&BW?ZQ=; 4!MB/
M6S>S&X^U^3W\B^WPRK<O#+*"@U5!E4.L$VIN'I*WITM,^%%:6Y&6V4M,1U.*
M#8!)2-8??+<)"*C+8L?:7/,UD;:6F.V,J30T<63;UZ+:OF+CYAMTU-=#&07F
M*AQ4D1&D*=:DH["TX" 96>OKKX*$\\\#T((X'!'PY'Q X\#X<Z>Y51T06,;7
M=U.^U&JZ#9O=V0J\0ZOBU(;5L&DVH_-KM^.*D.AK9KJ/Q;;PRXV03L:K+_?C
M)-Q[G(]U:%IG=W=G!;ZQG2O<9O71&%QL=MXB'&XM6EIF,I,;A3AXYYD!M!L:
MK;WK9ZE]Q,>VZAXEAFX^W>U9<R2MB,0HN79G6/7[EX[(;:^W)FPVI<?WTE:$
M=SCRA]L]RM3QXX3P/'C@=H'CGX@>GCUUP>3\ ">>#Z\<?DD^!^KX>G.DCDQA
MI-4FI$K=[2[ *(BHH!Q;=6*YBLM@)%(?,ES=J(;J^7&*$>L+H@S3>C.>K;<L
MXMN-<YG*S'IW@[&V%'E4NI15XU5?0?P]D8]&BOI8 4?I"9R93:E*4I13QQ]I
MJ=U.G++=L6X6 97C&Y<GI,B[^(R6XV^H[YU_-<N;<J#(DS*R1]-8L;'&&)C\
MUVP@Q)+11)=0>T< #9"X4>[GM/)0."./0_;///GD>4_(C32;O[%;6[]443'=
MT\3C9/6UEB+*N#TB9 DP9B4E!>B3:V3$EMI<;/NW6_?>[?1X=0H <13Z9;E"
M?Q+J!/ANU1J]J=O7Y[3Y?4L=)*-QC0T_$!&$?AM"QC9Y6U27C70V)V5WFWK]
MFGNSB&W>,Y8A.,Y7OHYL"UFD]NURV#E5IN(VUA@?3)<D)F5^+U"ER&E/%SW3
MJ"TKO4@#3U[9;-;NX#TT_P "?6?B>?;G9#C^Z.W&1[M9UB4MPO\ 4%C=CC[$
M>C8HXT&3"<3)PV>ZQ5WE!";KWBS7+>6A:>Y:K_<1P[&,#QVMQ+#J.NQO&Z:.
MF+64U5&1&@PV0HK(::2/M+<62MYUPJ<==4IU:U.+4HIG=7:+ MZ<2DX3N-2)
MOL?D2HTX1_I4R%(C3H:^^-,B38$B-,C/-JY^TT^CE!4@@I)!'IG2U(9OQ-@F
MKR))J(A0=MK3>A?I-NEC_!Z[_P"H/A+YW=F27]9L=KQ1ST>8GGE][,[K(P_;
M2JW+@S;+.]\JC9S',FMB_FE95&ZD,4M1%LW7GBA;+B'FF%./K+ _%J4"@@*#
MJ+Z.-TLKJ['>O'<>W">ZBL99Z6:S!;>MRF0Q JZB@KJB/G\>-5H>$!]"4":S
M;OOMK7(DE:DKX')O"P7 ,.VSQ:KPO!,?KL9QBF:4S7U-:R&X[*5K6ZZM945N
MOOONN+=?D/N./O.K4MQQ2E$Z5W!('< ./)2/(('/ ]!S\#]QT_Z.R(ZIL9$:
M2/#O)IOD-7?UV+PWZ2QE)A'9DOQ-M.BQ2N2%)OSZ6UJ=?.Y^\>VF!;30]J]L
M<GRK*<RL'<4R?<C&L0_#2UVEQF;1MHR2YA5+:B\]:6Z/>5D<H9?0V5J=6D=H
M(@=N;T]T>UV/8?8]+NU/5'5;SY#L7%PS87<S'8[(J:_*F+N7=..[KU\QT_@P
MLVDIR3.59Q6XCD"9)994I26P-AQ2$*\*2E0'D!20>#\_(.CL1X^PG[/Y/V1]
MG\WCQ^C2SR-4]6NJ"C2-;!=V"T>5[1NZW;E]1/+B1B!2KN_$/!+?@WKM4I%;
MJU2=8E9UA8]T:;6;BX/CR]R^K+:>PPFZR#%L5D(:K\JESTKHLW;9;0IEJ0PQ
M7V#\Q*$J0GWC)<;'V0-5R87TX>T)J=E^J7;.NJLIAVNT&+1H/35-R&]+KF<P
M=U9T?.]QH4J:VI2IS^.39,JEAI5V.)9:,-DJ6!SL[D<I(("OF. >?NX)X_KU
M\A([E^.>>/4)XXX [00.2/')[B>#X'C@!)]+EYDM4K6HCONZ2-+5#]7<JD43
MBEAU,X1TD8_6U#1L6.D[AR%)0M5O>J O8?KYC;0P[.FV]BRM@IV[C=UF&R3L
M+(HUP:./CC4218L5#B4Y [ EY$IEYZ/&>*5H:]XEOM!T[N4=)'M$,PVJZ<48
M/E PB5@\/.,HR.JKV7HS]AM-,N)DRIV)5)M6%3H=S-A*;<9D/+:4V.QE<P*/
M:=F$)';VEM/'\D =O'(^'''/!YX^[UT!(21]D>> >T'P>"/GP$<>./3GY\ZC
M.ARBMY;!VCOO?Q"(GS+V&VC$CUDTK1 ^+5M?E6])N]W:S9.^*L^N_%KS=7HL
MPN=CN*;M4BZ^=@^13L$Q*,ZYEL.HBPBS-QG(JMIQV38U[;BFXE@VPXX\\ AY
M"R%<ZK[L^FG=_+<;VYW*K>GO*<*W81T[YS@>'VF.6MDF5C]=69-(O*Z->.6L
MI4FFM;ZK5)9BQ):.%*=0P@@K'.RD4@@@I21\$\#@CX @\CUY^7]NC@>G:.!X
M'@<<'P>/NX]1^C3I])&4M6MBZ8Q^$K:.DH!-DC2=C8VVPR'4L(Z2$7XF6Z\)
M5<_WWNTN^[K+[N475+U(1LXOL8VIW^Q#;:JQGINQ?.\5R6)^#V3YC3X;;NR]
MPV\2CHEF5,DR$*A^]>C.-.3XS:E)*>\@,VWMQG'2ST]=0G4SL_M;N?M&Q@_5
M>UE>R>UV<3Y4#)-S,5S>'%PUZ!-JYTE^=,,>?<1;-B*Y(]\RU!>4E2DI<[ML
MSL2 0E* "/([0 3]_'J/T:0&<[68#N2YBSF<8U7Y$,-OV,HQYBP0MV)"O8S9
M;CSU10M+$E;'(4VB4VZVE:4K".X Z1Z5 J6K?4C8,E+MM:JVJ?BM$LI7J65&
M@ 38WN)6TKV5KG;9]#"0Z;L&MMNMD-N,5R&5)G9)"QN')R2;+?7(>DY!9 V%
MNX7%\$(^FR'$M("4I;;2E ' T^&@  < < > !Z ?+1R/F//I]^K)$C @<1CI
M/L*X,5EM5[J_?A%1_P#65S_?5_<7I:Z14?\ UE<_WU_U(7^_]W.EKK!\ $CU
MUB?Z9F\B=S%WK?\ AO3I<H?1WV?7!HT:-=#BC@T:-&C!@T:-&C!@T:-&C!@T
M:-&C!@U\J*N"$^#Z@D$C[QX\\\<\>-?6L8[=T[#BFG[6N9<3X4V[-C(6.#QY
M0IT*'Z0-(H<]\/A"<VH0E--ZC%DUZ@+6(>3L-M:[KII,V:R+/)53D&REU5/X
MV]*=>V_K9U=:P5,3&(J$AJ)=2VRH%QXA3K:5A!5R0F:B H#A1Y/]?/Q_1SZ?
M(>/AK"_7V.AQ3GUO4!WL *C/A]Y0#SQS[XD@>O'S_21E(TN/,;#T9YI]H_DN
M,N(=;4/F%MJ4D_H)TR$=.O<=4V17:PVOOQ=^M=L29T<ZH.9DSRR$(Y8N7*(A
M:,E U.K[2L1LZQL@V_Q?IPW.N=T9F80\&C4[ O?P"E28663(Z[")VUM3,B1Y
M3\95@X$193J6B!"<D!2DI)4(^>SGQZH@89N#D^-YE6S,9SK+(^2XYMG2W4J\
M@[6TC]1#8@TTZ9-_'G(+%EI-E>(0EMEN?(> 1W<\6)3Z^#:17H-E$CSH;Z>U
M^+*:0^PZGGGM<:<"D+'(!X(/G7@I<;H,;:?9H*:MIVI+OOI#=;$9B(>=XX]X
MXEE*0M?'CN()X^[2,%S8SLJ(B-W]GIOYUON+OA8YVGI\S)I_A)$EL8T,6J39
MN-ZAO@L+',._Q:_7PE1(2.5$<'D) \]Q^''GGC5(^W3-=2>T.VJ_@6M\BO\
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8#1HT:,&#1HT:,&#1HT:,&#1HT:,&/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
